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PROLOGUE 
Read in a French forum in September 2009 at this address 
http://www.cancerdusein.org, a forum for patients with breast 
cancer. 
Vero: “Hello to all the fairies, I have it again [breast cancer] for the 
2nd time, and I began a new protocol of chemo. Everything goes well 
except for these pains which arrive especially in the evening and 
which radiate to the entire body as electric shocks, the pain goes 
away after one hour or two with painkiller. I do not think that it is 
due to this chemo, because I had them before. My oncologist told me 
that it was neuropathic pain; neither more details, nor does he treat 
it. Does anybody know this problem? Thank you in advance. Vero” 
Naia: “Frankly I don’t know too much, I have had big pains but after 
surgery, it was as electric shocks but somebody told me it was normal 
and I have no more now. Kisses, Naia“ 
Mathilde: “Hello Vero. I do not know either about what it is, but I also 
had pains such as you describe them: a sensation of small electric 
shocks but especially in my legs since the beginning of my treatment 
under taxotere. I do not know if it is the same thing. But it was also 
stronger at night and it prevented me from sleeping. In any case, to 
delete these effects, I took a painkiller that worked very well: topalgic 
*tramadol+ 100mg. Good luck Véro!!!” 
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Neuropathic pain in patients with cancer in Europe 
 
1) Cancer in Europe and in France 
Cancer is the first cause of death in Europe and its prevalence 
increased in the past 30 years because of the ageing population, 
earlier diagnosis and more treatment options which lengthened 
survival and decreased mortality. (1) In 2008 about 3.2 million 
persons got cancer in Europe, with a mortality of 1.7 million and a 5-
year prevalence of 8.4 million of patients. Considering France, in 
2008 the incidence of cancer in men was the highest of all European 
countries and women were in the 10th position. (2)  
Cancer is responsible for a high impairment in quality of life and 
especially social life. This impairment can be a direct consequence of 
cancer itself but also a consequence of its treatment. Cancer causes 
several problems of which the most common encountered are in 
decreasing frequency pain, dyspnoea, and tiredness. (3) This thesis 
will study pain in cancer because it is the most common symptom 
associated with cancer namely pain due to cancer and more 
specifically neuropathic pain in cancer.  
2) Pain in cancer 
a. Epidemiology  
Pain in cancer is quite common: 40% to 60% of patients with cancer 
experience moderate or severe pain at least monthly. (4, 5) In France, 
like in Europe, the incidence of cancer has increased in the past 10 
years but the mortality rate remained the same, which means that 
the number of patients who recover from their cancer but have 
chronic cancer pain has increased and will even further increase. (6, 
Improving neuropathic cancer pain in Europe 
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7) Pain has a high impact on the patient’s quality of life: 43% of 
cancer patients with pain think that their pain is a burden, 67% 
describe it as causing stress, 36% as an intolerable aspect of their 
cancer and 32% would like to die because of their pain. (4) Pain is 
often the first symptom of the disease and when pain occurs, many 
patients fear that the cancer is getting worse or, in case of remission, 
is coming back. In 2007, a systematic review showed that 33% of the 
patients had pain after curative treatment, 59% during cancer 
treatment, 64% in advanced or metastatic stages of the disease and 
in 53% in total (when all stages are put together). (8) This symptom 
seems to be an indefatigable fellow traveler, difficult to leave for the 
patient but also for his family and his professional caregivers. It is 
obvious that the pain of so many patients with cancer should be 
relieved appropriately. However, this seems to be very difficult. (8) 
b. Pain definition in cancer 
Pain is “an unpleasant sensory and emotional experience associated 
with actual or potential tissue damage or described in terms of such 
damage”. (9) In 2007, Loeser and Treede proposed a revision of the 
terminology of pain. (10) Cancer pain can have nociceptive and 
neuropathic components. Nociceptive pain is defined as “an actually 
or potentially tissue-damaging event transduced and encoded by 
nociceptors.” (9) Neuropathic pain is a “pain arising as a direct 
consequence of a lesion or disease affecting the somatosensory 
system”. (11) These two types of pain can occur, often mixed. (12, 
13) Besides, they occur in a dynamic process where emotional 
impairment of the pain, sleep disorders and quality of life evaluation 
will be an important clue to manage the pain. (12, 13) The 
biopsychosocial model will influence pain management as presented 
in figure 1. (13) In fact, the initial lesion defined as nociceptive is a 
small part of the chronic pain. The fact that pain duration is over 3 
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months will develop a suffering for the patients and if this condition 
persists, a noxious pain behavior will develop creating a chronic pain 
syndrome. The direct consequence is the high need for a 
multidisciplinary approach and treatment: drugs for the pain but also 
psychological support, cognitive and behavioral therapy, 
physiotherapy and other techniques like hypnosis. (13) In cancer, 
pain can be a direct lesion of the cancer or due to its treatment 
(surgery, chemotherapy or radiotherapy). Neuropathic pain should 
be differentiating from nociceptive pain because the treatment is not 
the same. In this thesis, we will focus mainly on the pharmacological 
treatment advocated by national guidelines on cancer pain. 
Figure 1. Pain model from Loeser in his book definition of pain. (13) 
 
 
 
 
 
 
c. Pain in patients with cancer: a separate entity? 
To help practitioners, in 1987, the World Health Organization (WHO) 
proposed a guideline to treat cancer pain: the WHO analgesic pain 
Pain behavior 
Suffering 
Pain 
 
Nociceptive 
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ladder. (14) It recommends treating cancer pain by the following 
three steps. For slight to moderate pain, step I with paracetamol is 
proposed. For moderate pain, step II with weak opioids is 
recommended and for severe pain, step III, strong opioids should be 
prescribed. If this pain ladder is followed correctly, 80% of the 
patients with cancer can be treated effectively. (15) But there are still 
20% of patients for whom this guideline does not work: one of the 
causes of this inefficacy is the presence of neuropathic pain 
components. (8, 15) 
Pain in patients with cancer is complex because it is a combination of 
different pain mechanisms. In 1999, Caraceni was the first to map 
cancer pain: 25% of the patients presented at least two types of pain. 
About 90% of the pain was caused by the cancer itself and 21% of the 
patients had pain consecutive to the treatment of the cancer. (16) 
Pain was considered to be nociceptive in 72% of the patients, 
neuropathic in 40% and visceral in 35%; about 40% of patients 
suffered from a combination of pain types. (16) Thus, neuropathic 
pain in cancer is difficult to diagnose.  
3) Neuropathic pain in patients with cancer  
a. Epidemiology of an under-diagnosed type of pain 
Neuropathic pain can be caused by the tumor itself and/or by the 
treatment of cancer such as neurotoxic chemotherapy, invasive 
surgery or radiotherapy. (17) In patients suffering from cancer pain, 
between 19 and 39% also suffer from neuropathic pain. (18) Little 
information exists about this population of patients. Only few studies 
all with a small number of patients studied the treatment of 
neuropathic pain in patients with cancer. (19, 20) Conclusions were 
irrevocable: neuropathic pain appears hard to treat, and strong 
opioids are not always the first choice. (4, 21) In a recent 
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international study comparing patients with cancer having 
neuropathic pain and those having only nociceptive pain, the quality 
of life measured with the EORTC QLQ-C30 was worse in cancer 
patients with neuropathic pain than in cancer patients with only 
nociceptive pain concerning physical, cognitive and social functions. 
(5) 
b. Neuropathic pain signs and symptoms 
Signs of neuropathic pain can be: the sensation of burning, 
dysesthesia or paresthesia (like pins and needles), pruritus, electric 
shocks or cold pain. Symptoms can be associated with hyperesthesia 
(increased pain sensitivity) or allodynia (pain in response to a non-
nociceptive stimulus) in the same body location. (10) In cancer, this 
type of pain can occur in the legs or in the fingers after 
chemotherapy, around the scar of a surgery or in the area of previous 
radiotherapy.  
 
c. Management of neuropathic pain in non-cancer 
conditions 
Neuropathic pain was initially described in non-cancer conditions. Its 
diagnosis is challenging. Until now, no gold standard for the diagnosis 
of neuropathic pain has been accepted, although several screening 
instruments exist, like the McGill Pain Questionnaire, S-LANSS, 
Neuropathic Pain Questionnaire, DN4, PainDETECT and StEP. (22-26)  
 
These instruments are presented in table 1.  
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Table 1. The 6 questionnaire to screen neuropathic pain. 
Instrument Author Year Population included 
DN4 Bouhassira 2005 Chronic pain 
McGill Questionnaire Melzack 1975 Chronic pain 
NPQ Krause 2003 Chronic pain 
Pain DETECT Freynhagen 2006 Low back pain 
S-LANSS Bennett 2005 Chronic pain 
STeP Scholz 2009 Low back pain 
In 2011, an algorithm was created to help physicians and researchers 
to make a proper diagnosis of neuropathic pain. (Figure 2) (28) 
 
Figure 2. Algorithm of the neuropathic pain diagnosis adapted from 
the IASP (28) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Definite 
neuropathic pain 
Probable 
neuropathic pain 
Pain distribution is plausible and history 
suggests relevant lesion or disease 
Confirmatory tests : 
1) Negative or positive sensory signs in the innervation territory of 
the lesioned nervous structure 
2) Diagnosing test confirming the lesion or disease explaining pain 
Both 1+2 One 1 or 2 Neither 1 nor 2 
Unconfirmed as 
neuropathic pain 
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Up to now, there is also no consensus about the treatment of 
neuropathic pain in patients with cancer: Hall et al. found 951 
different treatment regimens prescribed as an initial therapy in this 
patient group. (29) Generally, neuropathic pain is treated with 
adjuvants like tricyclic antidepressants or anticonvulsants. (30) The 
evidence for these types of drugs, based on number needed to treat 
(NNT 1.2-3.6) and number needed to harm (NNH 6-28) was mainly 
derived from research performed in patients with painful diabetic 
neuropathy (PDN) or post herpetic neuralgia (PHN). (31, 32)  
d. Management of neuropathic pain in patients with cancer  
In 1989, Bruera et al. proposed a new classification for cancer pain, 
named the Edmonton Staging System (ESS), which was validated in 
1995. One of the assessed domains of this score was the mechanism 
of pain which considered visceral pain, bone-soft tissue, neuropathic 
pain, mixed pain or unknown. (33, 34) Neuropathic pain was defined 
as a “pain located in the region where the nerve or nerve root has 
been damaged”. In 2005, Fainsigner proposed to use the revised 
Edmonton Staging System (rESS) because the ESS is not efficient to 
detect neuropathic pain from nociceptive pain. (35) This tool was 
validated for clinical practice and research with the same definition 
of neuropathic pain, which did not exclude other kind of pains. The 
term “neuropathic pain components” was used to underline the fact 
that it is not a unique physiopathology but more an association of 
specific symptoms. In 2008, a study demonstrated that by following 
the WHO guidelines the treatment of neuropathic pain was effective 
using specific co-analgesics such as amitriptyline, gabapentine and 
dexamethasone in 53% of the patients. (36) In another study, 20% of 
the patients were not relieved by the treatments proposed in the 
WHO guideline of which the majority had neuropathic pain. (16) 
Concerning the treatment of neuropathic pain in patients with 
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cancer, amitriptyline only had little efficacy and important side 
effects although it is recommended in first line in CPGs. (20) In 
contrast, Caraceni proposed gabapentine because of better benefit 
risk ratio. (19) No studies compared tricyclic antidepressants drugs 
and anticonvulsants drugs in cancer. Other randomized controlled 
trials were rare. Possibly, it explains the lack of consensus on the 
treatment of neuropathic pain in cancer.  
A specific sub-category of neuropathic pain is chemotherapy-induced 
peripheral neuropathy (CIPN). Hausheer proposed the Patient 
Neurotoxicity Questionnaire to evaluate the risk to develop CIPN. 
(37) However, this tool was not appropriate to assess neuropathic 
pain components. (38) Cavaletti et al. proposed and validated a tool 
to evaluate CIPN using the Total Neuropathy Score with a 
questionnaire on quality of life (EORTC QLQ-CIPN20) and a simple 
pain intensity assessment. (39, 40) Yet, such a tool takes time and 
seems not specific for neuropathic pain components. 
e. Conclusion 
There is no gold standard for the management of neuropathic pain in 
patients with cancer. In such a case, evidence-based medicine (EBM) 
can contribute to help professionals. The following chapter will 
present the definition and describe the interest why making a clinical 
practice guideline (CPG) in cancer pain is important. 
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Developing clinical practice guidelines  
 
1) Definition and interest of a clinical practice guideline (CPG) 
Clinical Practice Guidelines (CPGs) have been developed to help 
practitioners to give the best available care (efficacy and safety) to 
their patients. (41) They are ‘statements that promote or advocate a 
particular course of action in clinical care’. (42) Also regarding 
neuropathic pain in cancer, CPGs can guide practitioners through a 
structured diagnosis and treatment process. (28, 41) CPGs should be 
based on a systematic literature review and should give 
recommendations as a response to specific questions, in a specific 
patient population for a specific practitioner population. (43) The 
principles of EBM changed the methodology of guideline 
development, with a more rigorous selection of references and a 
higher consensus in the redaction of recommendations. (44) EBM can 
be classified in four levels with 1 the highest and 4 the lowest level of 
evidence as presented in table 1. The combination of evidence about 
a same clinical question can be classified in four grades with grade A 
as highest grade and grade D as lowest as presented in table 1. When 
there is no evidence on a question, only a synthesis of experience of 
the guideline development group can be proposed as “good practice 
point”. (45) It is important that the quality of a CPG is high, as it aims 
to influence clinical practice of many practitioners and the care they 
provide to even more patients. Thus, a good methodology for 
choosing the evidence is essential.  
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Table 1. Key to evidence statements and grades of 
recommendations according SIGN 50 
LEVELS OF EVIDENCE 
Level Description 
1++ High quality meta-analyses, systematic reviews of RCTs, or RCTs with a very 
low risk of bias 
1+ Well-conducted meta-analyses, systematic reviews, or RCTs with a low risk 
of bias 
1- Meta-analyses, systematic reviews, or RCTs with a high risk of bias 
2++ High quality systematic reviews of case control or cohort or studies 
High quality case control or cohort studies with a very low risk of 
confounding or bias and a high probability that the relationship is causal 
2+ Well-conducted case control or cohort studies with a low risk of 
confounding or bias and a moderate probability that the relationship is 
causal 
2- Case control or cohort studies with a high risk of confounding or bias and a 
significant risk that the relationship is not causal 
3 Non-analytic studies, e.g. case reports, case series 
4 Expert opinion 
GRADES OF RECOMMENDATIONS 
 
Grade A  At least one meta-analysis, systematic review, or RCT rated as 1++, and 
directly applicable to the target population; or A body of evidence 
consisting principally of studies rated as 1+, directly applicable to the 
target population, and demonstrating overall consistency of results 
Grade B  
 
A body of evidence including studies rated as 2++, directly applicable to 
the target population, and demonstrating overall consistency of results; 
or Extrapolated evidence from studies rated as 1++ or 1+  
Grade C  
 
A body of evidence including studies rated as 2+, directly applicable to 
the target population and demonstrating overall consistency of results; 
or Extrapolated evidence from studies rated as 2++  
Grade D  Evidence level 3 or 4; or Extrapolated evidence from studies rated as 2+ 
Good 
practice 
points  
Recommended best practice based on the clinical experience of the 
guideline development group 
RCT randomized controlled trial. Extracted from the SIGN website on 
31-Jui-2012 in this URL: 
http://www.sign.ac.uk/guidelines/fulltext/50/annexb.html (44).  
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2) Development methodology for  a CPG 
In Europe, several institutes are specialized in the development of 
guidelines. The Dutch College of General Practitioners was the first to 
start guideline development, with the publication in 1989 of its 
guideline ‘diabetes mellitus’. In 1979, the Dutch Institute for 
Healthcare Improvement (CBO) was founded by the Dutch 
Association of Chief Medical Officers. This independent national 
organization focused in 1999 on the organizational aspects of the 
quality of care with the development of national guidelines. In 1993, 
the Scottish Intercollegiate Guidelines Network (SIGN) was created to 
improve quality of care in Scotland, by the development and 
dissemination of national CPGs based on current EBM. In 1999, the 
National Institute for Health and Clinical Excellence (NICE) in the 
United-Kingdom was developed to reduce the variation of the 
availability and quality of treatment and care. The same year, the 
Agence Nationale de Développement de l’Evaluation Médicale 
(ANDEM) was founded and proposed a specific methodology to 
create CPGs. More recently, in 2004, the Institute for Quality and 
Efficiency in Health Care (IQWIK) was created in Germany. Other 
developers can be proposed as national societies, for example, the 
French pain society in France or the Palliative Care Society of the 
Netherlands. 
Specific groups of guideline developers are often composed of only 
methodologists as is the case in the NICE guidelines but these 
developers are mostly not clinical experts. Consequently, the clinical 
expertise is lacking to make clinical relevant recommendations.  
Other developer groups are composed of clinicians and experts of the 
clinical question(s) but they have usually no training in the 
methodology of making guidelines. The advantage is that their 
clinical experience and their practice can help to built clinical 
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applicable recommendations. However, experts have often financial 
conflicts of interests (COI) with pharmaceutical industries and they 
should not take part to the decisions for some questions of the CPG 
in relation with their COI. (45) These COI should be written in the CPG 
in details. (45) The best would be combining expertise and knowledge 
of these two domains: methodological and clinical experiences. This 
was done in the Netherlands. A national scientific society started the 
process of making a guideline and invited several national recognized 
clinical experts together with the national institute of guideline 
development for the methodological support and guidance. 
The described situation raises the question how to develop a high 
quality CPG. How can we evaluate the rigor of development of a CPG 
and its applicability in practice? 
3) Evaluation of the quality of a CPG 
It is important to evaluate the quality of a guideline because it will be 
used by numerous physicians and other health care professionals as a 
guide reference to diagnose and treat numerous patients. The first 
tool to assess guidelines was the Appraisal of Guidelines, Research 
and Evaluation (AGREE) instrument. It was developed by an 
international methodologist group in 2003: the AGREE collaboration. 
(43) Its aim was to assess the methods used to develop a CPG and to 
know whether the resulting recommendations are sufficiently based 
on evidence. (43) This 23-item instrument consists of six domains: (1) 
scope and purpose (overall aim of the guideline and target groups, 3 
items); (2) stakeholder involvement (stakeholders involved in 
guideline development and views of its intended users, 3 items); (3) 
rigor of development (selection of the evidence and the method to 
create recommendations, 8 items); (4) clarity and presentation 
(structure and format of the guideline, 3 items); (5) applicability 
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(facilitators and potential barriers for guideline implementation, 4 
items); and (6) editorial independence (biases concerning conflicts of 
interest, 2 items) and one overall assessment item judging if the CPG 
is recommended for its use in clinical practice. (43) The ratings of the 
quality domains showed to be good predictors of outcomes 
associated with implementation of guidelines, very useful and easy to 
use. (43) The original AGREE Instrument has been refined to improve 
the original tool’s usability and its validity and reliability. (43) Thus, in 
2008 the AGREE II instrument, a revision of the AGREE instrument, 
was developed by the AGREE collaboration. (46) Revision was done 
because the four-point response scale of the AGREE instrument was 
not reliable enough. (47, 48) The seven-point response scale seemed 
more relevant, and the new user’s manual clear. (46) Yet, there is no 
abridged version of this time-consuming instrument (at least 90 
minutes per guideline), it appears not efficient for use in developing 
countries and finally is difficult to evaluate in case of multiple 
morbidities which means multiple CPGs. (49-51) However, the AGREE 
II instrument appeared valid to assess the quality of development of 
a CPG on cancer. (52) Table 2 presents the AGREE and AGREE II 
instruments. 
In conclusion, developing a CPG should follow a rigorous 
methodology, especially because it will be used by all health care 
providers and their patients (in fact the target population of the 
CPG).  
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Table 2: Comparison of the original AGREE and the AGREE II items. 
(43-46) 
Original AGREE Item AGREE II Item  
Domain 1. Scope and Purpose  
1. The overall objective(s) of the 
guideline is (are) specifically described.  
No change  
2. The clinical question(s) covered by 
the guideline is (are) specifically 
described.  
The health question(s) covered by 
the guideline is (are) specifically 
described.  
3. The patients to whom the guideline 
is meant to apply are specifically 
described.  
The population (patients, public, 
etc.) to whom the guideline is 
meant to apply is specifically 
described.  
Domain 2. Stakeholder Involvement  
4. The guideline development group 
includes individuals from all the 
relevant professional groups.  
No change  
5. The patients’ views and preferences 
have been sought.  
The views and preferences of the 
target population (patients, 
public, etc.) have been sought.  
6. The target users of the guideline are 
clearly defined.  
No change  
7. The guideline has been piloted 
among end users.  
Delete item. Incorporated into 
user guide description of item 19.  
Domain 3. Rigour of Development  
8. Systematic methods were used to 
search for evidence.  
No change in item. Renumber 
to 7.  
9. The criteria for selecting the 
evidence are clearly described.  
No change in item. Renumber 
to 8.  
NEW Item 9. The strengths and limitations of the body of evidence are 
clearly described.  
10. The methods for formulating the 
recommendations are clearly described.  
No change  
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Original AGREE Item  AGREE II Item  
11. The health benefits, side effects, and 
risks have been considered in 
formulating the recommendations.  
No change 
12. There is an explicit link between the 
recommendations and the supporting 
evidence.  
No change  
13. The guideline has been externally 
reviewed by experts prior to its 
publication.  
No change  
14. A procedure for updating the 
guideline is provided.  
No change  
Domain 4. Clarity of Presentation  
15. The recommendations are specific 
and unambiguous.  
No change  
16. The different options for 
management of the condition are clearly 
presented.  
The different options for 
management of the condition 
or health issue are clearly 
presented.  
17. Key recommendations are easily 
identifiable.  
No change  
Domain 5. Applicability  
18. The guideline is supported with 
tools for application.  
The guideline provides advice and/or 
tools on how the recommendations 
can be put into practice. AND 
Change in domain (from Clarity of 
Presentation) AND renumber to 19  
19. The potential organizational 
barriers in applying the 
recommendations have been 
discussed.  
The guideline describes facilitators 
and barriers to its application.  
AND change in order – renumber to 
18  
20. The potential cost implications 
of applying the recommendations 
have been considered.  
The potential resource implications 
of applying the recommendations 
have been considered.  
21. The guideline presents key 
review criteria for monitoring and/ 
or audit purposes.  
The guideline presents monitoring 
and/ or auditing criteria.  
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Original AGREE Item  AGREE II Item 
Domain 6. Editorial Independence  
22. The guideline is editorially independent 
from the funding body.  
The views of the funding 
body have not influenced 
the content of the 
guideline.  
23. Conflicts of interest of guideline 
development members have been recorded.  
Competing interests of 
guideline development 
group members have been 
recorded and addressed  
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Changing paradigms in understanding the building of 
CPGs on neuropathic pain in patients with cancer  
 
1) A CPG on neuropathic pain in patients with cancer? 
To develop a high quality CPG there is, next to expertise, a need for 
funding and time. (53) These financial and human means can be 
justified for public health problems such as diabetes or cardiovascular 
disease but the interest in an underestimated symptom as 
neuropathic pain in patients with cancer is far from obvious. Criteria 
for selection of topics for CPG are:  
 “Areas of medical uncertainty as evidenced by wide variation 
in practice or outcome, 
 Conditions where effective treatment is proven and where 
mortality or morbidity can be reduced,  
 Iatrogenic diseases or interventions carrying significant risks 
or cost,  
 Clinical priority areas for NHS Scotland: presently, coronary 
heart disease and stroke, cancer and mental health. The 
strategic aims of the NHS in Scotland are also considered: 
improving health and tackling inequalities, especially with 
regard to children and young people, developing primary and 
community care and reshaping hospital services.” (44) 
Thus, neuropathic pain in cancer is an eligible topic for a CPG: no 
consensus on its diagnosis or treatment, a specific treatment on 
neuropathic pain can improve the quality of life and inadequate 
treatment can increase side events in this frail population. Besides, 
cancer is a clear clinical priority in every European country. However, 
the development of a CPG with few publications of high quality on a 
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topic is challenging. Is there any CPG in Europe concerning 
neuropathic pain in cancer?  
2) Application of clinical practice guidelines in the primary care 
setting 
The research of this thesis was performed from 2010 to 2013, a 
period of changes in the attention for neuropathic pain in patients 
with cancer: a new definition of neuropathic pain in 2008, a new 
diagnosis algorithm in 2011, and a specific assessment in patients 
with cancer in 2012. (11, 28, 40) This was even the object of the 
clinical update of the journal ‘Pain’ in March 2012. (15) Although 
these recommendations were published and disseminated to a 
certain level of pain treating physicians, there was no information on 
their impact in practice. 
Since 2011, according to the World Organization of National Colleges, 
Academies and Academic Associations of General Practitioners 
(WONCA) in Europe proposed a new definition of the general 
practitioner. They are “personal doctors, primarily responsible for the 
provision of comprehensive and continuing care to every individual 
seeking medical care irrespective of age, sex and illness.” (54) This 
definition gave three main missions to the GP. First, he has to treat 
his patients in their global environment (physical, psychological, 
social, cultural and existential dimensions); the care he provides 
should be personalized in a comprehensive approach of the patient 
and its family. Second, he has to prevent disease in a public health 
dimension. Third, he also has to give effective and safe patient care 
according evidence-based medicine in a quality management.  
In conclusion, every GP should know the CPGs concerning all diseases 
involved in primary care, which seems not possible regarding 
available time. Thus, a CPG should be clear to help the GP in an 
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effective way. This should be particularly the case for pain 
management in cancer because usually the GP will support the 
patient and his family until the end.  
Literature illustrates that practitioners use CPGs according to their 
knowledge, attitude and skills. (55) They also use CPGs only if the 
level of evidence or expert opinion is high, recommendations are 
clearly linked to the evidence or levels of evidence or grade of 
recommendations are explicit. (55, 56) For these reasons, we studied 
whether CPGs on neuropathic pain in patients with cancer exist, if 
they have a good quality of development and if there are applicable 
in daily practice. 
The Dutch College of General Practitioner (NHG) provides CPGs and 
develops tools to improve their adherence. In a recent survey of 
Lugtenberg, more than 95% of the GPs thought that Dutch CPGs were 
useful sources of advices and based on sufficient evidence but they 
do not always use them. (57) Barriers to a good adherence were the 
lack of applicability of the CPG in general or with respect to individual 
patients, and this is understandable when we know that the care 
should be person-centered. (57) Besides, the patients’ ability and 
behavior as the patients’ preferences can contribute to different 
care, not always in concordance with the CPG recommendations. (57)  
3) What we know about neuropathic cancer pain 
Neuropathic pain for patients with cancer is an important public 
health problem in Europe as it: 1) is difficult to diagnose, 2) is difficult 
to treat, 3) has a high impairment on the quality of life and 4) has a 
high prevalence which will even increase. That is why a specific 
clinical practice guideline on neuropathic pain in patients with cancer 
can contribute to best care for our patients with neuropathic pain. 
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Looking to all the discussed material in this introduction, I started this 
research project with the following research questions. 
4) Research questions of this thesis 
1. Are there specific guidelines in Europe, describing the diagnosis 
and management of neuropathic pain in cancer patients? 
2. If there are specific guidelines found how many of them meet the 
criteria of a clinical practice guideline (CPG)? 
3. What is the quality of the development process and the content 
(reporting) of each CPG using an internationally validated instrument 
(AGREE II instrument)? 
4. What is the quality of the methodology and development of each 
recommendation in the selected CPG guideline that meets a basic 
level of quality? 
5. What are the recommendations regarding diagnosing and treating 
neuropathic pain in patients with cancer and how do they differ in 
the selected CPGs? 
6. Do French pain specialists adhere to the national guidelines on this 
topic in their clinical decision making as a clinical test of the 
implementation level of the national CPG? 
Outline of the thesis 
Chapter 2 answers the research question number 1 and 2. The first 
step of this work is to find recommendations on chronic pain, 
neuropathic pain or cancer pain used in Europe. As most of the 
guidelines are not written in English and not published in Pubmed, 
we chose to directly involve physicians in all European countries and 
finding such guidelines. The European Federation of IASP 
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[International Association for the Study of Pain] Chapters (EFIC) is 
composed of pain specialists, each of them being chair of their 
national association for pain. They are usually experts in their 
domains and participate in the development of guidelines on pain in 
their countries. Additionally, in Europe there are pain clinicians with a 
special interest in neuropathic pain and registered in the IASP in the 
special interest group on Neuropathic pain (NeuPSIG). In this chapter, 
these specialists will also be interrogated to know if guidelines on 
chronic pain, neuropathic pain and cancer pain exist in their country. 
This seems to be an interesting method to get the most exhaustive 
list of guidelines. The second part of the article will be to study the 
recommendations to know if they meet the definition of a CPG 
according Field’s definition. 
Chapter 3 answers the research question number 3. With the 
material collected in chapter 2 as a basis, we aimed to select CPGs on 
neuropathic pain in patients with cancer. They will be assessed with 
the AGREE II instrument to evaluate their quality of development. 
Results of this assessment will be compared between CPGs made by 
professional societies and those created by guidelines development 
organizations. 
Chapter 4 answers the research question 4. References used to make 
recommendations in these CPGs will be studied in relation to the 
recommendations and comparisons between the CPGs concerning 
the diagnosis of neuropathic pain in cancer. The methodology used 
has already been validated in an article on diabetes and will be used 
for this article. The aim is to assess the level of quality of the 
references and the grade of recommendations of the clinical 
messages. Chapter 5 answers research question 5 and uses the same 
methodology as chapter 4. It concerns the treatment of neuropathic 
pain.  
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Chapter 6 responds to the last research question. French pain 
specialists will be invited to participate in a case vignette study. It 
aims to answer if they know and use the recommendations on cancer 
pain and neuropathic pain, as given in French CPGs.  
Chapter 7 discusses the main findings of the thesis, considers the 
methods and limitations, and proposes specific recommendations to 
improve the implementation and development of CPGs in daily 
practice, for policymakers and future research. 
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SUMMARY 
Introduction: Clinical practice guidelines (CPGs) are statements that 
promote or advocate a particular course of action in clinical care. 
Chronic pain is a frequent disease and is often associated with co-
morbidities, so, CPGs are important to guide the practitioners. Are 
there specific guidelines in Europe, describing the diagnosis and 
management of neuropathic pain in cancer patients? Methods: A 
questionnaire was sent by email to the chairs of the IASP chapters of 
each European country with the support of the European Federation 
of IASP chapters and to the members specialized in neuropathic pain 
in Europe (NeuPSIG). Name and topic of each document (pain, cancer 
pain and neuropathic pain, other) was collected. Each document 
should meet the definition of a CPG. Statistical analysis was made 
with SPSS 16.0 for group description (number and frequency). 
Results: Forty-one of the 66 participants (62%) answered the 
questionnaire, representing 30 of the 38 European countries. With 
their participation, 54 documents were found and validated within 20 
of them were CPGs: 6 on chronic pain, 5 on neuropathic pain, 4 on 
cancer pain, 2 in geriatrics, 1 in pediatrics and 2 on chronic low back 
pain. Conclusion: An important heterogeneity exists in Europe 
concerning CPGs on the diagnosis and treatment of pain and cancer 
pain more specifically. A general European CPG can help to improve 
the European implementation of the CPG in each country and 
propose a safe and efficient management of the pain after specific 
adaptations to the health system of each country including pooling 
the financial and the human resources.  
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INTRODUCTION 
Acute pain is one of the first symptoms leading the patient to visit his 
practitioner: a diagnosis is made and a treatment is proposed. It is 
more difficult when pain is resistant to the specific analgesics which 
are the case for the diagnosis and treatment of cancer pain and 
chronic pain.  
The prevalence of patients with cancer is increasing. In Europe, the 
incidence of new cases of cancer was 3.2 million per year in 2008 (1). 
In this population, 64% suffered from pain among them 19-39% had 
neuropathic pain (2-5). These pains can occur due to the cancer or its 
treatment (4, 6-8). Chronic pain represented 30% of the French 
population with 7% of neuropathic chronic pain (9). In chronic and 
cancer pain, patients reported a severe diminution of their quality of 
life (10, 11). Thus, it is an important public health problem in Europe. 
To guide health caregivers for an optimal pain management of their 
patients, clinical practice guidelines (CPGs) were developed. These 
CPGs are “statements that promote or advocate a particular course 
of action in clinical care” (12, 13). One of these CPGs was published in 
1986 by the World Health Organization and concerned the 
management of cancer pain in three steps (14). Following these 
recommendations 80 % of these pains can be relieved in patients 
with cancer (15). However, it appeared that in the population who 
did not respond to the analgesic treatment, neuropathic pain was 
very prevalent (15). Chronic pain, especially in neuropathic pain is 
also resistant to treatment (10). 
Referential and documents exist to help practitioners and are 
published by an international society as the International Association 
for the Study of Pain (IASP) of its special group of interest on 
neuropathic pain (NeuPSIG), by a national organization as the 
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Scottish Intercollegiate Guidelines Network (SIGN) or a national pain 
society like the Société Française d’Evaluation et de Traitement de la 
Douleur (SFETD) in France (16-19). Nevertheless, most of the CPGs 
are national and not available in international database as Pubmed or 
Embase, especially when they are not written in English. The 
objective of this research is to make an inventory of European 
guidelines on chronic pain, neuropathic pain and cancer pain and to 
collect them all. Besides, all guidelines will be evaluated to check if 
they meet the criteria of a CPG. 
Methods                                               
Inclusion of participants 
Chairmen of the European national pain societies, all member of the 
European Federation of IASP Chapters (EFIC) and European 
physicians all member of the special interest group on neuropathic 
pain of the IASP who published in the last 5 years on pain were 
invited to participate to the study by email with the support of the 
president of the EFIC. 
Study design 
Participants received a questionnaire by email 15 days after 
presentation of the study. They had to quote available CPGs in their 
counties according the topic (chronic pain, neuropathic pain and 
cancer pain). Besides, the questionnaire asked if a website or a 
person can be contacted to have these documents. A reminder was 
sent 15 days after. In case of non-response, participants were 
contacted by phone or by fax. All the documents were collected and 
sent to the authors to validate the selection of documents. 
Translation of the documents 
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Documents were translated into English with the help of the Google 
translator software to determine easily if the document corresponds 
to the definition of a CPG. The authors of this article spoke English, 
French, Italian, Dutch, German and Norwegian. The documents which 
meet the inclusion criteria were translated a second time by native 
speaker and physician according to the language of the CPG. 
Document inclusion 
Translated documents had to meet the definition of a CPG from the 
Institute of Medicine: CPG should inform according to a systematic 
review of the literature and evaluate the benefit-risk of alternatives 
options (14). 
Statistical analysis 
Data collection was analyzed with the software: SPSS 16.0© (IBM, 
NY, USA) using descriptive what and frequencies. 
Results 
Population of participants 
From March the 1st to April the 30th 2010, 66 participants were 
contacted within the 34 EFIC and 32 NeuPSIG members. Response 
rate was 62% (41/66), representing 30 of the 38 European countries. 
No member was found for Belorussia, Macedonia and Moldavia. Five 
countries did not respond to our questionnaire: Iceland, Luxembourg, 
Montenegro, Poland and Latvia. Participants from Ukraine and Russia 
respond to the email but could not respond to the questionnaire 
because they were researchers in fundamental research and did not 
know their national CPGs. 
Collection of the documents 
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From the questionnaire, 71 documents were found. Some of them 
were quoted twice: once for chronic pain and once for neuropathic 
pain for example because it was the same document for these two 
topics (figure 1). After collection, 54 national documents were 
identified and validated by participants. In our study, 24 countries 
had a document on chronic pain (80%), 22 on cancer pain (73%) and 
20 on neuropathic pain (67%). Documents quoted by Ireland were 
the same as the United-Kingdom (UK). Five documents were about 
pain in another domain: 2 in elderly population in France and UK, one 
in pediatrics in France, 2 concerning low back pain in Denmark and 
UK. Three countries had no available document on pain: Bosnia 
Herzegovina, Lithuania and Romania (table 1). 
Collection of CPGs 
On the 54 available documents, 20 meet the definition of a CPG: 6 on 
chronic pain, 5 on neuropathic pain, 4 in cancer pain, 2 in geriatrics, 1 
in paediatrics and 2 on low back pain. Serbia quoted the European 
recommendation from the European Federation of Neurological 
Societies (EFNS) concerning neuropathic pain (table 1). 
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Figure 1. European collection of documents on chronic pain, 
neuropathic pain and cancer pain in April 2010. 
 
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
Legend. CPG clinical practice guideline. EFIC European Federation of 
IASP Chapter. NeuPSIG: special group of interest on neuropathic pain.  
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Table 1. Clinical practice guidelines in Europe on chronic pain, 
neuropathic pain and cancer pain in April 2010. 
Country Chronic 
pain 
Neuropathic 
pain 
Cancer 
pain 
Country Chronic 
pain 
Neuropathic 
pain 
Cancer 
pain 
Albania - - + Italia + CPG + CPG + CPG 
Austria + + + Lithuania - - - 
Belgium + - + Norway + CPG + + CPG 
Bosnia 
Herzegovina 
- - - Netherlands + + + 
Bulgaria + + + Portugal + - - 
Croatia + CPG + CPG + Romania + - - 
Czech 
Republic 
+ + - San Marino + + + 
Denmark + + + Serbia + + 
b
 + 
Estonia - - + Slovakia + + + 
Finland + + + Slovenia + - + 
France + CPG + CPG + CPG Spain + CPG + CPG - 
Germany + + - Sweden + + - 
Greece + - + Switzerland + + + 
Hungary + + + Turkey - - + 
Ireland + CPG
 a
 + CPG
 a
 + CPG
 a
 United-
Kingdom 
+ CPG + CPG + CPG 
 
Legend. + quoted as present by participants, - quoted as absent by the participants, 
CPG clinical practice guideline according to the definition of the Institute of 
Medicine. 2 CPG on low back pain (UK and Denmark), 2 in geriatrics (UK and 
France) and 1 in paediatrics (France). 
a 
CPG quoted in Ireland were the British ones 
b
 Serbia quoted the recommendation from EFNS. 
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Discussion 
On the 66 contacted participants, 41 answered our questionnaire 
with a satisfied response rate of 62%, representing 30 of the 38 
European countries. Seventy-one documents were quoted in 
questionnaires. After duplicates removed, 54 documents were 
collected and validated by the participants. On these documents, 20 
were CPGs: 6 on chronic pain, 5 on neuropathic pain, 4 on cancer 
pain, 2 in geriatrics, 2 for low back pain and 1 in paediatrics. This is 
the first study which made an inventory of all European guidelines on 
management of pain, including non-English documents. The 
existence of a CPG in a country can be an example of a quality 
indicator for the health system because the presence or absence of a 
CPG is decisive for an optimal (efficient, safe and updated) 
management of the disease (20). Few countries used pre-existing 
recommendations except Ireland and Serbia. Knowing that the 
development of a CPG is expensive, it is surprising that European 
countries did not use a translation of a existing guidelines, to reduce 
the financial cost and to guarantee an optimal quality of care, at the 
condition that the specific guideline should be adapted to the 
national health care system of the specific country, but together this 
GCP should be available for all European health caregivers (20). 
Strengths and limitations 
The proposed methodology facilitates to identification of CPGs which 
are rarely referenced in international database. This study is a quasi-
exhaustive overview of the European production of CPG in 2010. 
Besides, collected documents were validated by the participants. 
Nevertheless, it is possible that some CPGs were not quoted and 
thus, not at our disposition. A country without a national pain society 
did not give appropriate information. Concerning the translation of 
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the national guidelines, the authors translated the CPG with a good 
knowledge of the language but translation errors may occur even if it 
did not change the comprehension and the evaluation of the 
document as a CPG. Besides, in Switzerland or in Italy, where the 
health care system is organized by region, we received local CPGs 
which cannot give a national view. Finally, this study concerned only 
Europe because we had the opportunity to be supported by the EFIC. 
Recommendations and perspectives 
It would be interesting repeat this study within two years to observe 
whether the number of high quality CPGs increases in Europe: this 
increase can be used as a good quality indicator about pain 
management in Europe. The other perspective would be to assess 
their quality of development with a specific tool the Appraisal 
Guidelines for Research and Evaluation version II (AGREE II) (21). This 
instrument assesses the quality of development of a CPG using 6 
domains and can be a quality indicator to follow regularly. This work 
was already done for CPGs about neuropathic cancer pain (22-24). It 
is concluded that even if a topic was common in several CPGs, 
references used were different between recommendations and that 
the quality of development of these CPGs should be improved 
concerning editorial independence and applicability. European CPGs 
with a satisfied level of quality could be proposed internationally and 
translated in each country, according their healthcare system. Human 
and financial means could be pooled for the best management. A 
tool exists for that: ADAPTE which was translated in French (25). 
These new methodologies would be interesting to develop in the 
domain of pain. 
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Abstract:  
Between 19% and 39% of patients with cancer pain suffer from 
neuropathic pain. Its diagnosis and treatment is still challenging. Yet, 
national clinical practice guidelines (CPGs) have been developed in 
several European countries to assist practitioners in managing these 
patients safely and legally. The aim of this study was to assess the 
quality of the development and reporting of these CPGs. Methods: In 
collaboration with the European Federation of IASP Chapters, a 
European inventory of CPGs was conducted. Inclusion criteria were at 
least one paragraph dedicated to the treatment of neuropathic pain 
in cancer. Using the Appraisal of Guidelines, Research and Evaluation 
II instrument, 2 appraisers independently assessed the quality of the 
development process of the included CPGs in 6 quality domains. 
Besides, CPGs developed by governmental organization were 
compared with those developed by professional societies using t-
tests. Results: Mean scores of the domains “scope and purpose” 
(80%) and “clarity of presentation” (61%) were satisfactory, 
“stakeholder involvement” (58%), “rigor of development” (57%), and 
“editorial independence” (53%) were acceptable, and “applicability” 
was insufficient (39%). Governmental guidelines had higher quality 
scores than professional society guidelines for domain “stakeholder 
involvement” and “editorial independence” (P < 0.01). Conclusions: 
The quality of the development process of the 9 included CPGs varied 
widely. CPGs should be developed within a structured guideline 
program, including methodological support. As developing a CPG is 
expensive and time-consuming, we recommend more international 
cooperation to increase quality and lower the development costs.  
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INTRODUCTION 
Pain is a common symptom in cancer patients. In Europe, 56% of 
cancer patients suffer from moderate to severe pain and 
consequently report difficulties in their daily activities and high 
impairment of their quality of life. (1) For adequate treatment of 
pain, it is important that both nociceptive and neuropathic pain is 
diagnosed, as they need different treatments.  
In 1986, the World Health Organization (WHO) published the “WHO 
analgesic ladder”, a tool for a stepwise pharmacological approach for 
the treatment of nociceptive pain in cancer patients. (2) This 3-step 
approach can be effective in approximately 80% of cancer patients. 
(3) Despite the introduction of this pain ladder and new analgesic 
pain therapies, the prevalence of pain in cancer patients remained 
around 50% during the past 40 years. (4) One of the possible reasons 
for incomplete pain relief may be the presence of neuropathic pain, 
because 40% of patients with cancer on opioid therapy referred to a 
specialized pain clinic appeared to have neuropathic pain alone or in 
combination with nociceptive or visceral pain. (5) No evidence-based 
algorithm for the treatment of neuropathic pain in cancer exists. In 
clinical practice, neuropathic pain is often treated with adjuvants like 
tricyclic antidepressants (amitriptyline or nortriptyline) or 
anticonvulsants (gabapentin or pregabalin). (6) The evidence for 
these types of drugs, based on number needed to treat (NNT 1.2–3.6) 
and number needed to harm (NNH 6–28), is mainly derived from 
research performed in patients with painful diabetic neuropathy or 
postherpetic neuralgia (PHN). (7–9) Little scientifically sound data are 
available to determine these figures for cancer patients with 
neuropathic pain. (10) Hence, the benefit vs. risk ratio for cancer 
patients might be worse for these antineuropathic drugs. 
Additionally, adjuvant drugs for the treatment of neuropathic pain 
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are frequently prescribed in combination with opioids, which can 
increase side effects. (6) Lastly, the mechanisms of neuropathic pain 
in patients with DPN or PHN are most likely more localized than in 
patients with cancer, which also may decrease the chance that these 
patients will benefit from the same symptomatic approach. (11) 
Clinical practice guidelines (CPGs) can contribute to effective and safe 
prescription. (12) Systematically developed guidelines can support 
the practitioner in making appropriate decisions. (13) 
Therefore, in this study, we assessed the quality of the development 
process of national CPGs, developed in European countries, which 
contain at least one section about neuropathic pain treatment in 
patients with cancer. While professional societies of medical 
specialists should be better informed about clinical aspects, 
organizations specialized in guideline development should be better 
equipped to guide the process of guideline development. We also 
studied whether such differences have consequences for the 
guideline development quality. 
METHODS 
Collection and Selection of Guidelines  
Guideline collection was conducted in 2 steps: (1) a review of the 
literature and (2) an email with a questionnaire to European pain 
experts. This second step was needed, as most of the guidelines are 
non-English and not published in scientific papers, and thus, a review 
in usual databases would not be sufficient to obtain all guidelines. 
For the review, we searched CPGs in MEDLINE in Europe containing 
at least one chapter on the management of neuropathic pain in 
patients with cancer. A literature search of the English and non-
English literature indexed in Ovid-Medline, Pubmed, Embase, Cinahl, 
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and the National Guideline Clearinghouse database in April 2010 was 
conducted using the following search strategy: “Practice Guideline” 
*Publication Type+ or “Guideline”  *Publication Type+ or “Guidelines as 
Topic” *Mesh+, “Neuralgia” *Mesh+, or “neuropathic pain” *All Fields+ 
and “Neoplasms” *Mesh+ or “cancer” *All Fields+. Exclusion criteria 
were studies on guidelines about children or the elderly, guidelines 
from non-European countries, and international guidelines (when at 
least 2 countries are represented in the development of the 
guideline). All articles about clinical practice guideline (CPG) on 
cancer pain or neuropathic cancer pain were included. Selection was 
carried out by titles, then by abstracts and finally by reading full text.  
For step 2, an invitation for collaboration with the European 
Federation of IASP Chapters (EFIC) was accepted by as well the past 
and the current president. The official EFIC (n = 34), and 
representatives of the NeuPSIG (Neuropathic Pain Special Interest 
Group of the IASP), all pain specialists (n = 32), were invited by email 
in March 2010 to mention and send current guidelines in their 
country that contain information about neuropathic pain treatment 
in cancer patients. In a second mail, they were invited to validate the 
collected documents. 
Inclusion and Exclusion Criteria 
Inclusion criteria for further analyses of the collected guidelines were 
(1) fulfillment of the definition of the Institute of Medicine for 
practice clinical guidelines and (2) having at least one paragraph 
dedicated to the treatment of neuropathic pain in cancer. (14) The 
search period was from January 2007 to March 2010. A CPG was 
excluded if (1) it was restricted to specific groups, for example, 
children or frail elderly; (2) it did not include systematically collected 
literature to support the recommendations; or (3) if it was published 
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after our inclusion time (March 2010). Each collected CPG was sent to 
the participant to check and validate our collection. 
Translation Process 
Each non-English included CPG was translated with the help of a 
translator toolkit and checked by the authors. All authors were fluent 
in English. VP, MLM, and KV are French-speaking and able to 
translate the French guidelines; AS, SV, JB, YE, YH are Dutch, YH is 
also fluent in Norwegian, and HK, fluent in German. Additional native 
speakers were contacted for CPGs in other languages.  
Assessment Tool: The AGREE II Instrument 
At least 2 authors independently scored included CPGs according to 
the Appraisal of Guidelines, Research and Evaluation II (AGREE II) 
instrument. (15,16) The AGREE II instrument is widely used to assess 
the quality of development and reporting of CPGs. It provides an 
appraisal of the predicted validity of a CPG, that is, the likelihood of a 
CPG to achieve its intended outcome. This internationally validated 
23-item instrument consists of 6 domains divided in items: (1) scope 
and purpose, which covers the overall aim of the guideline and target 
groups for whom the guideline is intended (3 items); (2) stakeholder 
involvement, which evaluates the appropriate stakeholders involved 
in guideline development and the views of its intended users (3 
items); (3) rigor of development, which assesses the selection of the 
evidence and the method to create recommendations (8 items); (4) 
clarity and presentation, which evaluates the structure and the 
format of the guideline (3 items); (5) applicability, which assesses 
facilitators and potential barriers for guideline implementation (4 
items); and (6) editorial independence, which covers biases 
concerning conflicts of interest (2 items) and one overall assessment 
item, judging whether the guideline ought to be recommended for its 
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use in clinical practice. Each item was rated by using a 7-point Likert 
scale (from 1 “strongly disagree” to 7 “strongly agree”). All CPGs 
were integrally assessed. 
Appraisers 
According to the AGREE protocol, 2 appraisers (VP and AS) 
independently assessed each guideline with AGREE II. They were 
trained in using the AGREE II instrument. Each item score needed to 
be explained by specific comments. Differences on items scores of 
more than 1 point on the Likert scale were discussed until consensus 
was obtained. If no consensus was reached on a specific item, a third 
appraiser (YE) assessed it independently, and the same procedure of 
consensus with 3 appraisers was carried out. 
Data Collection 
An item rating < 4 was considered low, ≥ 4 acceptable, and ≥ 6 high. 
Domain scores per CPG were calculated by summing up the AGREE II 
item scores and standardizing them as a percentage of the maximum 
possible domain score, according to the instructions within the 
instrument with this formula: [(score obtained-minimum score 
possible)/(maximum score possible-minimum score possible)] x 100. 
A domain score < 60 % was considered as low, ≥ 60% as acceptable, 
and ≥ 80% as high. 
Statistical Analysis 
All data were collected and analyzed with SPSS 16.0 (NY, USA) using 
descriptive statistics. Median item and domain scores were 
calculated. Finally, median domain scores of CPGs developed by 
organizations specialized in guideline development and CPGs 
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developed by professional bodies were calculated and compared 
using t-test. 
RESULTS 
Literature Review 
Selection on Title. The Embase search yielded 177 articles, of which 8 
were selected (Figure 1). Of the Medline search, another 16 of 203 
retrieved articles were selected. The Cinahl database contained 2 
articles, none being selected. A Pubmed search found 35 articles, of 
which 4 were selected. The National Clearing House search yielded 
467 articles, of which 20 were selected. 
Selection of Abstract. Of the 48 articles selected by titles, 6 were 
selected by the abstract, and 2 were duplicates. On this selection, 
only 1 was included: the SIGN 2008 guideline from the National 
Clearing House database. (17) 
CPG Collection via EFIC 
Sixty-two percent of the EFIC and NeuPSIG members responded. 
Fifty-four documents about pain (including pain in children and pain 
in elderly), neuropathic pain, and cancer pain were collected. Of 
these, 17 contained at least one section about neuropathic pain 
treatment in patients with cancer and were validated by the 
participants. Nine of these fulfilled the definition of a clinical practice 
guideline (CPG) and thus met all inclusion criteria (Figure 2). (17–25) 
Only one included guideline was in English. The other included 
guidelines were translated into English by the authors for the French 
and the Dutch guidelines. The Norwegian guidelines were translated 
into English with the help of the translator toolkit and checked by YH. 
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The Italian and Spanish guideline translations were checked by native 
speakers who are also fluent in English.  
For each item, consensus in rating was reached between the 2 
appraisers. Domain scores for the 9 CPGs are presented in Table 1. 
The overall median scores were 81% for “scope and purpose”, 58% 
for “stakeholder involvement”, 57% for “rigor of development”, 61% 
for “clarity and prescription”, 39% for “applicability”, and 53% for 
“editorial independence”. 
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Figure 1. Review of clinical practice guidelines (CPGs) concerning the 
treatment of neuropathic pain in cancer patients in Europe. 
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Figure 2. Flow chart: collection of European national Clinical Practice 
Guidelines (CPGs) from March to April 2010. 
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Table 1. Assessment of the Quality of the 9 Clinical Practice Guidelines About Neuropathic Cancer Pain Treatment 
with AGREE II Instrument Between 2005 and 2010 
*Guideline development group ** Local initiative of guideline development; A domain score <60% was considered as low, ≥ 60% as 
acceptable and ≥ 80% as high (in bold). 
Guidelines Scope and 
purpose 
Stakeholder 
involvement 
Rigor of 
development 
Clarity and 
presentation 
Applicability Editorial 
independence 
All guidelines 81 58 57 61 39  53 
Netherlands 
2008-I 
Diagnosis and 
treatment of pain in 
patients with cancer * 
95 95 96 75 43 100 
Norway 2009 Pain treatment 86 86 61 61 79 79 
United Kingdom 
2008 
Control of pain in 
adults with cancer * 
91 81 70 64 48 79 
France 2010 Chronic neuropathic 
pain  
86 48 80 71 29 64 
Spain 2008 Palliative care * 86 67 52 64 25 79 
Netherlands 
2008-II 
Pain in palliative care 95 57 32 64 39 29 
Italy 2008 Pain management in 
cancer 
81 24 52 54 21 14 
Norway 2007 Palliative care * 67 33 41 29 29 21 
Italy 2006 Control of cancer pain 
** 
41 29 32 64 39 14 
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The 4 CPGs developed by a guideline development organization 
(17,20,22,23) had higher domain scores than the 5 CPGs developed 
by a medical society. (18,19,21,24,25) The difference was significant 
(P < 0.05) for the domains “stakeholder involvement” and “editorial 
independence” (Table 2). 
 
 
Table 2. Comparison of CPGs developed by professional societies 
with CPGs developed by guideline development organizations 
Origin Professional 
society 
Guideline 
development 
organization 
P-value 
Scope and purpose 74 89 0.20 
Stakeholder involvement 38 82 <0.01 
Rigor of development 48 70 0.14 
Clarity and presentation 56 66 0.32 
Applicability 31 49 0.15 
Editorial independence 29 84 <0.01 
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All items in the domain “scope and purpose” as well as in the domain 
“clarity and presentation” had a median score of 6 or higher (Table 
3). In the domain “stakeholder involvement”, all CPGs included a 
clear definition of the target users (item 6); other items within this 
domain received lower median scores. In the domain “rigor of 
development”, the “formulation of health benefits and safety” (item 
11) was the only item with no scores < 4. The domain “applicability” 
received the lowest median scores, with 3 of 4 items lower than 3 for 
all CPGs except Norway 2009. 
In total, for all guidelines, all items of the domain “scope and 
purpose” and “clarity and presentation” had high median scores. 
Three of the 4 items included in the domain “applicability” had 
median scores < 4. 
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Table 3. Median AGREE II item scores of included 9 CPGs 
 
Item Median Range CI (95%) 
Scope and purpose 
Overall objective(s) of the guideline is (are) 
specifically described 
6 3 7 4.9-6.74 
Health question(s) covered by the guideline is 
(are) specifically described 
7 3 7 4.7-7.1 
The population to whom the guideline is meant to 
apply is specifically described 
6 2 7 4.1-6.4 
Stakeholder involvement     
Guideline development group included individuals 
from all the relevant professional groups 
5 2 7 3.4-6.4 
Views and preferences of the target population 
have been sought 
1 1 7 0.7-4.2 
Target users of the guideline are clearly defined 6 2 7 3.2-6.4 
Rigor of development     
Systematic methods were used to search for 
evidence 
2 1 7 1.4-5.5 
Criteria for selecting the evidence are clearly 
described 
4 1 7 1.9-5.2 
Strengths and limitations of the body of evidence 
are clearly described 
5 1 7 2.9-6.1 
Methods used for formulating the 
recommendations are clearly described 
5 2 6 3.1-5.6 
Health benefits, side effects and risks have been 
considered in formulating the recommendations 
6 4 7 4.9-6.2 
Explicit link between recommendations and 
supporting evidence 
3.5 1 7 2.0-5.2 
Guideline has been externally reviewed by 
experts prior to its publication 
2 1 7 1.2-4.6 
Procedure for updating is provided 5 1 7 2.2-6.2 
Clarity and presentation     
Recommendations are specific and unambiguous 6 2 7 4.6-7.0 
Different options for management of the 
condition are clearly presented 
6 4 7 5.1-6.7 
Key recommendations are easily identifiable 6 2 7 4.1-6.6 
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AGREE, Appraisal of Guidelines, Research and Evaluation II instrument; CPG, clinical 
practice guidelines, Item scores below or equal to 3: insufficient quality of 
development. CI confidence interval. 
 
  
Item Median Range CI (95%) 
Applicability     
Guideline described facilitators and barriers to its 
application 
2 1 5 1.1-3.4 
Guideline provides advice and/or tools on how the 
recommendations can be put into practice 
4 3 7 3.6-5.8 
Potential cost implications of applying the 
recommendations have been considered 
1 1 5 0.7-2.9 
Guideline presents monitoring and/or auditing 
criteria 
2 1 5 1.1-3.4 
Editorial independence     
The views of the funding body have not influenced 
the content of the guideline 
5 1 7 2.2-5.6 
Competing interests of guideline development 
group members have been recorded and 
addressed 
4 1 7 1.6-5.5 
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DISCUSSION 
Main Findings 
This is the first study that systematically assessed the quality of CPGs 
developed in European countries about the treatment of neuropathic 
pain in cancer patients. There was much variation in quality between 
the CPGs. 
High-scoring domains were “scope and purpose” and “clarity of 
presentation”, which is consistent with findings from other studies. 
(26–28) Applicability of the guideline was low in 8 CPGs, implying that 
anticipating on implementation needs more emphasis in CPGs to 
increase practitioners’ use. This confirms the findings from a recent 
qualitative study among general practitioners about barriers to use 
guidelines. (29) 
One of the factors that could explain differences between CPGs may 
be the organization responsible for the CPG. In our study, 2 of the 
CPGs with the highest AGREE II scores were developed by institutes 
specialized in guideline development. Both the Scottish 
Intercollegiate Guidelines Network and the Dutch Institute for 
Healthcare Improvement (CBO, the Netherlands) used a 
development process that was based on the original AGREE 
instrument. (17,23) Burgers et al., who assessed the quality of 86 
European and Canadian guidelines with the AGREE instrument, 
concluded that the quality of the development process of CPGs 
developed in a guideline program and by government agencies was 
higher than that of CPGs from other organizations. (12) A recent 
systematic review of Alonso-Coello et al. (26) analyzed studies 
assessing guidelines published between 1980 and 2007 with the 
AGREE instrument and found a higher development quality in 
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recently developed guidelines. In our assessment with AGREE II, we 
found higher median scores mainly on the purpose and clarity 
domains. Guideline developers became more aware of the 
importance and methods of a systematic development process, 
maybe partly by publications on this topic and the availability of the 
AGREE and AGREE II instrument. (28) 
Most CPGs gave no information about views and preferences of the 
target patient population and their influence on the development of 
the recommendations; only 3 CPGs had patients’ representatives in 
their workgroup (Netherlands 2008-I, U.K. 2008 and Norway 2009). 
Probably, more guidance is needed on how to involve patients in the 
guideline development process. (30) Furthermore; most CPGs gave 
no attention to the applicability and implementation, while this is 
very important for clinicians to use them. (31) 
Strengths and Limitations 
With the help of EFIC and NeuPSIG collaboration, we were able to 
obtain an extensive overview of guidelines that contain information 
about neuropathic pain in cancer patients, and it was possible to 
overcome the obstacles of gray literature. We used AGREE II, the 
updated version of the AGREE instrument. AGREE II, which uses a 7-
point Likert scale (instead of the 4-point Likert scale in the AGREE 
instrument), improves the reliability of the item and domain scores. 
(15, 16) This instrument was used recently for the assessment of 
guidelines for migraine and gave a good overview of the 
development of guidelines in pain. (32) 
Although neuropathic pain in cancer patients is a worldwide problem, 
we only assessed European CPGs. The main reason for this restriction 
was the opportunity to collaborate with the EFIC and NeuPSIG, which 
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helped us to collect information from 30 of the 38 European 
countries. Second, we did not find a CPG merely dedicated to the 
treatment of neuropathic pain in cancer patients. Third, in contrast to 
other studies, we also included guidelines that were not written in 
the native language of the researchers. With the translator toolkit, 
we were able to assess also these 5 CPGs after validation of the 
translation by native or fluent speakers. 
Finally, results of the AGREE II assessment should be interpreted with 
caution. Using information only available in the CPG may limit the 
validity of the scores. Besides, AGREE II focuses on the methods and 
reporting of the guideline, but does not assess the validity of the 
diagnosis, medical content, and clinical recommendations. (33) In 
perspective, the comparison of the content of the guidelines could be 
very interesting for our knowledge about neuropathic pain in 
patients with cancer and its management in Europe. 
 
CONCLUSIONS AND RECOMMENDATIONS 
The quality of CPGs on neuropathic cancer pain is modest. All 
domains and items showed room for improvement in most CPGs. Yet, 
3 items need specific attention in future guideline development 
about this topic: incorporating the patients’ views, describing the 
systematic review process, and giving recommendations about the 
implementation of the CPG. We did not find a CPG merely dedicated 
to the treatment of neuropathic pain in cancer patients. Yet, this 
clinical problem in this specific patient group concerns an area of 
medical uncertainty, iatrogenic complications, and interventions 
carrying significant risks and costs, and therefore fits into the criteria 
for creating an independent CPG. (14) It implies that (1) CPG 
developers should emphasize that the scientific evidence is weak and 
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should be interpreted with caution and (2) there is a need for more 
research on neuropathic cancer pain patients to provide evidence for 
more reliable CPGs. As developing guidelines is time-consuming and 
expensive, international cooperation in CPG development could be a 
solution to increase quality and reduce costs. (34) 
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Abstract 
Background: Neuropathic pain is a prevalent symptom in patients 
with cancer, which needs a more specific algorithm than nociceptive 
pain or neuropathic pain from other origin. Clinical practice 
guidelines (CPGs) can be helpful in optimizing the diagnosis of 
neuropathic pain in patients with cancer. Methods: In this study, 9 
national CPGs in Europe on the diagnosis of neuropathic pain in 
patients with cancer were included. Recommendations with their 
grade (according SIGN 55 classification) and supporting literature 
(first author, patients’ population, year, and type of publication) were 
compared between CPGs. Results: Nine CPGs including 
recommendations on neuropathic pain could be selected and were 
assessed. In total, they used 149 references of which 72 (48%) were 
about cancer conditions, 39 (26%) about neuropathic pain, and only 3 
about neuropathic pain in patients with cancer (2%). Only 28 (19%) 
references were shared between 2 or more guidelines. There was 
only one shared reference specifically related to cancer neuropathic 
pain. Recommendations and their evidence grading strongly differ 
between CPGs. Conclusion: This work demonstrates an important 
heterogeneity between European recommendations on diagnosis 
and assessment of neuropathic pain in patients with cancer. The 
main weaknesses are the low level of evidence and the absence of 
specific data focusing on neuropathic pain in patients with cancer. 
We recommend that physicians dealing with neuropathic pain in 
patients with cancer should be specially trained, that a specific 
methodology to develop CPGs should followed, and that specific 
research should be developed on the diagnosis of neuropathic pain in 
patients with cancer. 
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INTRODUCTION 
In Europe, about 56% of patients with cancer suffer at least monthly 
from moderate to severe pain, causing difficulties in their daily 
activities. (1,2) In this context, pain is frequently neuropathic (19–
39%) with 3 etiologies: cancer-related neuropathic pain, cancer-
therapy induced neuropathic pain, and cancer-associated 
neuropathic pain. (3–6) Like neuropathic pain in general, neuropathic 
pain in patients with cancer proves to be difficult to treat and is more 
distressing than nociceptive pain. (3,7) Therefore, neuropathic pain is 
a considerable problem for patients with cancer, and its prevalence 
will increase as the global prevalence and incidence of cancer 
increase. (8) The diagnosis of neuropathic pain in patients with 
cancer is essential to (1) possibly detect the cause of cancer in an 
early state, (2) avoid or diminish neurotoxic events after oncological 
treatment; especially when chemotherapy is given, and (3) facilitate a 
mechanistically based approach, and (4) propose the optimal pain 
treatment. (6,9,10) Until now, no gold standard for the diagnosis of 
neuropathic pain has been accepted. The neuropathic nature of a 
pain complaint is diagnosed clinically with the evidence of a lesion or 
disease of the somatosensory system, primarily from history and 
clinical examination. (11,12) Several screening instruments, such as 
the McGill Pain Questionnaire, S-LANSS, Neuropathic Pain 
Questionnaire, DN4, Pain-DETECT, ID Pain, and StEP, have not been 
specifically validated in patients with cancer. (13–19) 
To guide practitioners through a structured diagnosis of neuropathic 
pain in patients with cancer, clinical practice guidelines (CPGs) were 
created as “statements that include recommendations intended to 
optimize patient care that are informed by a systematic review of 
evidence and an assessment of the benefits and harms of alternative 
care options.” (20) The aim of this study is to evaluate and compare 
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recommendations proposed in national CPGs from Europe 
concerning the specific diagnosis of neuropathic pain in patients with 
cancer and their evidence grading. 
METHOD 
Selection of CPGs 
The description of the selection of the CPGs was published in a recent 
article. 21 Nine CPGs from France (France 2010), Italy (Italy 2006, Italy 
2009), the Netherlands (Netherlands 2008-I, Netherlands 2008-II), 
United Kingdom (United Kingdom 2008) were included and used for 
this study. (22-26, 30) Four were developed by national supported 
organization such as the Scottish Network of Guidelines Network 
(SIGN), the Dutch Institute for Healthcare Improvement (CBO), the 
Spanish National Plan (Guias de practica clinica en el SNS, Ministerio 
de Sanidad y Consumo), and the Norwegian national program for 
Palliative Care. (25,27,29,30) Five were developed by a professional 
society (palliative care, oncology, or national pain 
society),(22,24,26,28,29) and 1 was developed by an Italian regional 
health organization. (23) All CPGs were on pain or palliative care 
management in patients with cancer except France 2010, which was 
related to neuropathic pain management in general and Norway 
2009, which was about pain management in general. 
Collection of the data and analysis 
We developed a procedure aimed to extract recommendations 
regarding the diagnosis and assessment of neuropathic pain in 
patients with cancer and their related references used as evidence in 
the CPG. Recommendations were defined as “statements that 
promote or advocate a particular course of action in clinical care”. 
(31) This process was performed in each CPG. Recommendations 
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were collected according to the diagnosis algorithm recommended 
by NeuPSIG (special interest group on neuropathic pain) and 
classified in 2 main domains with different sub-domains. (32) The first 
was the working hypothesis of a possible neuropathic pain if pain 
distribution is neuroanatomically plausible and history suggests 
relevant lesion or disease (3 sub-domains: pain intensity assessment; 
neuropathic pain screening tools use; and etiological context 
assessment). 
The second was the use of confirmatory tests in 4 sub-domains: 
negative (i.e., hypoesthesia) or positive (i.e., allodynia) sensory signs, 
confined to the innervations territory of the lesioned nerve, pain 
drawing for neuroanatomical plausibility, quantitative sensory tests 
(QST), diagnosis test confirming lesion, or disease explaining 
neuropathic pain. The final criterion for the diagnosis of neuropathic 
pain was an incomplete response to opioid treatment. For each 
domain, we collected the grade of recommendation given by CPGs 
authors according to the SIGN-50 criteria. (22) (Table 1) 
We performed a focused analysis of references related to the 
selected recommendations. These references were classified in 5 
categories: (1) “clinimetric studies” to validate the diagnosis tools 
according Feinstein’s definition, (2) “clinical studies” to evaluate the 
use of diagnosis tools in daily clinical practice, (3) “epidemiological 
studies”, (4) “clinical practice guidelines” (CPGs), and (5) “other 
studies”. (20, 32-33) Each reference was also classified according to 
country of the first author and/or of the work group, journal, and 
year of publication, and reference topic (cancer pain, acute and 
chronic pain, neuropathic pain, neuropathic cancer pain, and pain 
impairment). A reference used in at least 2 CGP was called a shared 
reference.  
Statistical analysis 
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Analysis was performed with SPSS 16.0 using descriptives and 
frequencies.  
 
Table 1a. Key to evidence statements according SIGN 50 
 
LEVELS OF EVIDENCE 
Level Description 
1++ High quality meta-analyses, systematic reviews of RCTs, or RCTs with 
a very low risk of bias 
1+ Well-conducted meta-analyses, systematic reviews, or RCTs with a low 
risk of bias 
1- Meta-analyses, systematic reviews, or RCTs with a high risk of bias 
2++ High quality systematic reviews of case control or cohort or studies 
High quality case control or cohort studies with a very low risk of 
confounding or bias and a high probability that the relationship is 
causal 
2+ Well-conducted case control or cohort studies with a low risk of 
confounding or bias and a moderate probability that the relationship is 
causal 
2- Case control or cohort studies with a high risk of confounding or bias 
and a significant risk that the relationship is not causal 
3 Non-analytic studies, e.g. case reports, case series 
4 Expert opinion 
 
Extracted from the SIGN website on 31-Jui-2012 in this URL: 
http://www.sign.ac.uk/guidelines/fulltext/50/annexb.html  
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Table 1b. Key to grades of recommendations according SIGN 50 
 
GRADES OF RECOMMENDATIONS 
GRADE DESCRIPTION 
A At least one meta-analysis, systematic review, or RCT rated as 1++, 
and directly applicable to the target population; or A body of 
evidence consisting principally of studies rated as 1+, directly 
applicable to the target population, and demonstrating overall 
consistency of results 
B A body of evidence including studies rated as 2++, directly 
applicable to the target population, and demonstrating overall 
consistency of results; or Extrapolated evidence from studies rated 
as 1++ or 1+ 
C A body of evidence including studies rated as 2+, directly applicable 
to the target population and demonstrating overall consistency of 
results; or Extrapolated evidence from studies rated as 2++ 
D Evidence level 3 or 4; or Extrapolated evidence from studies rated 
as 2+ 
GODD 
PRACTICE 
POINTS 
Recommended best practice based on the clinical experience of the 
guideline development group 
 
Extracted from the SIGN website on 31-Jui-2012 in this URL: 
http://www.sign.ac.uk/guidelines/fulltext/50/annexb.html  
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RESULTS 
Pages specifically dedicated to the diagnosis of neuropathic pain in 
patients with cancer  
The 9 included CPGs represented 1480 pages with only 76 (5%) pages 
focused on the diagnosis of neuropathic pain in patients with cancer. 
This specific part represented <10% of the whole guideline in 8 of 9 
included CPGs with a range from 1/24 pages (0.8%) in Norway 2009 
to 39/170 pages (23%) in France 2010. 
Characteristics of the references related to recommendations 
selected in the “neuropathic pain in patients with cancer” diagnosis 
and assessment section of CGPs 
Our work collected a total of 149 references related to 
recommendations selected in the “neuropathic pain in patients with 
cancer” diagnosis and assessment section of CPGs. Among these, 72 
(48%) were about cancer pain, 39 (26%) on acute and chronic pain, 
26 (18%) on neuropathic pain, 9 (6%) on pain impairment (emotional 
impact and quality of life), and only 3 (2%) specifically about 
neuropathic pain in patients with cancer. Category references were 
as follows: 46 clinimetric studies (31%), 37 clinical studies (25%), 12 
epidemiological studies (8%), 28 CPGs (19%), and 26 others studies 
(17%). In terms of topic and categories, distribution of references was 
similar considering each CGP individually (data not shown). Only 28 
(19%) of the 149 references were shared between at least two 
guidelines, 20 shared by two guidelines, 5 by three guidelines, 2 by 
four guidelines, and 1 by five guidelines. (34) Considering the seven 
references mentioned in at least three guidelines, 3 were used in a 
cancer population and 2 in a chronic pain population (one of them in 
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a neuropathic pain population). (34–40) There was only one shared 
reference specifically related to neuropathic pain in patients with 
cancer (Table 2). (41)  
 
The country of the first author of the references according to the 
origin of the CPG The proportion of references originating of the 
same country as the CPG varied from 0 (Spain 2008) to 57% (Norway 
2009). Half of the references had a US origin (Table 3). 
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Table 2. Characteristics of the references related to recommendations selected in the “neuropathic pain 
in patients with cancer” diagnosis and assessment section of CGP. 
 
Legend: CPG= Clinical Practice Guideline
 a
 Clinimetrics: to validate diagnosis tool, meeting the Feinstein’s criteria; b 
clinical studies: to evaluate the use of diagnosis tools in daily clinical practice; 
c 
shared references = number of references 
which are mentioned in at least 2 guidelines. Other: psychological impairment studies, quality of life studies. 
Reference topic Number of 
references 
Range of  
publication 
year 
References categories Shared 
reference
s c 
Clinimetric 
studies 
a 
Clinical 
studies 
b
 
Epidemiological 
studies 
CPG Other 
studies
 
Cancer pain 72 1980-2009 16 18 10 15 11 18  
Acute and 
chronic pain 
39 1974-2007 15 14 1 1 8 7  
 
Neuropathic 
pain 
26 1990-2010 11 4 1 7 3 2  
 
Neuropathic 
cancer pain 
3 2004-2007 1 0 0 0 2 1 
 
Pain impairment 9 1985-2007 3 1 0 5 0 0 
Total 149 1974-2010 46 37 12 28 26 28 
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Table 3. The country of the first author of the references according to the origin of the CPG 
Guidelines 
a 
Total France Italy Neth
 
Norway Spain UK
 
USA
 
Denmark
 
Canada Germany Other
b 
France 2010 54 19 (35) 1 (2) - (-) - - 5 (9) 23 (43) 3 (6) - 2 (4) 1 (2) 
Italy 2009 23 - 3 (13) - 3 (13) - 2 (9) 10 (43) 4 (18) 1 (4) - - 
Italy 2006 23 1 (4) - - - - 5 (22) 14 (61) - - 2 (9) 1 (4) 
Netherlands 
2008-I 
32 - 5 (16) 3 (9) 1 (3) - 2 (6) 12 (38) 1 (3) 2 (6) 1 (4) 1 (4) 
Netherlands 
2008-II 
14 - 2 (14) 4 (29) - - - 7 (50) 1 (7) - - - 
Norway 
2009 
7 - - - 4 (57) - - 3 (43) - - - - 
Norway 
2007 
7 1 (14) - - 1 (14) - 2 (29) - 1 (14) 1 (14) - 1 (14) 
Spain 2008 4 - - - - - 1 (25) 2 (50) - 1 (25) - - 
UK 2008 22 1 (5) 2 (8) 2 (8) 1 (5) - 2 (9) 9 (41) - 1 (5) 1 (5) 3 (14) 
Total 149 19 (13) 7 (5) 7 (5) 8 (5) 0 14 (9) 65 (44) 9 (6) 5 (3) 5 (3) 10 (7) 
 
Legend: Neth= the Netherlands, UK=United Kingdom, USA=United States of America. a Bold types contain 
percent of citations of studies from authors of the same country as the origin of the CPG b Other= Australia, 
China, Finland, Greece, India, Ireland, Japan and Switzerland. 
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Diagnosis and assessment of neuropathic pain in patients with 
cancer recommendations and their evidence grading in CPGs  
Recommendations on how to perform a pain intensity assessment 
were mentioned in all CPGs except Norway 2009. The systematic use 
of neuropathic pain screening tools was recommended in 2 
guidelines: the DN4 in the French CGP and the NPQ in the Dutch one 
(Netherlands 2008-I 1). The assessment of the etiological context 
(neuropathic pain due to nerve damage, by the cancer itself or 
related to the surgery, chemotherapy, or radiation) was 
recommended in all CPGs except the Italian CPG of 2009. The 
description of the pain with negative signs (i.e., hypoesthesia) or 
positive signs (i.e., allodynia) was recommended in 4 CPGs: France 
2010, Netherlands 2008-I, Netherlands 2008-II, and Norway 2009. 
Pain drawings were recommended in 3 CPGs (France 2010, Norway 
2007, and Norway 2009). 
Quantitative sensory testing (QST) was also recommended in 2 CPGs 
(France 2010 and Norway 2007). Search of a partial response to 
opioids treatment was recommended in 4 CPGs (Italy 2006, 
Netherlands 2008-II, Spain, and United Kingdom). The grade of 
recommendation was mentioned in 6 of the 9 guidelines for the 
working hypothesis and varied from grade A to grade D. The grade 
was also proposed in the confirmatory tests in the CPG for France 
2010 (grade D) and Netherlands 2008-I (grade B). The grade for the 
partial response to opioids in neuropathic pain was A for United 
Kingdom and B for Spain (Table 4).  
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Table 4a. Diagnosis and assessment of neuropathic pain in patients with cancer recommendations and their evidence grading in CPGs. 
Guidelines France 
2010 
Italy 
2009 
Italy 
2006 
Netherlands 
2008-I 
Netherlands 
2008-II 
Elements proposed to make a diagnosis of neuropathic pain 
1) Working hypothesis: possible neuropathic pain if pain distribution is neuroanatomically plausible and history suggests 
relevant lesion or disease. 
Pain intensity assessment + + + + + 
Neuropathic pain screening tools use +(DN4) - - +(NPQ) - 
Etiological context assessment + - + + + 
Grade of recommendation given by the developers +(A) +(A) +(B) +(B) - 
2) Confirmatory tests. 
Negative or positive sensory signs, confined to 
innervations territory of the lesioned nervous structure 
+ - - + - 
Pain drawing for neuroanatomical plausibility + - - - - 
Quantitative sensory tests + - - - - 
Diagnosis test confirming lesion or disease explaining 
neuropathic pain 
- - - - +(MRI, EMG) 
Grade of recommendation given by the developers +(D) - - +(B) - 
Neuropathic pain diagnosis and treatment response 
Neuropathic pain can respond to opioids although the 
response may be incomplete 
- - + - + 
Grade of recommendation given by the developers  - - - - - 
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Table 4b. Diagnosis and assessment of neuropathic pain in patients with cancer recommendations and their evidence grading in CPGs. 
Legend: X: information presented in the guideline. Grade of recommendation according SIGN 50: A (studies with a level of evidence of 1), B (studies with a level of 
evidence of 2 or extrapolate studies with a level of 1), C (extrapolate studies with a level of evidence of 2) D (studies with a level of 3 or 4). +, information present; -, 
information absent; QST, Quantitative Sensitive Test; cMRI, cerebral Magnetic Resonance Imaging; EMG,  ElectroMyoGramme; SEP, Somatosensitive Evoked 
Potentials. *The topic of the guideline concerned specifically the treatment of pain in cancer and not the diagnosis. 
Guidelines Norway 2009 Norway 2007* Spain 
2008 
United-Kingdom 
2008 * 
Elements proposed to make a diagnosis of neuropathic pain 
1) Working hypothesis: possible neuropathic pain if pain distribution is neuroanatomically plausible and history suggests relevant lesion or disease. 
Pain intensity assessment - + + + 
Neuropathic pain screening tools use - - - - 
Etiological context assessment + + + + 
Grade of recommendation given by the developers - - +(C) +(D) 
2) Confirmatory tests. 
Negative or positive sensory signs, confined to innervations territory of the 
lesioned nervous structure 
+ - - - 
Pain drawing for neuroanatomical plausibility + + - - 
Quantitative sensory tests - + - - 
Diagnosis test confirming lesion or disease explaining neuropathic pain - +(MRI, EMG, SEP) - - 
Grade of recommendation given by the developers - - - - 
Neuropathic pain diagnosis and treatment response 
Neuropathic pain can respond to opioids although the response may be 
incomplete 
- - + + 
Grade of recommendation given by the developers  - - + (B) + (A) 
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DISCUSSION 
In our previous study, from 54 national guidelines on neuropathic 
pain in cancer, 9 were selected with an acceptable level of quality. 21 
In these 9 national CPGs from Europe, 149 references were collected 
to argue recommendations on neuropathic pain diagnosis and 
assessment in patients with cancer. A large majority of references 
were not specifically related to neuropathic pain in patients with 
cancer. Hence, recommendations were made according to 
nonspecific data, extrapolated from references on cancer pain 
regardless of the neuropathic pain mechanism and references on 
neuropathic pain regardless on the cancer context. Only 3 (2%) of 
references used recommendations on neuropathic pain diagnosis and 
assessment in cancer and focused on neuropathic pain in patients 
with cancer. Regarding the range of the year of publication, these 
specific references appear to be more recent than the others. These 
data are in accordance with the recent interest of neuropathic pain in 
cancer field. (6) Moreover, our work demonstrates that only 19% of 
shared references in spite of the open criteria chosen (presence of 
reference in at least 2 CPGs) to define a shared reference. Such a 
data is in accordance with the weak level of the “Rigor of 
development” domain according the AGREE II evaluation of the 
selected CPGs. (21) 
The weakness of selected CPGs also concerned the details of 
proposed recommendations. Considering criteria used in the 
diagnosis algorithm recommended by NeuPSIG, proposed 
recommendations of national CPGs in Europe appear too general for 
a proper diagnosis of neuropathic mechanism in pain occurring in 
cancer context. (32) Consequently, these findings probably explain 
the heterogeneity of the evidence grading in these guidelines. 
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In spite of the limitation of our work detailed, results confirmed the 
need to consider with caution the recommendations proposed in 
Europe about the neuropathic pain in patients with cancer diagnosis 
and assessment. (21) Firstly, practitioners’ specific education should 
be promoted to develop the capacity to evaluate the evidence level 
of CPGs and to participate actively in their editorial board with 
methodologists. Secondly, efforts should be made to ensure that 
CPGs developers describe the extrapolation process when 
recommendations are not focused on the target population studies. 
Thirdly, efforts should also be realized in clinical research to obtain 
robust data on diagnosis and assessment of neuropathic pain in 
patients with cancer allowing the development of specific 
recommendations on this topic. This prospect would best be 
considered through international cooperation and regular updates. 
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Abstract 
 
Introduction: Neuropathic pain is a common symptom, present in 
39% of the patients with cancer pain. Treating this type of pain is 
challenging, as this patient group is often frail and has comorbidities 
which increase the risk of side events and hence influences their 
quality of life. Clinical practice guidelines (CPGs) can be helpful for 
clinicians, especially when scientific evidence is uncertain or weak. In 
this study, we focused on the quality of the review of the literature 
used in treatment recommendations in the selected European CPGs. 
Methods: In a previous study, 9 CPGs from European countries that 
contained at least one paragraph on treatment for neuropathic pain 
in cancer were included. Recommendations with their grade 
(according SIGN 55 classification) and supporting literature (first 
author, patients’ population, year and type of publication) were 
compared between CPGs. Results: In all CPGs, amitriptylin was 
mentioned as the drug of first choice. Six guidelines proposed also 
gabapentinoids. Only 30 of the 163 citations (18%) were based on 
studies in patients with cancer. Seven CPGs did not argue the indirect 
evidence due to extrapolation of study results from non-cancer to 
patients with cancer. Conclusion: The majority of guideline 
development groups extrapolated their results to formulate 
recommendations from non-cancer publications. Consequently, 
these guidelines fail to address important issues such as altered 
kinetics and side effect profiles in these patients. We recommend 
creating specific recommendations by an international expert group 
for the treatment for neuropathic pain in patients with cancer 
supported by targeted research in patients with cancer.  
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INTRODUCTION 
In Europe, the prevalence of moderate to severe pain in patients with 
cancer is about 56%. (1) Pain in patients with cancer is often related 
to a combination of nociceptive and neuropathic mechanisms. In a 
systematic review of Bennett, the prevalence of neuropathic pain in 
patients with cancer was found to be 19%. The combination of mixed 
pain (nociceptive pain) was found to be 39.7%. (2) Using the World 
Health Organization (WHO), analgesic ladder for cancer pain relief 
resolves the nociceptive component in 80% of the treated patients. 
However, the neuropathic pain component is often more difficult to 
treat. (3) Not all drugs are specifically registered for the treatment for 
neuropathic pain in patients with cancer in European countries. This 
implies that most specific drugs used for the treatment for 
neuropathic pain in patients with cancer are used off-label. (4) Most 
clinical research concerning neuropathic pain treatment is performed 
in patients with diabetic painful neuropathy (DPN) or post-herpetic 
neuropathy (PHN) and infrequently in patients with neuropathic 
cancer pain. Patients with cancer suffering from neuropathic pain 
should be considered different from patients with neuropathic pain 
in other context for several reasons. (5) Firstly, approximately 50% of 
the patients with cancer suffering from neuropathic pain also have 
nociceptive or visceral pain, in contrast to patients suffering from 
neuropathic pain in another context. (6) Secondly, they are more 
fragile with a potential life-threatening disease. Thirdly, in patients 
with cancer, the effect size of antiepileptic or antidepressant drug, 
used in addition to the opioids, is less than that seen in patients with 
non-cancer neuropathic pain. (2)  
Clinical practice guidelines (CPGs) were created to improve the 
treatment for a specific condition and are supposed to be based on 
the latest evidence. Concerning neuropathic pain in patients with 
cancer, a recent statement of the International Association for the 
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Study of the Pain (IASP) emphasized that the extrapolation of data 
from studies of other neuropathic conditions to patients with cancer-
induced neuropathic pain is far from straightforward. (5) In parallel of 
the evaluation of recommendations on neuropathic pain diagnosis 
and assessment in patients with cancer, (7) the aim of this study is to 
compare recommendations proposed in national CPGs from Europe 
concerning the treatment for neuropathic pain in patients with 
cancer and their evidence grading. 
 
METHODS 
Study Design 
The relation between chosen references, their level of evidence, and 
the recommendations given in CPGs was systematically studied. 
 
Selection of Guidelines 
A European inventory of CPGs was performed with the support of the 
European Federation of the IASP Chapters (EFIC). (7) Nine CPGs were 
included, and this material was used for this study. All CPGs were 
published between 2006 and 2009 from France (1), Italy (2), the 
Netherlands (2), Norway (2), Spain (1), and the United Kingdom (1). 
(8–16) Four were developed under responsibility of a national 
organization specialized in guideline development. (9,12,14,15) Five 
were developed by professional societies (oncology, palliative care, 
or pain societies). (8,10,11,13,16) One was developed by an Italian 
regional health organization (Italy 2). (8) None of the guidelines were 
developed solely or specifically for the treatment for neuropathic 
pain in patients with cancer. 
 
Collection of the Data and Analysis 
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We developed a procedure to extract recommendations about how 
to treat neuropathic pain in patients with cancer. Recommendations 
were defined as “statements that promote or advocate a particular 
course of action in clinical care”. (17) These treatment 
recommendations were extracted together with the related 
references and used as evidence in each CPG. The references were 
categorized by study design (meta-analysis and systematic review; 
randomized controlled trial [RCT] with ≥ 60 patients; RCT with < 60 
patients; CPG; other) and topic (neuropathic pain, cancer neuropathic 
pain, cancer pain, acute and chronic pain, and other). Each reference 
was also considered according to the country of the first author 
and/or of the work group, journal, and year of publication. A 
reference used in at least two CPGs was a shared reference.  
Recommendations were analyzed considering drugs proposed to 
treat neuropathic pain in patients with cancer in each CPG. We 
focused our analysis on three main drugs: amitriptyline; gabapentin; 
and pregabalin. For each of these three drugs, we collected 
positioning in therapeutic strategy (first or second line), start and 
maximum doses, titration scheme, mentioned side effects and 
contra-indications, the level of evidence, and the grade of the 
recommendation, according to the Scottish intercollegiate guidelines 
network (SIGN) 50 criteria.(13)  
 
Statistical Analysis 
Analysis was performed with SPSS 16.0 using descriptives and 
frequencies. 
 
RESULTS 
Pages Specifically Dedicated to the Treatment for Neuropathic Pain 
in Patients with Cancer 
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The nine included CPGs represented 1,480 pages with only 53.5 (4%) 
pages focusing on the treatment for neuropathic pain in patients with 
cancer. The sections about the treatment for neuropathic pain in 
patients with cancer ranged between half a page (Spain) to 37 pages 
(France) (0.2% to 22%, mostly bellow 5%). 
 
Characteristics of the References Related to Recommendations 
Selected in the “Neuropathic Pain in Patients with Cancer” 
Treatment Section of CPG  
Our work collected a total of 163 references related to 
recommendations selected in the “neuropathic pain in patients with 
cancer” treatment section of CPGs. Among these, a majority 
(116/163: 71%) were about neuropathic pain in non-cancer context. 
Eighteen (11%) references concerned specifically neuropathic pain 
treatment in patients with cancer (Table 1). A large majority (80%) of 
references were related to RCTs and meta-analysis, systematic 
review, or review. According to SIGN-50, 50 references (31%) could 
be classified as top evidence level (15 systematic reviews and 35 RCTs 
with a high number of patients).  
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Table 1. Description of clinical practice guidelines and characteristics of the references mentioned in the 
section treatment of neuropathic pain in patients with cancer. 
Legend: a SR+R= systematic review, meta-analysis and review; b RCT ≥ 60= randomized controlled trial with 60 
or more patients cRCT < 60 = randomised controlled trial with less than 60 patients; d CPG= clinical practice 
guideline; e Other = cohort study, observational study, case report, local statement; f shared references = 
number of references which are mentioned in at least 2 guidelines. 
Reference topic Number of 
references 
Publication 
year 
Publication type Shared 
references
f
 
SR+R
a 
RCT ≥ 60
b
 RCT <60
c
 CPG
d
 Other
e 
Neuropathic pain 
 
116 1969-2007 20 34 49 8 5 22 
 Cancer neuropathic 
pain 
 
18 1992-2008 4 1 8 0 5 4 
 Cancer pain
 
14 1980-2007 4 0 4 3 3 1 
 Acute and chronic 
pain
 
11 1999-2007 4 0 1 4 2 0 
 Other 4 2000-2004 2 0 0 0 2 3 
Total 163 1969-2008 34 35 62 15 17 30 
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Table 2. Neuropathic pain treatment in cancer references in nine national CPGs from European countries. 
Year Publication 
type
 
Title of the reference First 
author 
Publication Shared 
references 
2008 RCT, 44
a
 Amitriptyline in the treatment of chemotherapy-induced 
neuropathic symptoms. 
Kautio J Pain Symptom 
Manage 
- 
2007 RCT, 36 Tramadol in the treatment of neuropathic cancer pain: a double-
blind, placebo-controlled study. 
Arbaiza Clin Drug Investig - 
2007 Clinical 
trial, 65 
Gabapentin and an opioid combination versus opioid alone for the 
management of neuropathic cancer pain: a randomized open trial. 
Keskinboa J Pain Symptom 
Manage 
+(2 CPGs) 
2006 Review How to use antidepressants and anticonvulsants as adjuvant 
analgesics in the treatment of neuropathic cancer pain.  
McDonald J Support Oncol - 
2005 Clinical 
trial, 62 
Gabapentin is effective in the treatment of cancer-related 
neuropathic pain: a prospective, open-label study. 
Ross J Palliat Med - 
2004 RCT, 121 Gabapentin for neuropathic cancer pain: a randomized controlled 
trial from the Gabapentin Cancer Pain Study Group. 
Caraceni J Clin Oncol + (4 CPGs) 
2004 Review Adjuvant analgesics in cancer pain management.  Lussier Oncologist - 
2003 Systematic 
review 
Ketamine as an adjuvant to opioids for cancer pain. Bell J Pain Symptom 
Manage 
- 
2002 RCT, 16 Amitriptyline in neuropathic cancer pain in patients on morphine 
therapy: a randomized placebo-controlled, double-blind crossover 
study. 
Mercadente Tumori +(2 CPGs) 
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Legend: RCT: randomized controlled trial, CPGs: clinical practice guidelines. 
a
number of patients included in the trial 
 
Year Publication 
type
 
Title of the reference First 
author 
Publication Shared 
references 
2002 RCT, 51 Phase III evaluation of nortriptiline for alleviation of symptoms of 
cis-platinum induced peripheral neuropathy 
Hammack Pain - 
2002 RCT, 13 Venlafaxine in neuropathic pain following treatment of breast 
cancer. 
Tasmuth Eur J Pain - 
2001 Case report Gabapentine for pain control in cancer patients ‘wound dressing 
care 
Devulder J Pain Symptom 
Manage 
- 
1999 Clinical 
trial, 593 
Assessment and treatment of neuropathic cancer pain following 
WHO guidelines. 
Grond Pain - 
1999 Clinical 
trial, 22 
Gabapentin as an adjuvant to opioid analgesia for neuropathic 
cancer pain. 
Caraceni J Pain Symptom 
Manage 
+(2 CPGs) 
1997 Review Neuropathic pain in cancer patients: mechanisms, syndromes, and 
clinical controversies. (22) 
Martin J Pain Symptom 
Manage 
- 
1992 RCT, 25 Phenytoin as a co-analgesic in cancer pain. Yajnik J Pain Symptom 
Manage 
- 
1992 RCT, 11 A randomized double blind cross over trial of intravenous lidocaïne 
in the treatment of neuropathic cancer pain 
Bruera Cancer Treat Rep - 
1989 RCT, 10 Trial of intravenous lidocaïne on painful neuropathy in cancer 
patients. 
Elleman Clin J Pain - 
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Only 30 (18%) of the 163 references were shared between at least 
two guidelines: 21 shared by two guidelines; four by three guidelines; 
four by four guidelines; and only one by five guidelines. References 
specifically related to neuropathic pain in patients with cancer are 
presented in Table 2. Among these references specifically related to 
neuropathic pain in patients with cancer, only four were shared by at 
least two references. 
Treatment for Neuropathic Pain in Patients with Cancer 
Recommendations and Their Evidence Grading in CPGs 
Drugs recommended in selected CPGs are presented in Table 3. 
Among these, only three classes were recommended by all CPGs: 
tricyclic antidepressant drugs; α2δ agonists; and other anticonvulsant 
drugs. SNRI antidepressant drugs were recommended by four CPGs 
(France 2010, Italy 2009, Norway 2007, and Spain). Strong opioids, in 
combination with co-analgesic, were proposed by five CPGs (France 
2010, Italy 2009, the Netherlands 2008-I, Norway 2007, and Spain). 
However, the Netherlands 2008-II recommended not using them, and 
three CPGs did not mention them (Italy 2006, U.K., and Norway 
2009). Capsaicin plaster was recommended by five guidelines (France 
2010, the Netherlands 2008-I, Norway 2007, Spain, and U.K.) and not 
mentioned in the others. Lidocaine 5% plaster was recommended in 
three guidelines (France 2010, the Netherlands 2008-I, and Spain) not 
recommended in two guidelines (Norway 2007 and U.K.) and not 
mentioned in others. Regarding more invasive therapeutic 
approaches, only ketamine was recommended after indication 
confirmation by a pain specialist in four CPGs: Italy 2006, the 
Netherlands 2008-I, Spain, and U.K. Ketamine was not mentioned by 
the other CPGs, whereas systemic lidocaine was not recommended in 
four CPGs (France 2010, Italy 2006 and 2009, the Netherlands 2008-I) 
or not mentioned in other CPGs. 
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Table 3. Treatment of neuropathic pain in patients with cancer according to European national clinical 
practice guidelines. 
Treatment of neuropathic pain in cancer patients France Italy 
2009 
Italy 
2006 
Neth. 
2008-I 
Neth. 
2008-II 
Norway 
2009 
Norway 
2007
a 
Spain UK
a 
Paracetamol, NSAIDs,  - 0 0 0 - 0 0 0 0 
Weak opioids (i.e. dextropropoxyphene, tramadol) + 0 0 0 - 0 0 0 0 
Tricyclic Antidepressant drugs (i.e. amitriptiline, 
imipramine) 
+ + + + + + + + + 
SNRI Antidepressant drugs (i.e. venlafaxine, duloxetine) + + 0 0 0 0 + + 0 
α2δ agonists (i.e. gabapentine, prégabaline) + + + + + + + + + 
Others Anticonvulsant drugs (i.e. carbamazepine, 
valproate of sodium, phenitoine) 
+ + + + + + + + + 
Corticosteroides - 0 0 - 0 + - 0 0 
Opioids (i.e. morphine, oxycodone) in combination 
with coanalgesics 
+ + 0 + - 0 + + 0 
Lidocaïne 5% plaster (only in case of local neuropathic 
pain) 
+ 0 0 + 0 0 -
b 
+ - 
Capsaicin plaster (only in case of local neuropathic 
pain) 
+ 0 0 + 0 0 + + + 
Intravenous ketamine 0 0 +
c 
+
c 
0 0 0 +R +
c 
Intravenous lidocaine, mexiletine -
d 
- - - 0 0 0 0 0 
Cannabinoïdes 0 0 0 0 0 0 0 0 - 
Legend: 
a 
the topic of the guideline concerned specifically the treatment of pain in cancer. 
b 
no marketing in Norway, 
c 
consultation with a pain or palliative care specialist (+): should be proposed, (-): should not be proposed, (0): no 
information. R: refractory neuropathic pain. 
d
 no marketing concerning mexiletine.  
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Focused analysis on amitriptyline, pregabalin, and gabapentin is 
presented in Table 4. For amitriptyline, evidence level for its 
recommendation varied from 1++ to four according the SIGN 50 
criteria. For pregabalin, evidence level for its recommendation varied 
also from 1++ to 4. For gabapentin, this level varied from 1++ to 2. In 
accordance level of grading varied in the same way for the three 
drugs. A large majority of CPGs indicated the use rules of drugs but 
only three CPGs (France 2010, the Netherlands 2008-II and Norway 
2009) detailed systematically the side effects and contra-indications 
of these drugs. 
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Table 4a. Comparison of grade of recommendations and level of evidence proposed for treating neuropathic pain in 
cancer guidelines. 
 France 2009 Italy 2009 Italy 2006 Neth 2008-1 Neth 2008-2 Norway 2009 Norway 
2007 
Spain 
2008 
UK 2008 
Amitriptyline 
Evidence 
literature 
1 “low” nm 4 4 1
a 
nm 1 1++ 
Evidence 
recommendations 
A “weak 
positive” 
A nm nm nm B B A 
Start dose 10-25mg 10-25mg 10mg 10-25mg 10-25mg 10mg 2-4 hours 
before sleep 
nm 10-25mg nm 
Titration scheme 5-25 mg
b 
nm 10mg/ 3 
days 
25mg/week 25mg/ 3-7 
days 
10mg / 3 days  up to 
30 mg then 3 weeks 
stabile dose 
nm Slow 
titration
b
 
nm 
Maximum dose 75-150mg 50-75mg 75mg 50-150mg 75mg 40-50mg nm 150mg nm 
Contra-indicationsc + nm nm + + + nm nm nm 
Side-effects
c 
+ nm nm nm + + nm nm nm 
Pregabalin 
Evidence 
literature 
1 “low” No 
treatment 
option 
4 ? 1
 a 
nm 1 1++ 
Evidence 
recommendations 
A “weak 
positive” 
nm nm nm B B A 
 
Start dose 75-150 mg 2 x 25mg 2 x 75mg 2 x 75mg 2x25mg nm 2 x 25-
75mg 
nm 
Titration scheme 75mg
b
 nm 150mg / 2 
days 
150mg / 2 
days 
Slowly
b
 nm 50-
150mg/ti
me 
nm 
Maximum dose 300-600mg 600mg 2 x 300mg 2 x 300mg 2x300mg nm 600mg nm 
Contra-indicationsc + nm nm nm  nm nm nm 
Side-effects
c 
+ nm nm + + nm nm nm 
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Table 4b. Comparison of grade of recommendations and level of evidence proposed for treating neuropathic pain in 
cancer guidelines. 
 
Legend:
 a
 Non-cancer neuropathy; 
b 
No further information is given; 
c
 + = mentioned in the clinical practice guideline (CPG), nm = not 
mentioned in the CPG. 
 France 2009 Italy 2009 Italy 2006 Neth 2008-1 Neth 2008-2 Norway 2009 Norway 
2007 
Spain 
2008 
UK 2008 
Gabapentin 
Evidence 
literature 
2 “low” nm 2 2 1
a 
nm 1+ 1++ 
Evidence 
recommendations 
A “weak 
positive” 
A nm nm nm nm B A 
Start dose 1x100-
300mg 
2x100mg 1x300mg 1x 100-300mg 1x100-300mg 1x300mg nm 1x300mg nm 
Titration scheme 100-300mg
b
 nm 300mg/day 100-
300mg/day 
100-
300mg/day 
1x300mg/3 days nm 1x300mg/
d 
nm 
Maximum dose 1200-
3600mg 
3600mg 3600mg 3600mg 3600mg 3600mg nm 3600mg nm 
Contra-
indications
c 
+ nm + nm + nm nm + nm 
Side-effects
c 
+ nm nm nm + + nm nm nm 
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DISCUSSION 
In the nine included CPGs on cancer pain or neuropathic pain with at 
least one chapter on neuropathic pain in patients with cancer, all 
developed in European countries, 163 references were used to 
support the given recommendations on neuropathic pain treatment 
in patients with cancer. Although the proportion of population-
specific references was low (11%), it was higher than our previous 
study on diagnosis and assessment of neuropathic pain in patients 
with cancer (3%). (7) Moreover, the mean level of evidence of used 
references was high (44%). Nevertheless, few references were used 
in at least two CPGs (18%), and no reference was shared by all the 
CPGs. 
All CPGs recommended the use of antidepressant drugs, α2δ agonists 
and others anticonvulsant drugs. Proposal of these drugs in first line 
treatment is not supported by high evidence level. For example, 
amitriptyline is the oldest anti-neuropathic drug and well 
investigated in non-cancer populations, (18) but Mercadante et al. 
(19) demonstrated the analgesic effects on neuropathic pain of 50 
mg of amitriptyline were small and associated with side events in 
patients with cancer. Similar results were found in another study 
related to treatment for chemotherapy-induced neuropathic 
symptoms with amitriptyline. (20) We also found diversity in 
recommendations concerning strong opioids and more invasive 
approaches such as ketamine. Such second line therapeutic 
approaches were proposed by some CPGs, whereas they were not 
mentioned at all in others. This shows a gap between daily practice 
(wide utilization of ketamine or lidocaine in cancer pain, not only in 
case of neuropathic pain) and recommendations in part of the CPGs. 
Ideally, high quality CPGs should describe adverse events and risks of 
treatments. In the studied CPGs, these were well described for strong 
opioids. (7) However, in the majority of the CPGs, adverse events of 
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antidepressants or anticonvulsants as treatment for neuropathic pain 
were not mentioned. Up to now, the benefit-risk ratio of these drugs 
in patients with cancer is unknown. (19,21) Consequently, we 
recommend that CPGs mention restrictions when study findings in 
non-cancer populations are extrapolated to patients with cancer. 
Clinical practice guidelines differ in terms of used references, 
extrapolation techniques, and assigned levels of evidence. The origin 
and the composition of the guideline development groups seem to 
have influenced the clinical recommendations, (22,23) which are 
based on their clinical experiment and their choice of evidence-based 
references. 
Our results should be interpreted with caution. They are merely 
based on available information in the CPGs. Only one chapter per 
CPG concerned neuropathic pain in patients with cancer. These 
results emphasize the lack of robust references on the treatment for 
neuropathic pain in cancer conditions. As we limited ourselves to 
Europe, we were able to develop a detailed study including all 
European countries. In the future, it would be interesting to include 
CPGs from other continents. 
 
Recommendations and Perspective 
 
The majority of guideline development groups extrapolated results of 
studies on non-cancer neuropathic pain to recommendations for 
patients with cancer. Consequently, these CPGs fail to address 
important issues such as altered kinetics and side effect profiles in 
these patients. We recommend creating specific recommendations 
by an international expert group for the treatment for neuropathic 
pain in patients with cancer supported by targeted research in 
patients with cancer. For this purpose, there is a need for research 
protocols with prospective multicenter and multinational studies in 
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clinical practice comparing different treatment strategies and to 
publish all studies whether the results reported are positive or 
negative. 
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Abstract 
Background: From 19 to 39% of patients with cancer suffer from pain 
that is difficult to diagnose and to treat: neuropathic pain. In France, 
clinical practice guidelines (CPGs) on this topic exist; but to what 
extent French pain specialists know and use the recommendations 
from these CPGs are unknown. Aim: The aim was to investigate, with 
the help of a case vignette, whether pain specialists follow the 
recommendations in the CPGs in clinical practice on this topic. 
Design: The survey consisted of a case vignette about a patient with 
pain suffering from an intractable pancreatic cancer with multiple 
choice questions about diagnosis and treatment of (neuropathic) 
pain. Percentages of participants who treated the patient as 
suggested in the CPGs were calculated. Setting/participants: An 
email survey was conducted with the support of the Société 
Française d’Etude et de Traitement de la Douleur to all pain 
specialists (primary and secondary care) in France. Results: A total of 
214 of those invited to participate (921) answered the questionnaire 
(24%). More than 85% of the respondents declared to know and use 
these CPGs. Half of the participants diagnosed and treated 
neuropathic pain components in the case vignette according to the 
recommendations in the CPGs. Conclusions: Although participating 
pain specialists confirmed to know and to use CPGs on neuropathic 
pain in cancer patients, half of them did not answer in line with the 
recommendations. A nationwide program to implement these CPGs 
is necessary including better education and training of pain specialists 
in assessing and treating neuropathic pain.  
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Introduction 
In 2002, the 5 year partial cancer prevalence in the French population 
(the number of cases of people diagnosed with cancer between 1998 
and 2002 and still alive at the end of 2002) was 836,000 (1). In 2011, 
the incidence of cancer was about 365,000 in the French population 
(2). In patients with cancer, 64% suffer from pain of which between 
19% and 39% suffer from neuropathic pain, which seriously reduces 
their quality of life on a daily basis (3-6). Two reasons for the high 
prevalence of neuropathic pain in this patient group can be 
underlined. Firstly, its diagnosis is difficult, particularly in patients 
with cancer, because of the combination with other comorbidities (7-
9). Secondly, these patients are known to be resistant to usual 
nociceptive pain treatments (10, 11). Uncontrolled neuropathic pain 
in patients with cancer increases depression and insomnia rates (12, 
13). Thus, optimal neuropathic pain diagnosis and treatment are 
essential. 
Clinical practice guidelines (CPGs) for cancer or for neuropathic pain 
encourage practitioners to detect neuropathic components earlier 
with screening instruments and physical examination and to treat 
them with tricyclic antidepressant (TADs) or anticonvulsant drugs 
(AEDs) in combination with other drugs such as morphine (14-16). Yet 
previous studies have identified that practitioners do not always 
follow such CPGs (17-20). It is important to assess whether physicians 
are familiar with CPGs and use them in their daily practice. Use of a 
case vignette for this purpose appeared successful regarding a CPG 
on chronic pain (21-22). A case vignette uses a case study with “text, 
images or other forms of stimuli to which research participants are 
asked to respond” (23). This might be a convenient, valid and 
inexpensive way to evaluate knowledge of the content of the CPGs 
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on neuropathic cancer pain. To evaluate this method, we chose the 
population of pain specialists.  
In France, advanced training in pain, a two year course, has existed 
since 1998. Physicians with any medical specialty can follow this 
training. A majority of these are members of the Société Française 
d’Etude et de Traitement de la Douleur (SFETD). The practitioners in 
this group are pain specialists and are expected to have detailed 
knowledge of the recommendations in pain-related CPGs, but this 
has not been studied yet. We therefore studied whether French pain 
specialists know and use the most important recommendations from 
a practice-based perspective on neuropathic pain in patients with 
cancer.  
Method  
Participants  
All 931 physicians who were registered in the SFETD in March 2012 
were invited to take part in the survey.  
Survey mailings  
On 31 May 2012, SFETD sent an e-mail to all participants providing a 
link to an Internet-based survey (Copyright 1999-2012, 
SurveyMonkey, Palo Alto, CA). Non-responders received a reminder 
two weeks later. Inclusion finished on 1 July. Questionnaires were 
analyzed anonymously and only used if informed consent was given.  
The case vignette (Table 1 and annex) 
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Initial case vignette. The originally Dutch version of the case vignette 
was developed by two Dutch pain anaesthesiologists, who 
respectively took part in and chaired the Dutch cancer pain guideline 
development group in 2008 (KB, KV). The format was based on prior 
surveys regarding physician knowledge, communication and attitudes 
with respect to patients with cancer (18, 19). A forward backward 
translation procedure was used to develop the French version.  
Validation and pre-test. The French case vignette was approved by 
the board of the SFETD. It was pilot tested with the help of six pain 
specialists (an anaesthesiologist, a neurologist, a palliative care 
specialist, a general practitioner (GP) in a palliative care network at 
home and a GP in a pain centre) in order to adapt the case vignette 
to the recommendations in the French CPGs and to the French 
healthcare system. The results of the pilot were discussed by 
participants and researchers. Table 1 describes the main components 
of the French CPG used for the construction of this case vignette: the 
recommendations for each theme, their justification, their clarity and 
the referenced question(s) in the case vignette (14-16). (Tables 1a 
and b) The final questionnaire, translated into English by an English 
native speaker, is presented in annex 1.  
We studied whether the medical specialty influenced adherence to 
CPGs recommendations. The population of the SFETD included 921 
physicians with, among other specialties, 258 anaesthesiologists and 
277 general practitioners (GPs). Anaesthesiologists usually focus on 
the underlying health problem and are trained to perform invasive 
treatments, whilst GPs focus on the global health problem of the 
patient and home care. Our hypothesis was that GPs would be more 
influenced by the context at home, while anaesthesiologists would be 
more experienced in the diagnosis of the pain. Furthermore, we 
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expected the latter to propose invasive treatment earlier in the 
trajectory.  
The case vignette was divided into 5 consecutive parts, in which the 
disease stage worsened. Part I concerned the occurrence of pain in 
the diagnosis of an intractable pancreatic cancer pain, in a patient 
with a good performance status, using the WHO pain analgesic 
ladder. Part II studied the adaptation of the pain treatment, with the 
patient still having a good performance status. Part III explored how 
the participants managed the impairment of the pain: the emotional 
management for the patient and their family and the care of 
insomnia. Part IV concerned specifically neuropathic components of 
the pain: its diagnosis and its treatment in an oncological context. 
Part V assessed the choice of invasive treatment and the route 
administration of pain treatment in the patient, in a terminal stage at 
home. 
Statistical analysis.  
Statistical analysis was performed with SPSS 20.0 (IBM, New York, NY, 
USA) and consisted of descriptive statistics: proportions, medians and 
range. For inter-group comparisons of continuous or ordinal 
variables, t tests or nonparametric Wilcoxon rank sum tests were 
used. Chi-square tests were used to compare categorical variables. 
All statistical testing was carried out with a p-value <0.05. 
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Table 1a. Summary of the French clinical practice guidelines on cancer 
pain to construct the case vignette. 
Guidelines 
a
 Recommendations References Question(s)
b
 
Pain diagnosis Necessary to make a diagnosis of 
the pain (nociceptive and/or 
neuropathic pain) 
Chapter 
2.1.2 p. 37-
38 
1,3,4 
Pain 
assessment 
One dimensional scale and 
multidimensional scales 
Chapter 
2.1.3 p. 39-
42 
1,4, 12 
Neuropathic 
pain 
Tricyclic antidepressant drugs or 
anticonvulsants 
Chapter 
4.1.3 p. 66-
67 
3, 13, 14 
Paracetamol  In 1
st
 line in mild pain Chapter 
3.1.1 p. 58 
2,5 
NSAIDs  For inflammatory pain or bone 
pains 
Chapter 3.1 
p. 58 
2,5 
Corticosteroids Elevated intra cranial  pressure, 
medullar compression, peripheral 
nervous compression, bones 
metastasis  
Chapter 4.1 
p. 63-66 
14,16 
Weak opioids For moderate pain, precaution 
with tramadol if epilepsy or 
association with antidepressants, 
no association with 
dextropropoxyphen and 
carbamazepin 
Chapter 3.2 
p. 59 
2,5 
Strong opioids For moderate to severe pain, 
titration is always necessary 
Chapter 1 p. 
15-34 
2,5 
Opioid route Oral administration in 1
st
 line, 
subcutaneous or intravenous in 
2
nd
 line 
Chapter 1 p. 
15, chapter 
5.4.1-4 p. 
86-87 
14 
Opioid 
rotation 
In case of intractable side effects 
or phenomenon of opioid 
resistance defined by no efficacy 
and no side events despite a rapid 
and massive increase of the opioid 
dose 
Chapter 
2.4.3 p. 73-
77 
4,6 
Constipation Prophylactic laxative in case of 
weak or strong opioids with 
dietetic rules 
Chapter 
1.7.1 p. 22-
25 
6 
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Guidelines 
a
 Recommendations References Question(s)
b
 
    
Nausea Anti-emetic only if nausea occurs Chapter 
1.7.2 p. 26 
6 
Sedation No treatment Chapter 
1.7.3 p. 27 
6 
Blocks Celiac plexus block or splanchnic 
nerve block for the cancer of the 
pancreatic corpse  
Chapter 
5.2.1 p. 78-
79 
7,12,15 
Spinal route Specialized consultation in case of 
intractable pain 
Chapter 
5.4.5 p. 87 
7,12,15 
Insomnia Amitriptyline is useful in case of 
insomnia with pain and 
depression. Benzodiazepine has 
an interest only in case of acute 
pain or agitation in patient in late 
stage. Relaxation and 
psychological control. 
Chapter 4.2 
p. 66 
Chapter 4.5 
p. 68-69 
Chapter 
5.3.2 p. 82 
9, 10 
Psychological 
evaluation 
Systematically at the beginning 
and if psychiatric troubles and for 
pain assessment 
Chapter 
2.1.4 p. 42-
43 
8, 9 
Depression Psychologist consultation and 
antidepressant drugs 
Chapter 
2.1.2 p. 66 
11 
Familial 
evaluation 
By the medical team, contact the 
family also without the patient 
Chapter 
2.1.4 p. 43-
45 
8 
Social 
assessment 
By the medical team and the 
general practitioner 
Chapter 
2.1.4 p. 45 
8 
a 
Cancer pain clinical practice guidelines of 1995 (12-13)
 
b
 Questions are presented in annex 1 with the answers following the clinical 
practice guidelines (CPGs) 
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Table 1b. Summary of the French clinical practice guidelines on 
neuropathic in cancer pain to construct the case vignette. 
Guideline 
a
 Recommendations References Question(s)
c
 
Neuropathic 
pain
c 
Diagnostic of neuropathic pain in 
cancer conditions 
Chapter 2.3 
table 2.2 p. 
68 
3,13,14 
 
Tricyclic antidepressant drugs 
 
Chapter 
5.1.1.1 p.: 
62-63, table 
4.1 p. 123 
 
 
Gabapentin 
 
Chapter 
5.1.2 table 
4.2 p.125 
 
 
Tramadol 
 
Chapter 
5.1.3.2 
table 4.3 p. 
127 
 
a
 Neuropathic pain clinical practice guideline 2010 (14) 
b
 Questions are presented in annex 1 with the answers following the clinical 
practice guideline (CPGs) 
 
Results 
Ten of the 931 mailed surveys were returned unopened, leaving 921 
surveys. A total of 214 completed surveys were returned (response 
rate 24%). Of those, 158 (74%) answered the questionnaire in full. 
Demographic data (Table 2) 
Median age of the respondents was 51 (range 28-72) years; 54% 
were women (Table 2). Most of them were GPs (43%) representing 
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91/277 GPs of the SFETD or anaesthesiologists (30%) representing 
65/258 anaesthesiologists of the SFETD (25%). Two thirds of the 
respondents (63%) had been practicing medicine for at least 20 years. 
More than half (58%) worked in a state hospital; 57% in pain 
consultations or a pain centre. Only three participants did not treat 
patients with cancer. Sixteen percent of the respondents treated 
fewer than 10 patients with cancer per year, 35% between 10 and 49, 
17% between 50 and 100 and 31% more than 100 patients yearly. 
Almost all of them confirmed that they were aware of the existence 
of a cancer pain CPG (94%) and a neuropathic pain CPG (97%) and 
that they used them (88% and 94% respectively). Participants spent 
15 minutes on average to complete the questionnaire. 
Pain management in patients with cancer by French pain specialists 
and comparison to CPGs (Table 3) 
Table 3 illustrates the number and proportion of respondents who 
answered the case vignette as recommended in the French CPGs.  
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Table 2. Demographic and Practice Characteristics of Eligible Study 
Respondents. 
Characteristics of participants Respondents 
 N0 (N=214) % 
Sex Women 116 54.9 
Men 98 45.1 
Medical specialty  Anesthesiology 65 30.4 
General practice 91 42.5 
Geriatric 12 5.6 
Neurology 5 2.3 
Oncology 11 5.1 
Pediatric 6 2.8 
Psychiatry 1 0.6 
Rehabilitation practice 6 2.8 
Rheumatology 6 2.8 
Other 11 5.1 
Number of years 
of practice after 
education 
Less than 5 years 14 6.5 
5-10 years 16 7.5 
11-20 years 49 22.9 
More than 20 years 135 63.1 
Location of 
medical practice 
(multiple 
response 
possible) 
In an office 24 11.2 
Retiring house 15 7.0 
Public hospital 124 57.9 
Private hospital 30 14.0 
Non-governmental funding 
housing 
2 0.9 
Pain clinic consultations 122 57.0 
Oncology 19 8.9 
Palliative care unit 31 14.5 
Other 21 9.8 
Number of 
patients with 
cancer followed 
per year 
No patient 3 1.4 
<10 patients 34 15.9 
10-49 patients 74 34.6 
50-100 patients 37 17.3 
> 100 patients 66 30.8 
Cancer pain 
guidelines 
Do you know this guideline? Yes 201 93.9 
Do you use this guideline? Yes 190 88.8 
Neuropathic pain 
guideline 
Do you know this guideline? yes 208 97.2 
Do you use this guideline? Yes 202 94.4 
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In part I, concerning the management of the initial pain, almost all 
pain specialists followed the CPG recommendations to assess the 
pain and made a clear diagnosis (97%). However, only 60% treated 
the pain in accordance with the CPGs (which used the WHO analgesic 
ladder). There was no significant difference between the medical 
specialties. 
In part II, more than 70% of the participants adapted the treatment 
after a pain evaluation and followed the WHO analgesic ladder as 
recommended in the guidelines. The prevention of side effects was in 
accordance to the CPGs in slightly more than half of the respondents 
(56%) and 44% had an early proposal for invasive treatment (celiac 
plexus block or splanchnic nerve block for cancer of the pancreatic 
corpse). There was no significant difference between the medical 
specialties.  
In part III, 98% of the respondents proposed a psychologist for the 
management of depression. Only 24% of the participants proposed a 
multidimensional assessment of the pain, a consultation with a 
psychologist and addition of an antidepressant drug for the 
treatment of depression. There was a significant difference between 
the percentage of anaesthesiologists who followed the CPGs (37%) 
and GPs (14%, p=0.007). 
In part IV, neuropathic pain was diagnosed and treated by more than 
50% of the pain specialists. AEDs were proposed by 30% of them 
(47/158) and TADs by 9% (15/158) or an increase of opioids by 6% 
(9/158) as presented in the recommendations. Specific treatment of 
neuropathic pain without specification was quoted by 6% (10/158). 
Other treatments of the cancer CPG were proposed: ketamine by 
11% (18/158) and lidocaine by 2.5% (4/158). There was no significant 
difference between medical specialties. 
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In part V, 57% of the participants chose, as recommended, 
intrathecal infusion of opioids or a specialized consultation for 
invasive treatment, with no significant difference between medical 
specialties. More than 80% of the participants correctly proposed the 
sub-cutaneous or the intravenous administration of the medication. 
There was no significant difference between medical specialties. 
Answers were not related to practice location, number of years of 
practice, number of cancer patients seen per year, sex or age. The 
details of each response on the case vignette are described in annex 
1. 
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Table 3. Case vignette: management of pain in patient with a 
pancreatic cancer by French pain specialists 
Number and proportion of French pain specialists who 
followed the cancer and neuropathic pain clinical practice 
guidelines 
Respondents 
Number % 
Initial pain management (188 respondents)   
Strategy of the pain management (Question 1) 159 85 
Treatment of the pain (Question 2) 112 60 
Diagnosis of the pain (Question3) 182 97 
Adaptation of pain management (178 respondents)   
Strategy of the pain management (Question 4) 127 71 
Treatment of the pain (Question 5) 153 86 
Prevention of side effect with strong opioids (Question 6) 100 56 
Choice of an invasive treatment (Question 7) 150 44 
Impairment of the pain: ( 172 respondents) 
 
 
Mourning management (Question 8) 168 98 
Strategy of the insomnia management (Question 9) 55 32 
Treatment of insomnia (Question 10) 47
 
28 
Strategy of the depression management (Question 11)  42
 a 
24 
Neuropathic pain management (158 respondents)   
Strategy of the pain management (Question 12) 119 75 
Diagnosis of the neuropathic pain (Question 13) 86 54 
Treatment of the neuropathic pain (Question 14) 79 50 
Pain management in end of life (158 respondents)   
Choice of an invasive treatment (Question 15) 91 57 
Choice of administration route after thrombus at home 
(Question 16) 
135 85 
a
 significant difference between anaesthesiologists (37%) versus general 
practitioners (14%) to follow CPG concerning depression impairment (p=0.007). 
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Discussion 
This study assessed the knowledge and the use of CPGs among 
French pain specialists concerning neuropathic pain in a patient with 
cancer. Although over 85% of the respondents claimed they know 
and use the CPGs, only some of them followed the recommendations 
regarding this case vignette. Three important messages can be 
learned from our survey.  
Firstly, the management of nociceptive cancer pain using the WHO 
analgesic ladder was good with over 75% of the participants 
following the CPGs. This ladder was published in the eighties and 
apparently well known by pain specialists (24).  
Secondly, there was very little adherence to the CPGs with regard to 
the management of the impairment caused by the pain such as 
depression and insomnia. Regarding insomnia, only 26% of the 
respondents proposed a multidimensional pain assessment. 
Concerning depression, only 28% of the anaesthesiologists compared 
with 11% of the GPs proposed antidepressant drugs and a 
consultation with a psychologist. The lack of precision in the CPGs 
concerning these two topics can be underlined (table 1). There are 
several explanations for this low number of GPs who adhered to the 
CPG regarding the treatment of depression. Antidepressants drugs 
are not proposed as the first choice in the treatment of depression in 
the French CPG for GPs. (25) In 2012, a Dutch study revealed that GPs 
find it difficult to differentiate between normal and abnormal 
sadness. They did not strictly apply criteria of depressive disorder. 
They rely on their clinical judgment, strongly consider the patient’s 
context and background factors, and rarely prescribe antidepressant 
drugs (26). Furthermore, a meta-analysis demonstrated the 
importance of the association of psychotherapy and a 
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pharmacological approach to improve patients with depressive 
disorders in cancer but without assessing the TADs (27). In these 
conditions, it is difficult to make a clear recommendation in CPGs.  
Thirdly, only half of the respondents followed the CPGs regarding 
neuropathic pain management. Although this figure can be 
considered high compared to literature on guideline adhesion, they 
are quite low in this population of pain specialists with extensive 
training in neuropathic pain (28). It is probable that these CPGs are 
not clear enough on neuropathic pain management in patients with 
cancer (Table 1). In fact, recommendations in CPGs are not 
sufficiently based on clinical practice and thus not easily applicable 
(29). Besides, only 2% of the references used in European CPGs on 
neuropathic pain in cancer concerned patients with cancer (30). 
There is an urgent need of good randomized controlled trials on this 
specific population (31). Moreover, no implementation strategies 
were linked to the publication of the CPGs, although this, together 
with monitoring its impact, is necessary to improve the use of a CPG 
(32).  
Strengths and limits  
To our knowledge, this is the first study to investigate the practical 
knowledge of pain specialists concerning neuropathic pain 
components in cancer pain. This is also the first vignette study in 
which practitioners had to deal with pain in patients with cancer. 
Relevant points for patient care were identified: 1) physicians should 
realize that they have a responsibility to know and use a CPG and 
consult the updated CPGs, especially in the case of limited knowledge 
on a topic, 2) specific training in pain is beneficial to improve the 
professionals’ knowledge.   
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Although the response rate was low (24%), it was comparable to 
other French surveys using case vignettes and seemed to be a good 
representation of the whole population of the SFETD (33, 34). 
However, the respondents of the case vignette were probably more 
involved in cancer pain management, giving the best responses. 
Finally, they were not familiar with this method of knowledge 
assessment. Consequently, those who did not complete the 
questionnaire probably had difficulty using it to use it. This also 
explains the decline in the number of participants from the beginning 
to the end of the questionnaire.  
The aim of this study was not to validate the case vignette, but to 
assess the knowledge of pain physicians. Yet, as well the Dutch 
version of the vignette as the French one were pilot tested.  
 
Recommendations 
A case vignette seems to be an interesting method for evaluating the 
knowledge and application of CPGs in pain management. Specific 
case vignettes should be developed and tested for several aspects of 
pain education as they are an inexpensive tool, convenient for 
assessing this implementation in a large group of physicians and are 
easy to repeat, for example after a training or implementation 
program (36-39). Structured training and evaluations resulting in a 
diploma will improve the knowledge of the practicing physicians 
about specific problems. There is a need to implement the CPG on 
neuropathic pain in France, probably with specific communication on 
this subject and a dedicated educational module in the curricula. 
Case vignettes assessing specific key messages of pain 
recommendations contained in CPGs could be a way to evaluate the 
level of the educational module and adapt the training. 
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Supplement file. Case vignette questionnaire, responses following the 
CPGs and responses of the participants 
PART I- INITIAL PAIN MANAGEMENT IN CANCER – 
Mrs. A is 45 years old. She is married and has got 2 children (12 and 15 
years old). After the discovery of a silent icterus (abnormal blood 
chemistry), a non-operable pancreas cancer is diagnosed. The family is 
informed that the prognosis is bad. The (bile) excretion was secured with a 
stent in the bile duct. The patient is in good conditions and had a good 
appetite. Mrs. A. received chemotherapy on her demand. 
Few weeks after leaving the hospital, she consults you because she has pain 
in the upper abdomen. It is vise like pain with a stabbing component. 
1) You decide the following strategy (many possible answers): 
A. Pharmacological treatment   170 (90%) 
B. Pain measurement with one-dimensional scale  66 (35%) 
(only intensity of the pain) 
C. Pain measurement with multidimensional scale 141 (75%) 
(pain intensity and others dimensions as social, psychological or 
quality of life impairment) 
D. Others investigations for diagnosis, precise: 92 (92%) 
Answers recommended in CPGs: A in combination with B or C, +/-D 
2) The pharmacological treatment included (if you choose an association, 
cross all boxes you need): 
A. Paracetamol     106 (56%) 
B. Non Steroid Anti-Inflammatory drug (NSAID) 15 (8%) 
C. Corticosteroids in short cure   55 (29%) 
D. Weak opioids     65 (35%) 
E. Strong opioids     101 (54%) 
F. Other, precise:     67 (36%) 
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Answers recommended in CPGs: A, B, D, E alone or in combination but no 
C, and no treatment of neuropathic pain components (tricyclic 
antidepressant or anticonvulsant) in answer E: other. 
3) What kind of pain is it? 
A. Nociceptive pain    23 (12%) 
B. Neuropathic pain    5 (3%) 
C. Mixed pain     114 (31%) 
D. Visceral pain     40 (21%) 
E. Other, precise:     6 (3%) 
Answer recommended in CPGs: no B 
PART II- ADAPTATION OF PAIN MANAGEMENT IN CANCER - 
The pain is acceptable during a few months. After a while, the pain 
increases. The patient suffers from pain in her upper abdomen; mainly the 
night and her pain make her wake up early in the morning. 
4) You decided the following strategy (many answers possible): 
A. Adaptation of the pharmacological treatment 171 (96%) 
B. Research for constipation   122 (69%) 
C. Pain measurement with one-dimensional scale 61 (34%) 
(only intensity of the pain) 
D. Pain measurement with multidimensional scale 117 (66%) 
(pain intensity and others dimensions as social, psychological or 
quality of life impairment) 
E. Invasive pain treatment (nerve block)  70 (39%) 
F. Others investigations for diagnosis, precise: 39 (22%) 
Answers recommended in CPGs: A in combination with B+/-F, in 
combination with C and/or D, E non obligatory 
5) The adaptation of the pharmacological treatment included (if you choose 
an association, cross all boxes you need): 
A. Add or increase paracetamol   33 (19%) 
B. Add or increase a Non Steroid Anti-Inflammatory 14 (8%) 
drug (NSAID) 
Chapter 6 – Case vignette study 
 
145 
 
C. Add or increase a short cure of corticosteroids 85 (48%) 
D. Add or increase weak opoioids   8 (5%) 
E. Add or increase strong opioids   167 (94%) 
Answers recommended in CPGs: E if mention of a pain assessment in 
question 4 (answer C and/or D) 
6) To treat or avoid possible side effects of strong opioids, you prescribe 
systematically the following drug (many possible answers): 
A. Laxative     171 (96%) 
B. Anti-emetic     70 (39%) 
C. A treat to avoid sedation   2 (1%) 
D. Other, precise:     12 (7%) 
Answer recommended in CPGs: A, B accepted only if mention in D “in case 
of nausea” 
7) An invasive pain treatment can be: 
A. Chordotomy     1 (1%) 
B. Celiac plexus block    146 (82%) 
C. Splanchnic nerve block    21 (12%) 
D. Hypogastric nerve block   10 (6%) 
E. A “lower end” block    0 (0%) 
F. Intraspinal administration of opioids   86 (48%) 
G. Other, precise:     12 (7%) 
Answers recommended in CPGs: B and/or C +/- F. Accepted if no answer 
but mentioned in G: specialized consultation 
PART III - MANAGEMENT OF PATIENT PAIN AND ENVIRONMENT – 
8) The patient worries about her children reactions concerning her future 
death. In addition to a discussion with her general practitioner, you 
proposed to help her to meet (many answers possible): 
A. A psychologist     169 (98%) 
B. A social worker     92 (53%) 
C. A pastoral assistant    58 (34%) 
D. Other, precise:     53 (31%) 
Answers recommended in CPGs: A obligatory 
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9) The pain decreases after your treatment but the problem of sleepiness 
are still present. You decided (many answers possible):  
A. Adaptation of the pharmacological treatment 138 (80%) 
B. Pain measurement with one-dimensional scale  28 (16%) 
(only intensity of the pain) 
C. Pain measurement with multidimensional scale 75 (44%)  
(pain intensity and others dimensions as social,            
psychological or quality of life impairment) 
D. Psychological consultation   121 (70%) 
E. Other proposal, precise:   39 (23%) 
Answers recommended in CPGs: A in combination with C +/- B and D 
10) The adaptation of pharmacological treatment included (many answers 
possible): 
A. Add a benzodiazepine    137 (80%) 
B. Add antidepressant drug   81 (47%) 
C. Use methylphenidate    1 (1%) 
D. Other, precise:     27 (16%) 
Answers recommended in CPGs: B 
11) The patient always present insomnia and she feels a lot of fear of 
suffering. You decided the following strategy (many possible answers): 
A. Discussion about her case in a multidisciplinary 130 (76%) 
team meeting 
B. Refer the patient to a clinical psychologist 129 (75%) 
C. To meet pastoral assistance   13 (8%) 
D. Refer the patient to the nurse specialized in  19 (11%) 
cancer announcement 
E. Prescribe an antidepressant drug  42 (24%) 
F. Propose hospitalization at home  56 (33%) 
G. Other, precise:     48 (28%) 
Answers recommended in CPGs: B and E obligatory 
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PART IV - MANAGEMENT OF NEUROPATHIC CANCER PAIN – 
Few days after, the pain increases and is located in the whole abdomen. 
The status of the patient has decreased drastically and the chemotherapy 
was interrupted because of the progression of the disease.  
12) The patient had stabbing pain and paroxysmal pain and permanent 
burning gastric pain. The viselike pain has increased. She suffers from 
paresthesia in her legs. You decided the following strategy (many possible 
answers): 
A. Adaptation of the pharmacological treatment 129 (82%) 
B. Pain measurement with one-dimensional scale  39 (25%) 
(only intensity of the pain) 
C. Pain measurement with multidimensional scale 82 (52%) 
(pain intensity and others dimensions as social,  
psychological or quality of life impairment) 
D. Invasive pain treatment (nerve block)  95 (60%) 
E. Others investigations for diagnosis, precise: 43 (27%) 
Answers recommended in CPGs: A in combination with C +/-B and D. E 
non obligatory 
13) In your opinion, what kind of pain is it? 
A. Nociceptive pain    1 (1%) 
B. Neuropathic pain    23 (15%) 
C. Mixed pain     116 (73%) 
D. Visceral pain     15 (10%) 
E. Other, precise:     3 (2%) 
Answers recommended in CPGs: B, E if “neuropathic pain 
components” is mentioned and C if treatment neuropathic pain 
mentioned in question 14 
 
14) Despite an optimal titration of strong opioids, the pain persists. Which 
adaptation(s) of the pharmacological treatment can be proposed? 
A. Increase opioids dose    9 (6%) 
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B. Opioids rotation    95 (60%) 
C. Intravenous administration of opioids  94 (60%) 
D. Adjuvant treatment, precise:   67 (61%) 
Answers recommended in CPGs: D (with mention of: neuropathic pain 
treatment or anticonvulsant or tricyclic antidepressants drugs) and/or (A 
or B or C)  
PART V- MANAGEMENT OF PAIN IN END OF LIFE – 
 
15) An invasive treatment can be: 
A. Chordotomy     4 (3%) 
B. Celiac plexus block    39 (25%) 
C. Splanchnic nerve block    5 (3%) 
D. Hypogastric nerve block   5 (3%) 
E. A “lower end” block    5 (3%) 
F. Intraspinal administration of opioids   87 (55%) 
G. Other, precise:     13 (8%) 
Answers recommended in CPGs: F or G: specialized consultation 
The patient doesn’t want an invasive pain treatment at this moment. The 
disease is complicated with a venous pelvic thrombosis and the patient has 
to take acenocoumarol. After a while, the situation of the patient becomes 
worse and worse. The patient is very tired. She cannot eat, drinking is an 
effort. The life expectancy is estimated between one and two weeks. The 
opioids cannot be taken orally and the intensity of the pain is high. 
16) You choose the new administration of opioids at home: 
A. Intraspinal administration    13 (8%) 
B. Sub-cutaneous administration   36 (23%) 
C. Transcutaneous administration   10 (6%) 
D. Intravenous administration   84 (53%) 
E. Other, precise:     15 (10%) 
Answers recommended in CPGs: B and/or D 
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This thesis analysed the quality of all available guidelines on 
neuropathic pain in patients with cancer in European countries. This 
chapter discusses the different research questions of this thesis: the 
quality and limitations of the individual results of the research 
questions, the main findings, and the conclusions of the chapters. 
Further, implications for practice, education and future research are 
considered. 
BACKGROUND 
Cancer is the first cause of death in Europe. (1) The most 
inconvenient symptom is pain, present in about 60% of the patients 
with cancer. (2, 3) Between 19 and 39% of them suffer from 
neuropathic pain. (4) This type of pain is well known for its 
pharmacologic resistance and may cause high disability like 
depression or insomnia. (5, 6) Despite the high prevalence of 
neuropathic pain in patients with cancer and its high impact on the 
quality of daily life, there is no consensus in the literature concerning 
its diagnosis or its treatment. General guidelines to improve the 
management of neuropathic pain have been published recently: 
diagnosis and treatment recommendations of the European 
Federation of Neurological Societies (EFNS) were launched in 2010 
and updated in the past two years. Besides, an algorithm for 
neuropathic pain diagnosis was published in 2011. (7, 8) However, 
these recommendations were created for non-oncological 
neuropathic pain; specific guidelines for patients with neuropathic 
cancer pain in Europe are absent in recent literature.  
Another important issue is the quality of the development of a 
guideline. If guidelines on this topic exist in Europe, the content 
should be assessed. In fact, clinical practice guidelines (CPGs) are 
“statements that promote or advocate a particular course of action in 
clinical care”. (9) These statements should be proposed according to 
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the recent review of the literature. (10) The lack of specific literature 
on neuropathic pain in cancer makes the development of specific 
recommendations challenging or impossible. A specific tool has been 
developed to assess the quality of development of guidelines: the 
Appraisal of Guidelines, Research and Evaluation (AGREE) instrument. 
(10) This internationally validated instrument consists of 6 domains: 
1) scope and purpose (overall aim of the guideline and target 
groups); 2) stakeholder involvement (stakeholders involved in 
guideline development and views of its intended users); 3) rigor of 
development (selection of the evidence and the method to create 
recommendations); 4) clarity and presentation (structure and format 
of the guideline); 5) applicability (facilitators and potential barriers 
for guideline implementation); 6) editorial independence (biases 
concerning conflicts of interest) and one overall assessment item 
judging if the CPG is recommended for its use in clinical practice. (10) 
The ratings of the quality domains showed to be good predictors of 
outcomes associated with implementation of guidelines, very useful 
and easy to use. (10) The original AGREE instrument has been refined 
to improve the original tool’s usability and its validity and reliability. 
(11) Thus, in 2008 the AGREE II instrument, a revision of the AGREE 
instrument, was developed by the AGREE collaboration. (11) Revision 
was done because the four-point response scale of the AGREE 
instrument was not reliable enough. (12, 13) The seven-point 
response scale seemed relevant, and the new user’s manual clear. 
(11) Besides, the AGREE II instrument appeared valid to assess the 
quality of development of a CPG on cancer. (12) For those reasons, 
we used the AGREE II instrument to assess the quality of 
development of European guidelines that contain at least one 
chapter on neuropathic cancer pain. 
Assessing the whole quality of a guideline is interesting, but this 
instrument is not built to evaluate the quality of the 
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recommendations in a guideline in detail. A systematic review of the 
references used to create recommendations can be useful to 
evaluate their robustness as proposed in an article on diabetes. (14) 
Particularly the diagnosis of neuropathic pain should be studied well: 
an early diagnosis guarantees a specific treatment and critically 
improves the quality of life of the patients. The treatment of 
neuropathic pain in patients with cancer is also an important issue of 
the thesis: recommendations are mostly based on extrapolation of 
recommendations in studies about neuropathic pain in a non-cancer 
population to this type of pain in a cancer population. (15-17) 
The number of guidelines has exponentially increased over the past 
decades and practitioners are supposed to know them and to use 
them properly. (18, 19) Knowing the numerous recommendations 
proposed, their application in clinical practice seems not possible 
without a very clear and short message for each clinical question. 
There is no consensus on how to evaluate the application of a 
guideline but the methodology using a case vignette in cancer and in 
pain seemed promising. (20, 21) A case vignette uses a case study 
with “text, images or other forms of stimuli to which research 
participants are asked to respond”. (22) This method, easy to use and 
inexpensive, showed a good reliability and reproducibility. (21, 23) 
The applicability of neuropathic cancer pain guidelines can be 
assessed using a case vignette, and might also give direction to future 
adaptation of guidelines in Europe. 
MAIN FINDINGS 
In chapter 2, the aim was to make an inventory of guidelines in 
Europe concerning neuropathic cancer pain. To be exhaustive, we 
aimed to check all guidelines concerning pain: guidelines on pain in a 
non-cancer context, on neuropathic pain, on cancer pain and on 
neuropathic pain in patients with cancer. As most guidelines are not 
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published in peer reviewed journals, the inventory was made using 
an email questionnaire addressed to European physicians with a 
special interest in neuropathic pain, namely members of the 
International Association for the Study of Pain (IASP) and of the 
European Federation of IASP Chapters (EFIC). The response rate was 
high: 41 of the 66 invited physicians answered the questionnaire 
(62%), representing thirty of the 38 European countries (79%). With 
their participation, 54 documents were found, of which 20 were 
CPGs: 6 on chronic pain, 5 on neuropathic pain, 4 on cancer pain, 2 in 
geriatrics, 1 in pediatrics and 2 on chronic low back pain. The number 
of countries with guidelines on pain was higher than we expected 
and each country used its own guideline. Only Serbia used the EFNS 
guideline and Ireland used the British CPGs. This framework was the 
basis for the assessment of 9 of these CPGs, all containing at least 
one chapter on neuropathic pain in patients with cancer: two Italian, 
one French, one British, two Dutch, two Norwegian and one Spanish 
CPG. (24-32) 
In chapter 3, the aim was to assess the quality of the development of 
these 9 guidelines that contained at least a chapter on neuropathic 
pain in cancer. There was much variation in quality between the 
CPGs. Scope and purpose of most CPGs was good, as well as the 
clarity of presentation, which is consistent with findings from other 
studies. (18, 33-34) Applicability of the CPGs was mostly low, 
implying that anticipating on implementation needs more emphasis 
in order to increase practitioners’ use. (35) One of the factors that 
could explain differences between CPGs may be the organization 
responsible for the CPG. In our study, two of the CPGs with the 
highest AGREE II scores were developed by institutes specialized in 
guideline development. A same result was demonstrated in a study 
of Burgers. (36) The review of Alonso-Coello et al. found a higher 
developmental quality in recently developed guidelines. (18) In our 
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assessment with AGREE II, we found higher median scores on the 
“purpose” and “clarity” domains in more recent CPGs. Guideline 
developers became more aware of the importance and methods of a 
systematic development process, maybe partly by publications on 
this topic and the availability of the AGREE and AGREE II instrument. 
(34) Most CPGs gave no information about views and preferences of 
the target patient population and their influence on the development 
of the recommendations; only three CPGs had patient’ 
representatives in their workgroup. (30-32) Probably, more guidance 
is needed on how to involve patients in this process. (37) 
Furthermore; most CPGs gave no attention to the applicability and 
implementation, while this is very important for clinicians. (38) 
In chapter 4, the aim was to study to which articles was referred 
regarding the recommendations on diagnosis of neuropathic pain in 
patients with cancer. About 149 articles were linked to the 
recommendations on neuropathic pain diagnosis and assessment in 
patients with cancer. More than 95% of them were not specifically 
related to patients with cancer. Only three references used 
recommendations on neuropathic pain diagnosis and assessment in 
cancer and focused on this patient population. Regarding the year of 
publication, these specific references appeared to be more recent 
than the others, in accordance with the recent interest of 
neuropathic pain in the cancer field. (39) Moreover, we found that 
only to 19% of the articles was referred in more than one CPG. These 
findings are in accordance with the weak rigor of development, as 
found in the AGREE II evaluation of the CPGs. (15) Concerning the key 
messages, in all CPGs it was recommended that the diagnosis of 
neuropathic pain should be done with a clinical examination: a good 
interrogation of the patient concerning the location of the pain and 
its components. Only two CPGs recommended using questionnaires 
to diagnose neuropathic pain, the “Douleur neuropathique en 4 
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questions (DN4) in the French CPG and the “neuropathic pain 
questionnaire (NPQ) in the Dutch one. (25, 32) No further 
investigation was mentioned in the CPGs, except for the Dutch (29) 
and the Norwegian CPG (26): IRM and EMG were recommended. This 
difference can be explained recommendations made by the EFNS to 
confirm the lesion by further tests to make a diagnosis of “certain 
neuropathic pain” and if the results are negative or not contributive, 
a diagnosis of “probable neuropathic pain”. (8) 
In chapter 5, 163 references were used to support the 
recommendations on neuropathic pain treatment in patients with 
cancer. Although the proportion of population-specific references 
again was low (11%), it was higher than regarding the diagnosis of 
neuropathic pain in patients with cancer (3%). (16) Moreover, the 
mean evidence level of the references was higher (44%). 
Nevertheless, few references were used in at least two CPGs (18%), 
and no reference was shared by all the CPGs. All CPGs recommended 
the use of antidepressant drugs, α2δ agonists and others 
anticonvulsant drugs. Yet, prescribing these drugs in first line 
treatment is not supported by high evidence level literature. For 
example, amitriptyline is the oldest anti-neuropathic drug and well 
investigated in non-cancer populations. (40) However Mercadante et 
al. demonstrated that the analgesic effects on neuropathic pain of 50 
mg of amitriptyline were small and associated with severe side 
events in patients with cancer. (41) Similar results were found in 
another study related to treatment for chemotherapy-induced 
neuropathic symptoms with amitriptyline. (42) In the majority of the 
CPGs, adverse events of antidepressants or anticonvulsants as 
treatment for neuropathic pain were not mentioned. Up to now, the 
benefit-risk ratio of these drugs in patients with cancer is unknown. 
(41, 43) Consequently, we recommend that CPGs mention 
restrictions when study findings in non-cancer populations are 
extrapolated to patients with cancer.  
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In chapter 6, we assessed the knowledge and the use of CPGs of 214 
French pain specialists concerning neuropathic pain in a patient with 
cancer. Although more than 85% of the respondents declared to 
know and to use the CPGs, only part of them followed the 
recommendations regarding this case vignette. About 95% followed 
recommendations for the management of nociceptive cancer pain, 
using the WHO analgesic ladder. This ladder was already published in 
the eighties and apparently well known by pain specialists. (44) 
Concerning depression, only 28% of the anaesthesiologists versus 
11% of the GPs proposed antidepressant drugs and a consultation 
together with a psychologist. These results can be explained: 
antidepressants drugs are not proposed as first choice in the 
treatment of depression in the French CPG for GPs and literature 
showed the lack of efficacy of these drugs without frequent 
psychotherapy. (45-47) In these conditions, it is difficult to make a 
clear recommendation in CPGs. Only 50% of the respondents 
followed the CPGs regarding neuropathic pain management. 
Although this figure can be considered as high in comparison to 
literature on guideline adhesion, they are quite low in this population 
of pain specialists with an extensive training in neuropathic pain. (48) 
In fact, recommendations in CPGs are not sufficiently based on 
clinical practice and thus not easily applicable. (15) Moreover, there 
was no implementation strategy connected to the publication of the 
CPGs, although this, together with monitoring its impact, is necessary 
to improve the use of a CPG. (49)  
 
STRENGHTS AND LIMITATIONS OF THIS THESIS 
This thesis is innovative, as well in the choice of the topic as in the 
methods used.  
Neuropathic cancer pain in Europe and GPGs 
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Lately, neuropathic pain in patients with cancer has started to get 
more attention from the professional community as confirmed by a 
recent article in the IASP newsletter. (39) Neuropathic cancer pain 
was described as difficult to diagnose and to treat. A need for 
randomized placebo-controlled trials was underlined by the authors. 
(39) Yet, studies concerning this topic are scarce. In this thesis, 
literature concerning the management of neuropathic pain in cancer 
used in CPGs was studied in a structure and detailed way. Diagnosis 
and treatment were clearly described and the lack of uniformity in 
the choice of the evidence was underlined. (15-18) Moreover, the 
choice of a European overview was interesting: most of the studies 
used only English guidelines and a lot of information was lacking. (18-
19) Using this methodology, it was possible to explore different 
cultures and medical context in Europe, which can differ from Anglo-
Saxon literature. Our results emphasized the heterogeneity and the 
extent of guidelines on pain and especially neuropathic cancer pain 
CPGs in Europe and their different level of quality. Of the 30 
countries, 8 had no CPG on cancer pain, despite the international 
recommendation of the WHO published in 1986. (44) Ten countries 
had no CPG on neuropathic pain, despite the EFNS guideline. (7) In 
conclusion, neuropathic pain in patients with cancer should be 
scientifically studied and translated to CPGs by a special group of 
interest in international pain society. Efforts should be made to 
integrate physicians’ point of view and knowledge to increase the 
implementation of a CPG. In this aspect, a cultural and economical 
adaptation of the guideline is needed, to facilitate implementation. 
Method and design of the studies 
Inventory of CPGs in Europe. An extensive overview of guidelines that 
contain information about pain was made with the help of EFIC and 
the NeuPSIG members. In contrast to other studies, we also included 
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guidelines that were not written in the native language of the 
researchers. (18, 19) With the translator toolkit of Google, we were 
able to assess the non-English CPGs after validation of the translation 
by native or fluent speakers to improve the quality of the translation. 
Although neuropathic pain in cancer patients is a worldwide problem, 
we only assessed European CPGs. The main reason for this restriction 
was the opportunity to collaborate with the EFIC and NeuPSIG, which 
helped us to collect information from 30 of the 38 European 
countries.  
The AGREE II instrument. We used AGREE II, the updated version of 
the AGREE instrument. AGREE II, which uses a 7-point Likert scale 
(instead of the 4-point Likert scale in the AGREE instrument), 
improves the reliability of the item and domain scores. (12, 13) This 
instrument was used recently for the assessment of guidelines for 
migraine and gave a good overview of the development of guidelines 
in cancer. (18, 19) However, results of the AGREE II assessment 
should be interpreted with caution. Using information only available 
in the CPG may limit the validity of the scores. Besides, AGREE II 
focuses on the methods and reporting of the guideline, but does not 
assess the validity of the diagnosis, medical content, and clinical 
recommendations. (10) For that reason, each reference and clinical 
messages in these 9 CPGs were studied and analyzed in article 3 and 
4. 
Levels of evidence and grades of recommendation. In a precedent 
article on diabetes, the levels of evidence and grades of 
recommendation were analyzed according the references quoted in 
CPGs (14). This method was used for the first time in neuropathic 
cancer pain for the diagnosis and the treatment. (16, 17) Considering 
criteria used in the diagnosis algorithm recommended by NeuPSIG, 
proposed recommendations of national CPGs in Europe appeared too 
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general for a proper diagnosis of neuropathic mechanism in pain 
occurring in a cancer context. (8) The results emphasized also the lack 
of robust references on treatment for neuropathic pain in cancer 
conditions. (17) These findings might be partly explained by the 
heterogeneity of the evidence grading in these guidelines. Detailed 
recommendations are available to evaluate the level of evidence of 
an article and the grade of a recommendation. (50) However, their 
utilization becomes difficult when there are few references on a 
clinical topic.  
Case vignette for pain specialists training. This is the first study that 
investigated practical knowledge of pain specialists and the first 
vignette study in which they had to deal with pain in a patient with 
cancer. Relevant points for patient care were identified: 1) physicians 
should realize that they have responsibility to know and use a CPG 
and look at the updated CPGs, especially in case of limited knowledge 
on a topic, 2) a specific training in pain is interesting to improve the 
professionals’ knowledge. Although the response rate was low (24%), 
it was comparable with other French surveys using case vignettes and 
seemed to be a good representation of all members of the French 
pain society. (51, 52) Yet, the respondents of the case vignette were 
probably the ones most involved in cancer pain management, giving 
the best responses. Pain physicians were not familiar with this 
method of case vignette, explaining that those who did not complete 
the questionnaire probably had problems to use it, explaining the 
number of participants that did not complete the entire 
questionnaire.  
PERSPECTIVES FOR FUTURE RESEARCH 
There are several reasons why developing a CPG on neuropathic pain 
in cancer preferably should be done with an international team. The 
most important reason is to improve the quality of the CPGs for a 
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better implementation. Besides, it would help to pool costs and time. 
Up to now there are too few high quality studies to give strong 
recommendations: in a European or international context studies can 
be performed with a better power and better methodology than per 
country. Each participating country will have the opportunity to fine-
tune the international guideline to the national health care and 
cultural situation. A European CPG can be interesting to obtain a high 
quality CPG on neuropathic pain in patients with cancer. The aim is to 
have the best review of the literature, an exhaustive experts’ opinion, 
studies on patients’ view and a good description of the possible 
barriers and facilitators for guideline application. However, this 
international guideline can be interesting only if it is adapted to the 
specificity and culture of each country, its medical obligations and its 
social environment. The ADAPTE working group developed a 
procedure to adapt each international guideline for the national 
context. (53) Proposed in 2006, 7 steps were described, presented in 
table 1. (53) A global European CPG, not too detailed to have room to 
adapt it to each specific situation, as a “blueprint” can be interesting. 
This blueprint document should be a document with the most 
important information about the specific topic that can be adapted 
by every professional group according their local standards in 
implementable material. 
A European CPG on neuropathic pain in patients with cancer would 
facilitate the creation of a high quality CPG with the best experts and 
the best methodologists, including GPs and patients.  
Next, each country can adapt such a European CPG to the national 
context. For example, in 2009 the IASP proposed the 
“Recommendations for Pain Treatment Services” which was adapted 
by each Chapter for their own country. (54) Another example is the 
adaptation and the translation of the definition and roles of a GP by 
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the WONCA Europe. (55) Good quality of care for every patient in 
combination with saving time and money. 
Table 1. The ADAPTE procedure in 7 steps. (54) 
Step 1 Definition of the clinical question: healthcare setting and 
context should be studied. 
Step 2 Literature search: the language should be chosen 
according to the target population 
Step 3 Assessing clinical content of the source guideline: the 
target population interest should be clearly studied 
Step 4 Quality and coherence of the source: CPG should be 
assessed using AGREE II instrument 
Step 5 Adaptations of the recommendations should be done by 
national experts 
Step 6 External review of the adapted guideline 
Step 7 Adoption, endorsement and implementation of the 
adapted CPG should be regularly realized and updated 
 
The European collection of the guidelines gave an important amount 
of data, wealthy in clinical messages and literature on neuropathic 
pain in patients with cancer. A worldwide overview, using North-
American and Australian CPGs could be interesting to complete this 
topic. 
GENERAL CONCLUSION 
In Europe in 2010, 54 documents on chronic pain, neuropathic pain 
or cancer pain were available to guide physicians. Among them, only 
20 met the criteria of CPGs. It is surprising that European countries 
did not use available CPGs already present in other pain societies. An 
international inventory is needed to improve the data collection and 
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give more guidance on the management of neuropathic pain in 
patients with cancer. 
Concerning CPGs on neuropathic cancer pain in Europe, their quality 
is modest. All domains and items showed room for improvement in 
most CPGs, in particular incorporating the patients’ views, describing 
the systematic review process, and giving recommendations about 
the implementation of the CPG. The majority of guideline 
development groups extrapolated results of studies on non-cancer 
neuropathic pain to recommendations for patients with cancer. 
Consequently, these CPGs fail to address important issues such as 
altered kinetics and side effect profiles in these patients. This can be 
explained by the fact that we did not find a CPG merely dedicated to 
the treatment of neuropathic pain in cancer patients.  
This clinical problem in this specific patient group concerns an area of 
medical uncertainty, iatrogenic complications, and interventions with 
significant risks and costs, and therefore fits into the criteria for 
creating an independent CPG. (9) CPG developers should emphasize 
that the scientific evidence is weak and should be interpreted with 
caution. Besides, more research is needed on neuropathic cancer 
pain patients to provide evidence for more reliable CPGs.  
As developing guidelines is time-consuming and expensive; 
international cooperation in CPG development might be a solution to 
increase quality and to reduce costs. (56) We advise more 
international central cooperation (clinicians and methodologists) for 
the development of a European CPG on neuropathic pain in cancer 
patients: it would help to pool resources into a high quality guideline 
module. 
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A high quality level of the CPG is required but not sufficient. Their 
applicability is often not evaluated. One of the barriers to use a CPG 
was its unsuitability in daily practice. (57)  
Next step can be the assessment of the knowledge and the 
application of CPGs in Europe. Specific case vignettes can be 
developed and tested for several aspects of pain education as they 
are an inexpensive tool, easy to use to assess this in a large group of 
physicians, which can easily be repeated, for example after a training 
or implementation program (58-61). It will help to evaluate the level 
of the educational module and adapt the training accordingly. 
Structured education and evaluations resulting in a diploma will 
improve the knowledge of the practicing physicians.  
 
REFERENCES 
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. 
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. 
2.  Rayment C, Hjermstad MJ, Aass N, Kaasa S, Caraceni A, Strasser F, Heitzer E, 
Fainsinger R, Bennett MI; On behalf of the European Palliative Care Research 
Collaborative (EPCRC). Neuropathic cancer pain: Prevalence, severity, analgesics 
and impact from the European Palliative Care Research Collaborative-
Computerised Symptom Assessment study. Palliat Med. 2012 Nov 21. 
3. Caraceni A, Portenoy RK. An international survey of cancer pain characteristics 
and syndromes. IASP Task Force on Cancer Pain. International Association for the 
Study of Pain. Pain. 1999 Sep;82(3):263-74. 
4. Bennett MI, Rayment C, Hjermstad M, Aass N, Caraceni A, Kaasa S. Prevalence 
and aetiology of neuropathic pain in cancer patients: a systematic review. Pain, 
2012; 153(2), 359-365.  
5. Breivik H, Cherny N, Collett B, et al. Cancer-related pain: a pan-European survey 
of prevalence, treatment, and patient attitudes. Ann Oncol. 2009;20:1420–1433. 
   Chapter 7 - Discussion 
165 
 
6. van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van 
Kleef M, Patijn J. Prevalence of pain in patients with cancer: a systematic review of 
the past 40 years. Ann Oncol. 2007 Sep;18(9):1437-49. 
7. Cruccu G, Sommer C, Anand P, Attal N, Baron R, Garcia-Larrea L, et al. EFNS 
guidelines on neuropathic pain assessment: revised 2009. Eur J Neurol 2010 Mar 8. 
8. Haanpaa M, Attal N, Backonja M, Baron R, Bennett M, Bouhassira D, et al. 
NeuPSIG guidelines on neuropathic pain assessment. Pain. 2011;152(1):14-27. 
9. Field MJ, Lohr KN. Guidelines for clinical practice: from development to use. 
Washington: National Academy Press, 1992. 
10. Burgers J, Grol R, Klazinga N, Mäkela M, Zaat J. AGREE Collaboration. Towards 
evdience-based clinical practice: an international survey for 18 clinical guideline 
programs. Int J Qual Health Care, 2003; 15 (1): 31-45. 
11. Bouwers M, Kho ME, Browman GP, Burgers JS, Cluzeau F, Feder G, Fervers B, 
Graham ID, Grimshaw J, Hanna S, Littlejohns P, Makarski J, Zitzelsberger L for the 
AGREE Next Steps Consortium. AGREE II: Advancing guideline development, 
reporting and evaluation in healthcare.  Can Med Assoc J.  2010.  Dec 2010. 
12. Brouwers MC, Kho ME, Browman GP, et al. Development of the AGREE II, part 
1: performance, usefulness and areas for improvement. CMAJ. 2010;182:1045–
1052. 
13. Brouwers MC, Kho ME, Browman GP, et al. Development of the AGREE II, part 
2: assessment of validity of items and tools to support application. CMAJ. 
2010;182:E472–E478. 
14. Burgers JS, Bailey JV, Klazinga NS, Van Der Bij AK, Grol R, Feder G, Agree C. 
Inside guidelines: comparative analysis of recommendations and evidence in 
diabetes guidelines from 13 countries. Diabetes care 2002;25(11):1933-1939. 
15. Piano V, Schalkwijk A, Burgers J, Verhagen S, Kress H, Hekster Y, Lanteri-Minet 
M, Engels Y, Vissers K. Guidelines for neuropathic pain management in patients 
with cancer: a european survey and comparison. Pain Pract. 2012 Oct 13. 
16. Piano V, Verhagen S, Schalkwijk A, Burgers J, Kress H, Treede RD, Hekster Y, 
Lanteri-Minet M, Engels Y, Vissers K. Diagnosing neuropathic pain in patients with 
cancer: comparative analysis of recommendations in national guidelines from 
European countries. Pain Pract. 2012 Dec 19. 
17. Piano V, Verhagen S, Schalkwijk A, Burgers J, Kress H, Treede RD, Hekster Y, 
Lanteri-Minet M, Engels Y, Vissers K. Treatment of neuropathic pain in patients 
Improving neuropathic cancer pain in Europe 
166 
 
with cancer: comparative analysis of recommendations in national guidelines from 
European countries. Pain practice 2012 in press. 
18. Alonso-Coello P, Irfan A, Sola I, et al. The quality of clinical practice guidelines 
over the last two decades: a systematic review of guideline appraisal studies. Qual 
Saf Health Care. 2010,19:e58. 
19. Loder E, Burch R, Rizzoli P. The 2012 AHS/AAN guidelines for prevention of 
episodic migraine: a summary and comparison with other recent clinical practice 
guidelines. Headache. 2012;52:930–945. 
20. Henderson TO, Hlubocky FJ, Wroblewski KE, Diller L, Daugherty CK (2010). 
Physician preferences and knowledge gaps regarding the care of childhood cancer 
survivors: a mailed survey of pediatric oncologists. Journal of Clinical Oncology, 
28(5), 878-83. 
21. Rutten GMJ, Harting J, Rutten STJ, et al. Measuring physiotherapists’guideline 
adherence by means of clinical vignettes: a validation study. J Eval Clin Pract 2006; 
12, 491-500. 
22. Hughes R. & Huby M. The application of vignettes in social and nursing 
research. J Adv Nurs 2002 Fev; 37 (4), 382–86. 
23. Bishop A, Foster NE, Thomas E, et al. How does the self-reported clinical 
management of patients with low back pain relate to the attitudes and beliefs of 
health care practitioners? A survey of UK general practitioners and 
physiotherapists. Pain 2008 Mar; 135 (1-2): 187-95.  
24. ASL. Raccomandazioni per il controllo del dolore neoplastico. Ravenna: ASL; 
2006. 
25. Martinez V, Attal N, Bouhassira D, Lanteri-Minet M. Douleurs neuropathiques 
chroniques: diagnostic, évaluation et traitement en me´decine ambulatoire. 
Douleurs. 2011;11:3–21. 
26. Nasjonale faglige retlingslinjer. Nasjonalt handlingsprogram med retningslinjer 
for palliasjon i kreftomsorgen; 2007. 
27. AIOM linea guida. Terapia del dolore in oncologia; 2008. 
28. Plan Nacional para el SNS del MSC. Guı´a de Practica Clınica sobre cuidados 
paliativos; 2008. 
29. Vereniging Integrale Kankercentra. Pijn in de palliatieven fase; 2008. 
30. Den Norske Legeforening Retningslinjer for smertelindring; 2008. 
   Chapter 7 - Discussion 
167 
 
31. SIGN. Control of Pain in Adults with Cancer. Edinburgh: Scottish Intercollegiate 
Guidelines Network publication; 2008. 
32. CBO. Richtlijn diagnostiek en behandeling van pijn bij patienten met kanker; 
2008. 
33. Fervers B, Burgers JS, Haugh MC, et al. Predictors of high quality clinical practice 
guidelines: examples in oncology. Int J Qual Health Care. 2005;17:123–132. 
34. Santos F, Sola I, Rigau D, et al. Quality assessment of clinical practice guidelines 
for the prescription of antidepressant drugs during pregnancy. Curr Clin Pharmacol. 
2012;7:7–14. 
35. Lugtenberg M, Burgers JS, Besters CF, Han D, Westert GP. Perceived barriers to 
guideline adherence: a survey among general practitioners. BMC Fam Pract. 
2011;12:98. 
36. Verhagen CC, Niezink AG, Engels YY, Hekster YY, Doornebal JJ, Vissers KC. Off-
label use of drugs in pain medicine and palliative care: an algorithm for the 
assessment of its safe and legal prescription. Pain Pract. 2008;8:157–163. 
37. Krahn M, Naglie G. The next step in guideline development: incorporating 
patient preferences. JAMA. 2008;300:436–438. 
38. Van Fenema E, Van Der Wee NJ, Bauer M, Witte CJ, Zitman FG. Assessing 
adherence to guidelines for common mental disorders in routine clinical practice. 
Int J Qual Health Care. 2012;24:72–79. 
39. Naleschinski D, Baron R, Miaskowski C. Identification and treatment of 
neuropathic pain in patients with cancer. IASP newsletter. Pain clinical updates. 
2012;XX:1–4. 
40. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database 
Syst Rev. 2005;3:CD005454. 
41. . Mercadante S, Arcuri E, Tirelli W, Villari P, Casuccio A. Amitriptyline in 
neuropathic cancer pain in patients on morphine therapy: a randomized placebo-
controlled, doubleblind crossover study. Tumori. 2002;88(3):239–242. 
42. Kautio AL, Haanpaa M, Saarto T, Kalso E. Amitriptyline in the treatment of 
chemotherapy-induced neuropathic symptoms. J Pain Symptom Manage. 
2008;35(1):31–39. 
43. Wolf J, Hubbard H, Faraday M, Forrest J. Clinical practice guidelines to inform 
evidence-based clinical practice. World J Urol. 2011;29(3):303–309. 
Improving neuropathic cancer pain in Europe 
168 
 
44. World Health Organization. Cancer Pain relief. Geneva, 1986. 
45. HAS. Dépression de l’adulte : épisode isolé pris en charge par le psychiatre en 
ambulatoire. Référentiel d’évaluation. 2005. 
46. Warmenhoven F, van Rijswijk E, van Hoogstraten E, et al. How family physicians 
address diagnosis and management of depression in palliative care patients. Ann 
Fam Med 2012 Jul-Aug; 10(4):330-6.  
47. Hart SL, Hoyt MA, Diefenbach M, et al. Meta-analysis of efficacy of 
interventions for elevated depressive symptoms in adults diagnosed with cancer. J 
Natl Cancer Inst 2012 Jul 3;104(13):990-1004.  
48. Mickan S, Burls A, Glasziou P. Patterns of 'leakage' in the utilisation of clinical 
guidelines: a systematic review. Postgrad Med J 2011 Oct; 87(1032):670-9. 
49. Grol R, Grimshaw J. From best evidence to best practice: effective 
implementation of change in patients' care. Lancet 2003; 362(9391), 1225-1230. 
50. SIGN 50 A guideline developer’s handbook. Annex B, page 51. Revised edition 
November 2011. ISBN 978 1 905813 25 4. SIGN executive, Edinburg EH7 5EA. 
51. Ventelou B, Rolland S, Verger P. A Case Study on the Substitution Effect 
between the Length of GP Consultation and Drug Prescribing Practices. Healthc 
Policy 2010; 5(4), 58-68. 
52. Falchi A, Lasserre A, Gallay A, et al. A survey of primary care physician practices 
in antibiotic prescribing for the treatment of uncomplicated male gonoccocal 
urethritis. BMC Fam Pract 2011 May 18; 12(1), 35.  
53. Fervers B, Burgers JS, Haugh MC, et al.  Adaptation of clinical guidelines: 
literature review and proposition for a framework and procedure. Int J Qual Health 
Care 2006;18(3):167-76. 
54. Recommendations for pain treatment services. IASP, May 2, 2009, Washington. 
55. Extract from internet in January the 21th, 2013 at this URL address: 
http://www.woncaeurope.org/gp-definitions 
56. Burgers JS, Anzueto A, Black PN, Cruz AA, Fervers B, Graham ID, Metersky M, 
Woodhead M, Yawn BP; on behalf of the ATS/ERS Ad Hoc Committee on 
Integrating and Coordinating Efforts in COPD Guideline Development. Adaptation, 
Evaluation, and Updating of Guidelines: Article 14 in Integrating and Coordinating 
Efforts in COPD Guideline Development. An Official ATS/ERS Workshop Report. 
Proc Am Thorac Soc. 2012 Dec;9(5):304-310. 
   Chapter 7 - Discussion 
169 
 
57. Cabana MD, Rand CS, Powe NR, et al. Why don't physicians follow clinical 
practice guidelines? A framework for improvement. JAMA 1999; Oct 
20;282(15):1458-65. 
58. Peabody JW, Luck J, Glassman P, et al. Comparison of vignettes, standardized 
patients, and chart abstraction. JAMA 2000 Apr 5; 283, 1715-22. 
59. Lucet JC, Nicolas-Chanoine MH, Lefort A et al. Do case vignettes accurately 
reflect antibiotic prescription? Infect Control Hosp Epidemiol. 2011 Oct; 
32(10):1003-9. 
60. Peabody JW, Luck J, Glassman P, et al. Measuring the quality of physician 
practice by using clinical vignettes: a prospective validation study. Ann Intern Med 
2004 Nov 16;141(10):771-80. 
61. Dresselhaus TR, Peabody JW, Luck J, et al. An evaluation of vignettes for 
predicting variation in the quality of preventive care. J Gen Intern Med 2004 
Oct;19(10):1013-8. 
 
Improving neuropathic cancer pain in Europe 
170 
 
  
 171 
 
 
 
 
 
Chapter 8 – Summary 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Virginie PIANO 
Improving neuropathic cancer pain in Europe 
 
172 
 
  
  Chapter 8 - Summary 
173 
 
Summary 
This thesis concerns the quality of clinical practice guidelines (CPGs) from 
European countries on neuropathic pain in patients with cancer. This work 
was co-funded by the Netherlands Organisation for Health Research and 
Development (ZonMw). 
Chapter 1. Introduction 
Between 19% and 39% of patients with cancer pain suffer from neuropathic 
pain (NP). Diagnosing and treating NP in this group of patients is difficult 
and built on weak support in the scientific literature. Yet physicians need 
guidance on how to screen, to diagnose and to treat. CPGs can be a useful 
aid. CPGs are ‘systematically developed statements to assist practitioners and 
patient decisions about appropriate health care for specific circumstances’. 
However, do CPGs on this topic for this patient group exist in Europe? And 
if so, what is their quality? Are they based on systematic reviews? Are they 
applicable in practice? This thesis studied these questions in five articles. 
CHAPTER 2. Inventory of clinical practice guidelines in Europe for the 
treatment of neuropathic pain in patients with cancer 
CPGs are ‘systematically developed statements to assist practitioners and patient 
decisions about appropriate health care for specific circumstances’. Many 
patients in Europe suffer from chronic pain, often in combination with co-
morbidities. If available and of good quality, CPGs can guide practitioners in 
diagnosing and treating pain. Therefore, we studied the number and quality 
of CPGs in European countries for chronic pain, cancer pain and 
neuropathic pain.  
A questionnaire was sent by email to the European Federation of IASP 
chapters (EFIC) and IASP members specialised in neuropathic pain in Europe 
(NeuPSIG). Data on the name and topic (pain, cancer pain and neuropathic 
pain, other) of each document was collected. The documents had to meet 
the criteria of a CPG. Frequencies were calculated using SPSS 16. The 
questionnaire was completed by 41 of the 66 email recipients (62%), 
representing 30 of the 38 European countries. Together, they mentioned 54 
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documents, of which 20 met the CPG criteria: 6 for chronic pain, 5 for 
neuropathic pain, 4 for cancer pain, 2 in geriatrics, 1 in paediatrics and 2 for 
chronic lower back pain.  
There was significant heterogeneity within Europe concerning the 
availability, quality and content of CPGs. An international CPG could be 
helpful in making the management of pain safer and more efficient. Such a 
blueprint could be adapted for use in each country according to its health 
system.  
CHAPTER 3.  Guidelines for neuropathic pain management in patients with 
cancer: a European survey and comparison 
Between 19% and 39% of patients with cancer pain suffer from neuropathic 
pain. Diagnosing and treating NP is challenging. CPGs have been developed 
in several European countries to assist practitioners in managing NP in 
these patients safely and legally. The aim of this study was to assess the 
quality of the development and reporting of these CPGs. 
A European inventory of CPGs was conducted in collaboration with the 
EFIC. The inclusion criterion was that at least one paragraph should be 
dedicated to the treatment of neuropathic pain in cancer. Using the 
Appraisal of Guidelines, Research and Evaluation II instrument (AGREEII), 
two appraisers independently assessed the quality of the development 
process of the CPGs included with regard to its six domains. Furthermore, t-
tests were used to compare CPGs developed by governmental organisations 
with those developed by professional societies. The mean scores of the 
domains of ’scope and purpose’ (80%) and ‘clarity of presentation’ (61%) 
were satisfactory, ‘stakeholder involvement’ (58%), ‘rigour of development’ 
(57%), and ‘editorial independence’ (53%) were acceptable, and 
‘applicability’ was insufficient (39%). Governmental guidelines had higher 
scores than professional society guidelines for the domains of ‘stakeholder 
involvement’ and ‘editorial independence’ (P < 0.01). The quality of the 
development process of the nine CPGs included varied widely. CPGs should 
be developed within a structured guideline programme that includes 
methodological support. As developing a CPG is expensive and time-
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consuming, we recommend more international cooperation to increase the 
quality and lower the developmental costs.  
CHAPTER 4.  Diagnosing neuropathic pain in patients with cancer:  
comparative analysis of recommendations in national guidelines in 
European countries 
Neuropathic pain is a prevalent symptom in patients with cancer and it 
needs a more specific algorithm than nociceptive pain or neuropathic pain 
originating from a source other than cancer or its treatment. Clinical 
practice guidelines (CPGs) can be helpful in optimising the diagnosis of 
neuropathic pain in patients with cancer. In this study, all nine national 
CPGs in Europe on the diagnosis of neuropathic pain in patients with cancer 
were examined. A comparison was made between CPGs of the 
recommendations, the quality (grading) of the supporting literature 
(according to the SIGN 55 classification) and characteristics of the 
supporting literature (first author, patients’ population, year and type of 
publication). In total, 149 references were used in the 9 CPGs, of which 72 
(48%) were about cancer conditions, 39 (26%) about neuropathic pain, and 
only 3 about neuropathic pain in patients with cancer (2%). Only 28 (19%) 
references were shared between 2 or more guidelines. There was only one 
shared reference specifically related to neuropathic pain in patients with 
cancer.  
Recommendations and the grading of the supporting evidence differed 
substantially between the CPGs. This study showed significant 
heterogeneity in European recommendations on the diagnosis and 
assessment of neuropathic pain in patients with cancer. The main 
weaknesses are the low level of the supporting evidence and the absence of 
specific data focusing on neuropathic pain in patients with cancer. We 
recommend that physicians dealing with neuropathic pain in patients with 
cancer should be specially trained for this, that a specific methodology for 
developing CPGs should be adopted and that high quality research is 
needed on the diagnosis of neuropathic pain in patients with cancer. 
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CHAPTER 5.  Treatment of neuropathic pain in patients with cancer: 
comparative analysis of recommendations in national clinical practice 
guidelines from European countries 
Of patients with cancer, 19-39% suffer from neuropathic pain. Treating this 
type of pain is challenging as this patient group is often frail and has co-
morbidities that increase the risk of side-effects and hence affect their 
quality of life. CPGs can be helpful for clinicians, especially when scientific 
evidence is uncertain or weak. In this study, we focused on the quality of 
the review of the literature used to give treatment recommendations in the 
selected European CPGs. Nine CPGs from European countries that 
contained at least one paragraph on neuropathic pain in cancer were 
included. A comparison was made between CPGs of the recommendations, 
the quality (grading) of the supporting literature (according to the SIGN 55 
classification) and characteristics of the supporting literature (first author, 
patients’ population, year and type of publication). In all the CPGs, 
amitriptyline was mentioned as the drug of first choice. Six guidelines also 
proposed gabapentinoids. Only 30 of the 163 citations (18%) were based on 
studies of patients with cancer. Seven CPGs did not discuss the indirect 
evidence through the extrapolation of study results from non-cancer 
patients to patients with cancer. The majority of guideline development 
groups extrapolated their results to formulate recommendations based on 
non-cancer publications, without explicitly mentioning this as a limitation. 
Consequently, these guidelines fail to address important issues such as the 
different kinetics and side-effect profiles in these patients. We recommend 
creating specific recommendations by an international expert group for the 
treatment for neuropathic pain in patients with cancer, supported by 
targeted research on patients with cancer.  
CHAPTER 6.  A vignette study to evaluate the practical knowledge of 
French pain specialists concerning clinical practice guidelines on 
neuropathic pain in patients with cancer 
Between 19% and 39% of patients with cancer suffer from pain that is 
difficult to diagnose and to treat: neuropathic pain. In France, CPGs on this 
topic exist, but the extent to which French pain specialists are aware of the 
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recommendations from these CPGs and use them is unknown. The aim was 
to investigate, with the help of a case vignette, whether pain specialists 
follow the recommendations in the CPGs in clinical practice. The survey 
consisted of a case vignette about a patient with pain suffering from an 
intractable pancreatic cancer. The vignette included multiple choice 
questions about the diagnosis and treatment of (neuropathic) pain. An 
email survey was conducted with the support of the Société Française 
d’Etude et de Traitement de la Douleur *French society for the study and 
treatment of pain], with questionnaires being sent to all pain specialists 
(primary and secondary care) in France. The percentages of respondents 
who treated the patient as suggested in the CPGs were calculated. A total 
of 214 (24%) of those invited to participate (921) completed the 
questionnaire. More than 85% of the respondents said that they were 
familiar with and used these CPGs. Half of the respondents diagnosed and 
treated neuropathic pain components in the case vignette in accordance 
with the recommendations in the CPGs. Although the responding pain 
specialists stated that they knew and used the CPGs on neuropathic pain in 
cancer patients, half of them did not give answers that were in line with the 
recommendations. A nationwide programme to implement these CPGs is 
necessary, including better education and training of pain specialists in 
assessing and treating neuropathic pain.  
Chapter 7.  General discussion  
In 2010, we collected 54 documents from European countries with 
recommendations on diagnosing and treating chronic pain, neuropathic 
pain or cancer pain. Twenty documents met the clinical practice guideline 
criteria. Their developmental quality, as determined with the AGREEII 
instrument, was moderate. Greater efforts need to be made in 
incorporating patients’ views, describing the systematic review process and 
giving recommendations on the implementation of the CPG. The majority of 
guideline development groups extrapolated the results of studies of non-
cancer neuropathic pain to arrive at recommendations for patients with 
cancer.  
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NP in patients with cancer is an area where medical knowledge is lacking, 
where iatrogenic complications are involved and where interventions carry 
significant risks and costs; it therefore meets the criteria for creating a 
separate CPG. As the development of guidelines is time-consuming and 
expensive, international cooperation in CPG development can be a solution 
that can increase quality and reduce costs. For that reason, we recommend 
more international and centralised cooperation (involving clinicians, general 
practitioners and researchers) for the development of a European CPG on 
neuropathic pain in cancer patients; it would enable the pooling of 
resources to produce a high quality CPG. Specific case vignettes can be 
developed and tested for various aspects of pain education as they are an 
inexpensive tool and easy to use. They can be used to assess the 
implementation of the CPG among a large group of physicians, and can 
easily be repeated, for example after a training programme or 
implementation programme. This will help to evaluate the standard of the 
educational module and adapt the training programme accordingly.  
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Samenvatting 
 
Dit proefschrift gaat over de kwaliteit van klinische praktijk richtlijnen 
(CPGs) uit Europese landen met betrekking tot neuropathische pijn bij 
patiënten met kanker. Dit werk werd mede gefinancierd door de 
Nederlandse organisatie voor gezondheidsonderzoek en zorginnovatie 
(ZonMw). 
Hoofdstuk 1. Introductie 
Tussen 19% en 39% van de patiënten met kanker lijdt aan neuropathische 
pijn (NP). Diagnose en behandeling van NP in deze groep patiënten is 
moeilijk en is beperkt onderbouwd in de wetenschappelijke literatuur. Toch 
hebben de artsen aanwijzingen nodig over hoe te screenen, te 
diagnosticeren en te behandelen. Hiervoor kunnen CPGs een handig 
hulpmiddel zijn. CPGs zijn 'systematisch ontwikkelde richtlijnen om artsen 
en patiënten te helpen beslissen over passende zorg in specifieke 
omstandigheden’. Echter, bestaan er CPGs over dit onderwerp voor deze 
groep patiënten in Europa? En zo ja, wat is hun kwaliteit? Zijn ze gebaseerd 
op systematische reviews? Zijn ze toepasbaar in de praktijk? Dit proefschrift 
bestudeerde deze vragen in vijf artikelen. 
HOOFDSTUK 2. Inventarisatie van klinische praktijk richtlijnen in Europa 
voor de behandeling van neuropathische pijn bij patiënten met kanker 
CPGs zijn 'systematisch ontwikkelde richtlijnen om artsen en patiënten te 
helpen beslissen over passende zorg in specifieke omstandigheden'. Veel 
patiënten in Europa lijden aan chronische pijn, vaak in combinatie met 
comorbiditeiten. Indien beschikbaar en van goede kwaliteit, kunnen CPGs 
artsen begeleiden in het diagnosticeren en behandelen van pijn. Daarom 
bestudeerden wij het aantal en de kwaliteit van CPGs in Europese landen 
voor chronische pijn, pijn bij kanker en neuropathische pijn. 
Een vragenlijst werd toegezonden via e-mail naar de Europese Federatie 
van IASP afdelingen (EFIC) en IASP leden gespecialiseerd in neuropathische 
pijn in Europa (NeuPSIG). Gegevens over de naam en het onderwerp (pijn, 
pijn bij kanker en neuropathische pijn, of andere soorten pijn) werden van 
elk document verzameld. De documenten moesten aan de criteria van een 
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CPG voldoen. De frequenties werden berekend met behulp van SPSS 16. De 
vragenlijst werd ingevuld door 41 van de 66 personen aan wie de e-mail 
was gestuurd (62 %), wat neerkomt op 30 van de 38 Europese landen. 
Samen hebben ze 54 documenten genoemd, waarvan er 20 voldeden aan 
de criteria voor CPGs: 6 voor chronische pijn, 5 voor neuropathische pijn, 4 
voor pijn bij kanker, 2 in de geriatrie, 1 in de pediatrie en 2 voor chronische 
lage rugpijn.  
Er was een significante heterogeniteit binnen Europa met betrekking tot de 
beschikbaarheid, de kwaliteit en de inhoud van CPGs. Een internationale 
CPG zou nuttig kunnen zijn bij het veiliger en efficiënter behandelen van de 
pijn. Een dergelijke blauwdruk kan worden aangepast voor gebruik in elk 
land volgens de daar aanwezige gezondheidszorg. 
HOOFDSTUK 3. Richtlijnen voor neuropathische pijn bij patiënten met 
kanker: een Europees onderzoek en vergelijking  
Tussen 19% en 39% van de patiënten met pijn bij kanker hebben last van 
neuropathische pijn. De diagnose en behandeling van NP zijn een uitdaging. 
CPGs zijn ontwikkeld in verschillende Europese landen om artsen te helpen 
bij het veilig en legaal behandelen van NP bij deze patiënten. Het doel van 
deze studie was de kwaliteit van de ontwikkeling en de rapportage van deze 
CPGs te beoordelen.  
Een Europese inventarisatie van CPGs werd uitgevoerd in samenwerking 
met de EFIC. Het inclusiecriterium was dat tenminste één paragraaf moest 
zijn gewijd aan de behandeling van neuropathische pijn bij kanker. Met 
behulp van het ‘Instrument voor Beoordeling van Richtlijnen’  (AGREE II)  
hebben twee onderzoekers, onafhankelijk van elkaar, de kwaliteit met 
betrekking tot de zes domeinen beoordeeld van het ontwikkelingsproces 
van de CPGs. Verder werden t-toetsen gebruikt om CPGs ontwikkeld door 
overheidsorganisaties te vergelijken met die ontwikkeld door 
wetenschappelijke organisaties. De gemiddelde scores van de domeinen 
van 'onderwerp en doel' (80%) en ‘helderheid en presentatie' (61%) waren 
bevredigend, 'betrokkenheid van belanghebbenden' (58%), 
'methodologie’(57%) en ‘onafhankelijkheid van de opstellers’ (53%) waren 
acceptabel, en 'toepassing' was ontoereikend (39%). Overheidsrichtlijnen 
hadden hogere scores dan wetenschappelijke organisatie richtlijnen voor 
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de domeinen van 'betrokkenheid van belanghebbenden' en 
'onafhankelijkheid van de opstellers' (P<0.01). De kwaliteit van het 
ontwikkelingsproces van de negen geïncludeerde CPGs varieerde sterk. 
CPGs moeten worden ontwikkeld binnen een gestructureerd programma 
voor richtlijn ontwikkeling dat methodologische ondersteuning bevat. 
Omdat het ontwikkelen van een CPG duur en tijdrovend is, raden we meer 
internationale samenwerking aan om de kwaliteit te verhogen en de 
ontwikkelingskosten te verlagen. 
HOOFDSTUK 4. Diagnose van neuropathische pijn bij patiënten met 
kanker: vergelijkende analyse van de aanbevelingen in nationale 
richtlijnen van de Europese landen  
Neuropathische pijn is een veel voorkomend symptoom bij patiënten met 
kanker en het behoeft een meer specifiek algoritme dan nociceptieve pijn 
of neuropathische pijn die afkomstig is van een andere bron dan kanker of 
de behandeling er van. Klinische praktijk richtlijnen (CPGs) kunnen 
behulpzaam zijn bij het optimaliseren van de diagnose van neuropathische 
pijn bij patiënten met kanker. In deze studie werden alle negen nationale 
CPGs in Europa op het gebied van neuropatische pijn bij patiënten met 
kanker onderzocht. Er werd een vergelijking gemaakt tussen CPGs op het 
gebied van de aanbevelingen, de kwaliteit van de ondersteunende 
literatuur (volgens de SIGN 55 -classificatie) en de kenmerken van de 
ondersteunende literatuur (eerste auteur, populatie van patiënten, jaar en 
soort publicatie). In totaal werden 149 referenties gebruikt in de 9 CPGs, 
waarvan er 72 (48%) waren over kanker, 39 (26%) over neuropathische pijn, 
en maar 3 over neuropathische pijn bij patiënten met kanker (2%). Slechts 
28 (19%) referenties werden gedeeld tussen 2 of meer richtlijnen. Er was 
maar één gedeelde verwijzing specifiek gerelateerd aan neuropathische pijn 
bij patiënten met kanker.  
De aanbevelingen en de kwaliteit van het ondersteunende bewijs verschilt 
wezenlijk tussen de CPGs. Deze studie toont een aanzienlijke heterogeniteit 
in de Europese aanbevelingen over de diagnose en evaluatie van 
neuropathische pijn bij patiënten met kanker. De belangrijkste 
tekortkomingen zijn het lage niveau van het ondersteunend bewijs en het 
ontbreken van specifieke gegevens gericht op neuropathische pijn bij 
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patiënten met kanker. We raden aan dat artsen die omgaan met 
neuropathische pijn bij patiënten met kanker speciaal worden opgeleid, dat 
er een specifieke methodologie voor het ontwikkelen van CPGs moet 
worden aangenomen en dat er meer wetenschappelijk onderzoek van hoge 
kwaliteit wordt gedaan over de diagnose van neuropathische pijn bij 
patiënten met kanker. 
HOOFDSTUK 5. Behandeling van neuropathische pijn bij patiënten met 
kanker: vergelijkende analyse van de aanbevelingen in de nationale 
klinische praktijk richtlijnen uit Europese landen  
Van de patiënten met kanker heeft 19-39% last van neuropathische pijn. 
Het behandelen van dit soort pijn is een uitdaging want deze 
patiëntengroep is vaak kwetsbaar en heeft comorbiditeiten die het risico op 
bijwerkingen verhogen en daarmee invloed heeft op hun kwaliteit van 
leven. CPGs kunnen nuttig voor clinici, vooral wanneer wetenschappelijk 
bewijs onzeker of zwak is. In deze studie hebben we ons gericht op de 
kwaliteit van de literatuur die is gebruikt om aanbevelingen voor de 
behandeling te geven in de geselecteerde Europese CPGs. Negen CPGs uit 
Europese landen, die tenminste één paragraaf over neuropathische pijn bij 
kanker bevatten, werden opgenomen. Er werd een vergelijking gemaakt 
tussen CPGs van de aanbevelingen, de kwaliteit van de ondersteunende 
literatuur (volgens de SIGN 55 -classificatie) en de kenmerken van de 
ondersteunende literatuur (eerste auteur, populatie van patiënten, jaar en 
soort publicatie). In alle CPGs werd amitriptyline genoemd als het middel 
van eerste keus. Zes richtlijnen stelden ook gabapentinoïden voor. Slechts 
30 van de 163 citaties (18%) waren gebaseerd op studies met patiënten 
met kanker. Zeven CPGs hebben het indirect bewijs door de extrapolatie 
van de studieresultaten van patiënten met pijn door een niet-oncologische 
oorzaak naar patiënten met kanker niet bediscussieerd. De meerderheid 
van de richtlijnontwikkelingsgroepen extrapoleerden hun resultaten om 
aanbevelingen te formuleren op basis van niet-kanker publicaties, zonder 
expliciet aan te geven dat dit geldt als een beperking. Daardoor zijn deze 
richtlijnen niet in staat belangrijke kwesties, zoals de verschillen in de 
kinetiek en bijwerkingprofielen bij deze patiënten, aan te geven. Wij raden 
aan om een internationale groep van deskundigen specifieke aanbevelingen 
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te laten opstellen voor de behandeling van neuropathische pijn bij 
patiënten met kanker ondersteund door gericht onderzoek bij patiënten 
met kanker. 
HOOFDSTUK 6. Een case vignette studie naar de praktische kennis van 
Franse pijn specialisten betreffende klinische praktijk richtlijnen over 
neuropathische pijn bij patiënten met kanker  
Van de patiënten met kanker lijdt tussen de 19% en 39% aan pijn die 
moeilijk te diagnosticeren en te behandelen is: neuropathische pijn. In 
Frankrijk bestaan CPGs over dit onderwerp, maar de mate waarin de Franse 
pijn specialisten zich bewust zijn van de aanbevelingen uit deze CPGs en ze 
gebruiken is niet bekend. Het doel was om te onderzoeken, met behulp van 
een case vignette, of pijn specialisten de aanbevelingen uit de CPGs in de 
klinische praktijk volgen. Het onderzoek bestond uit een case vignette over 
een patiënt met pijn die lijdt aan onbehandelbare alvleesklierkanker. In de 
vignette zijn meerkeuzevragen opgenomen over de diagnose en 
behandeling van (neuropathische) pijn. Een e-mail enquête met 
vragenlijsten werd in Frankrijk uitgevoerd met de steun van de Société 
Française d' Etude et de Traitement de la Douleur (Franse vereniging voor 
de studie en behandeling van pijn). Deze enquête werd aan alle pijn 
specialisten (primaire en secundaire zorg) verzonden. De percentages van 
de respondenten die de patiënt behandelden zoals gesuggereerd in de 
CPGs werden berekend. Een totaal van 214 (24%) van hen die waren 
uitgenodigd om deel te nemen (921) vulden de vragenlijst in. Meer dan 85% 
van de respondenten zei dat ze bekend waren met deze CPGs en deze 
gebruikten. De helft van de respondenten diagnosticeerde en behandelde 
de neuropathische pijn onderdelen in de case vignette volgens de 
aanbevelingen in de CPGs. Hoewel de reagerende pijn specialisten 
verklaarden dat zij de CPGs over neuropathische pijn bij patiënten met 
kanker kenden en gebruikten, gaf de helft van hen antwoorden die niet in 
overeenstemming waren met de gegeven aanbevelingen. Een landelijk 
programma om deze CPGs implementeren is noodzakelijk, inclusief beter 
onderwijs en training van de pijn specialisten in de beoordeling en 
behandeling van neuropathische pijn. 
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Hoofdstuk 7. Algemene discussie  
In 2010 hebben we 54 documenten verzameld van Europese landen met 
aanbevelingen over de diagnose en behandeling van chronische pijn, 
neuropathische pijn of pijn bij kanker. Twintig documenten voldeden aan 
de criteria voor een klinische praktijk richtlijn. Hun ontwikkelingskwaliteit, 
bepaald met het AGREEII instrument, was matig. Grotere inspanningen 
moeten worden gedaan om de mening en opvattingen van patiënten een 
plek te geven, het systematisch review proces te beschrijven en het geven 
van aanbevelingen over de implementatie van de CPG. De meerderheid van 
de werkgroepen voor richtlijnontwikkeling extrapoleerden de resultaten 
van studies van niet-kanker neuropathische pijn om te komen tot 
aanbevelingen voor patiënten met pijn bij kanker. 
NP bij patiënten met kanker is een gebied waar medische kennis ontbreekt, 
waar iatrogene complicaties voorkomen en waar interventies significante 
risico's en kosten met zich meebrengen. Daarom voldoet het aan de criteria 
voor het creëren van een aparte CPG. Aangezien de ontwikkeling van 
richtlijnen tijdrovend is en veel geld kost, kan internationale samenwerking 
in CPG ontwikkeling een oplossing zijn om de kwaliteit te verhogen en de 
kosten te verlagen. Om die reden raden we een meer internationale en 
gecentraliseerde samenwerking aan (waarbij medisch specialisten, 
huisartsen en onderzoekers zijn betrokken) voor de ontwikkeling van een 
Europees CPG over neuropathische pijn bij patiënten met kanker. Het 
bundelen van de middelen maakt het mogelijk om een CPG van hoge 
kwaliteit te ontwikkelen. Specifieke case vignettes kunnen worden 
ontwikkeld en getest voor de verschillende aspecten van pijn onderwijs 
omdat ze een goedkoop hulpmiddel en gemakkelijk in gebruik zijn. Ze 
kunnen worden gebruikt om de implementatie van de CPG onder een grote 
groep artsen te beoordelen, en kunnen gemakkelijk worden herhaald, 
bijvoorbeeld na een training of implementatieprogramma. Dit zal helpen 
om de kwaliteit van de onderwijsmodule te evalueren en het 
trainingsprogramma daaraan aan te passen. 
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Cette thèse étudie la qualité des recommandations européennes portant 
sur la douleur neuropathique des patients souffrant d'un cancer. Ce travail 
a été financé par l’organisation néerlandaise pour la recherche et le 
développement en santé (ZonMw). 
Chapitre 1 – L’introduction. 
Dix-neuf à 39% des patients avec des douleurs cancéreuses souffrent de 
douleur neuropathique. Diagnostiquer et traiter la douleur neuropathique 
dans ce groupe de patients est difficile et fondé sur des données 
scientifiques de faible niveau. Or, il est nécessaire de guider les médecins à 
détecter, diagnostiquer et traiter ces douleurs. Des recommandations de 
bonne pratique peuvent être utiles. Ce sont des « recommandations 
systématiquement développées pour aider les praticiens et les décisions 
des patients sur les soins de santé appropriés dans des circonstances 
spécifiques ». Or, existe-t-il de telles recommandations en Europe ? Si oui, 
quelle est leur qualité de développement ? Sur quelle revue de la littérature 
sont-elles fondées ? Sont-elles applicables ? Cette thèse va répondre à ces 
questions en 5 articles. 
Chapitre 2 - L’inventaire des recommandations de bonne pratique portant 
sur la douleur en Europe. 
Les recommandations de pratique clinique (RPC) « recommandations 
systématiquement développées pour aider les praticiens et les décisions 
des patients sur les soins de santé appropriés dans des circonstances 
spécifiques ». Beaucoup de patients en Europe souffrent de douleur 
chronique, souvent en association avec des comorbidités. Si elles sont 
disponibles et de bonne qualité, les RPC peuvent guider les praticiens dans 
le diagnostic et le traitement de la douleur. De ce fait, nous avons étudié le 
nombre et la qualité des RPC dans les pays européens concernant la 
douleur chronique, la douleur cancéreuse et la douleur neuropathique. 
Un questionnaire envoyé par email aux responsables des sociétés savantes 
de la douleur et les cliniciens appartenant au groupe des douleurs 
neuropathiques de l’International Association for the Study of Pain (IASP) en 
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Europe. Le nom et le thème de chaque document cité (douleur chronique, 
douleur cancéreuse, douleur neuropathique et autre) a été collecté. 
Chaque document devait répondre à la définition d’une RPC. L’analyse 
statistique a été réalisée avec le logiciel SPSS 16.0. Quarante-et-un des 66 
participants (62%) ont répondu au questionnaire, représentant 30 des 38 
pays européens. Parmi les pays répondeurs, 54 documents ont été collectés 
et parmi eux, 20 répondaient à la définition de RPC : 6 sur la douleur 
chronique, 5 sur la douleur neuropathique, 4 sur la douleur cancéreuse, 2 
sur la prise en charge des douleurs de la personne âgée, 1 pour la pédiatrie 
et 2 sur la douleur lombaire chronique.  
Il existait une importante hétérogénéité en Europe sur la disponibilité, le 
contenu et la qualité des RPC. La rédaction d’une RPC européenne 
permettrait de proposer une prise en charge plus sûre et efficace. Celle-ci 
pourrait ensuite être adaptée dans chaque pays selon son système de 
santé. 
Chapitre 3 - Recommandations pour la prise en charge des douleurs 
neuropathiques des patients souffrant de cancer : une enquête 
européenne et comparaison. 
Entre 19 et 39% des patients souffrant d'un cancer ont des douleurs 
neuropathiques. Son diagnostic et son traitement est toujours un défi. En 
fait, des recommandations de pratique clinique (RPC) nationales ont été 
développées dans plusieurs pays européens afin d’aider les médecins à 
gérer ces patients de façon sûre et légale. L’objectif de cette étude était 
d’évaluer la qualité de développement de ces RPC.  
En collaboration avec la fédération européenne des chapitres de l’IASP 
(EFIC), un inventaire européen de RPC a été élaboré. Les critères d’inclusion 
étaient d’avoir au moins un chapitre concernant le traitement des douleurs 
neuropathiques dans le cancer. L’instrument Appraisal of Guidelines, 
Research and Evaluation II (AGREE II) a été utilisé par deux évaluateurs 
indépendants afin de mesurer la qualité du processus de développement de 
ces RPC inclues selon 6 items. De plus, les RPC développées par les 
organisations gouvernementales ont été comparées à celles développées 
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par les sociétés savantes en utilisant des tests-t. La moyenne des scores 
pour le domaine « champ et objectifs » (80%) et « clarté de présentation » 
(61%) était satisfaisante. La moyenne pour les domaines « participation des 
groupes concernés »  (58%), « rigueur d’élaboration de la RPC » (57%) et 
« indépendance éditoriale » (53%) était acceptable. La moyenne des scores 
pour le domaine « applicabilité » était insuffisante (39%). Les 
recommandations gouvernementales avaient un score de qualité supérieur 
aux recommandations des sociétés savantes pour les domaines 
« participation des groupes concernés » et « indépendance éditoriale » 
(p<0,01). La qualité du processus de développement des 9 RPC inclues était 
très variable. De ce fait, les RPC devraient être développées sur le modèle 
d’un programme structuré, incluant un support méthodologique. Comme 
cela est onéreux et chronophage, nous recommandons une plus grande 
coopération internationale afin d’améliorer la qualité et de diminuer les 
coûts. 
Chapitre 4 – Diagnostiquer la douleur neuropathique chez les patients 
souffrant de cancer : une analyses comparative des recommandations de 
bonne pratique nationales dans les pays européens. 
La prévalence de la douleur neuropathique est élevée chez les patients 
souffrant de cancer. Cela requiert un algorithme de diagnostic plus 
spécifique que lors des études des douleurs non cancéreuses qu’elle soit 
nociceptive ou neuropathique. Les RPC peuvent aider en optimisant le 
diagnostic des douleurs neuropathiques dans le cancer. Dans cette étude, 9 
RPC nationales en Europe portant sur le diagnostic des douleurs 
neuropathiques cancéreuses ont été inclues. Les recommandations avec 
leur grade d’évidence (selon la classification SIGN-50 du Scottish 
Intercollegiate Guidelines Network) et les références utilisées (premier 
auteurs, population de patients, année et type de publication) ont été 
comparées entre les RPC. Neuf RPC concernant la douleur neuropathique 
cancéreuse ont été sélectionnées et analysées. Au total, 149 références ont 
été citées dont 72 (48%) concernaient le cancer, 39 (26%) concernaient la 
douleur neuropathique et 3 (2%) concernaient la douleur neuropathique 
chez les patients souffrant de cancer. Seulement 28 références (19%) 
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étaient partagées entre 2 RPC ou plus. Seule une référence partagée 
concernait la douleur neuropathique cancéreuse.  
Les recommandations et leur grade d’évidence différaient largement entre 
les RPC. Cette étude montrait une hétérogénéité importante entre les RPC 
européennes portant sur le diagnostic et l’évaluation des douleurs 
neuropathiques chez les patients souffrant de cancer. La principale 
faiblesse était le niveau faible d’évidence et l’absence de données 
spécifiques concernant la douleur neuropathique cancéreuse. Nous 
recommandons que les médecins s’occupant des douleurs neuropathiques 
chez les patients souffrant de cancer soient formés spécifiquement et que 
la recherche s’intéresse à ce domaine précis. 
Chapitre 5 – Le traitement des douleurs neuropathiques chez les patients 
souffrant d’un cancer : analyse comparative des recommandations 
nationales issues des recommandations de pratique clinique  en Europe. 
Des patients souffrant de cancer, 19 à 39 % souffraient de douleur 
neuropathique. Traiter ce type de douleur reste un défi parce que ce 
groupe de patients est souvent fragile et a des comorbidités qui vont 
augmenter le risque d’événements indésirables et donc influencer sa 
qualité de vie. Les RPC peuvent aider les médecins, en particulier parce que 
l’évidence scientifique est incertaine ou faible. Dans cette étude, nous 
avons étudié en détail la qualité de la revue de la littérature utilisée dans les 
recommandations portant sur le traitement des RPC européennes 
sélectionnées. Dans une étude précédente, 9 RPC européennes qui 
contenaient au moins un paragraphe sur le traitement des douleurs 
neuropathiques dans le cancer ont été inclues. Les recommandations avec 
leur grade d’évidence  (selon la classification SIGN-50) et les références 
utilisées (premiers auteurs, population de patients, année et type de 
publication) ont été comparées entre les RPC. Dans toutes les RPC, 
l’amitriptyline a été mentionnée comme le traitement de première 
intention. Six RPC proposaient aussi la gabapentine. Seulement 30 des 163 
références (18%) étaient des études portant sur les patients souffrant de 
cancer. Sept RPC n’argumentaient pas l’extrapolation des résultats des 
études portant sur des patients sans cancer vers des patients avec un 
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cancer. La majorité des groupes de développement des RPC extrapolait les 
résultats des populations en dehors d’un contexte oncologique pour 
formuler des recommandations sur le cancer. En conséquence, ces RPC 
échouaient à donner les points principaux concernant la cinétique altérée 
et les événements indésirables chez ces patients. Nous conseillons de créer 
des recommandations spécifiques par un groupe international d’experts 
pour le traitement des douleurs neuropathiques chez les patients souffrant 
de cancer avec le support d’une recherche ciblée dans cette population 
spécifique. 
Chapitre 6 – Une vignette clinique pour évaluer la connaissance et la 
pratique des médecins français spécialisés en douleur concernant les 
recommandations de pratique clinique portant sur la douleur 
neuropathique cancéreuse. 
Entre 19 et 39% des patients ayant un cancer souffrent de douleur 
neuropathique, celles-ci sont difficiles à diagnostiquer et à traiter. En 
France, il existe des RPC sur ce sujet mais leur connaissance et leur 
utilisation par les algologues n'est pas répertoriée. L’objectif de l’étude était 
d’étudier si les médecins français spécialisés en douleur suivaient ces 
recommandations en utilisant une vignette clinique d’un patient souffrant 
de douleur neuropathique cancéreuse dans la cadre d’un cancer du 
pancréas. Les participants, membres de la SFETD, ont répondu à un 
questionnaire en ligne. Plusieurs options diagnostiques et thérapeutiques 
étaient proposées. Le pourcentage de participants qui suivaient les RPC ont 
été calculés pour chaque question de la vignette clinique. Sur les 921 
médecins de la SFETD, 214 (24%) ont répondu au questionnaire. Plus de 
85% d’entre eux déclaraient connaitre et utiliser les RPC. La moitié d'entre 
eux  diagnostiquait et traitait la douleur neuropathique dans la vignette 
clinique en concordance totale avec les RPC. Bien que les médecins 
spécialisés en douleur connaissent et utilisent les RBP, seulement la moitié 
d’entre eux les suivent pour prendre en charge la douleur neuropathique. 
Un programme national d’implémentation de ces RBP sera utile afin 
d’évaluer les facteurs limitant l’utilisation de ces RBP. 
Chapitre 7 – Discussion générale. 
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En 2010, dans les pays européens, 54 documents sur la douleur chronique, 
la douleur neuropathique ou la douleur cancéreuse ont été disponibles 
pour guider les médecins. Vingt documents répondaient à la définition 
d’une recommandation de pratique clinique (RPC). Leur qualité, définie par 
l’AGREE II instrument, était modeste concernant les RPC spécifiques de la 
douleur neuropathique cancéreuse. Des efforts sont encore nécessaires 
pour faire participer les patients à leur développement, pour décrire le 
processus de réalisation dans la revue de la littérature ou encore donner 
des indications sur le moyen d’implémenter ces RPC. La majorité des 
groupes de développement des RPC extrapolaient les résultats d’études 
d’une population non cancéreuse pour aboutir à des recommandations 
pour la population souffrant de cancer.  
La douleur neuropathique dans le cancer est un domaine où la 
connaissance médicale est insuffisante, où les complications iatrogènes 
sont fréquentes et où les interventions médicales portent un risque et un 
coût significatif, il s’agit donc de critères justifiant la création d’une 
recommandation spécifique. Comme développer une RPC est chronophage 
et onéreuse, une coopération internationale dans le développement d’une 
RPC pourrait être une solution pour améliorer la qualité des soins et réduire 
les coûts. Pour cette raison, nous conseillons une plus grande collaboration 
internationale (avec des méthodologistes et des cliniciens dont les 
médecins généralistes) pour le développement d’une RPC européenne 
portant sur la douleur neuropathique cancéreuse : cela aiderait à 
mutualiser les ressources pour obtenir un bon niveau de qualité. Des 
vignettes cliniques spécifiques devraient être développées et testées pour 
plusieurs aspects concernant la formation en douleur parce que ce sont des 
outils bon marché et faciles à utiliser. Elles pourraient être utilisées pour 
évaluer l’implémentation des RPC dans un large groupe de médecins, 
pouvant être facilement répétés dans le temps, après une formation ou 
pour tester l’implémentation du programme d’une RPC. Cela permettra 
d'évaluer le module actuel de formation et d’adapter éventuellement 
l'enseignement des cliniciens en fonction de nouvelles données 
enregistrées. 
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Epilogue 
Marseille, May the 14th 2013 
Dear Vero, Naia and Mathilde, 
 
I am physician, general practitioner, pain specialist and I would like to 
answer your questions. 
 
Each of you has neuropathic pain: it is a pain caused by a lesion of a nerve. 
In your case, Naia, I think that it is caused by the surgery. Vero, your 
neuropathic pain seems related to the chemotherapy you received. And 
Mathilde, the cancer itself seems responsible for the pain. Indeed, this pain 
is often described as burning, like pins and needles or electric shocks. Your 
physician can diagnose it during a physical examination; no other tests will 
be necessary. And like all three of you experience: this pain is very 
uncomfortable and needs treatment with other drugs than you are used to 
take for other kinds of pain. Although it sounds strange, drugs that are also 
meant to treat epilepsy or a depression are the best options to reduce 
neuropathic pain. These treatments might help you, but they can have 
unpleasant side effects, which your physician needs to discuss with you. By 
starting with a small dose and monitoring the effect and side effects of the 
drugs, you have the highest change that your pain will be relieved with 
limited and tolerable side effects. Don’t hesitate to discuss this with your 
doctor, and to ask him as your partner in improving the quality of your life.  
 
The research on treating neuropathic pain that is related to cancer is still 
poor. I have been studying it in the past few years, and will continue to 
study it. I will follow the discussions on this forum, and will keep you up to 
date if new developments are available. All the best for the three of you! 
 
Yours sincerely, 
 
Virginie Piano, MD 
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